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Many cancers have long been known to display an absolute requirement for the 
amino acid methionine (L-Met). Studies have shown that in the absence of L-Met, 
sensitive neoplasms experience cell cycle arrest and perish. Without the metabolic 
deviations that characterize L-Met auxotrophs, normal cells are able to grow on 
precursors such as homocysteine and tolerate periods of L-Met starvation. The 
differential requirement for this amino acid between normal and tumor cells has been 
exploited through enzymatic serum degradation of L-Met by a bacterial methionine-γ-
lyase (MGL). Though MGL was able to deplete L-Met to therapeutically useful levels in 
animal models and exert a significant cytotoxic effect on malignant cell lines in vitro and 
on tumor xenografts in vivo, the clinical implementation of this enzyme is hampered by 
its short serum half-life and potential for catastrophic immune response.  
 vii 
In the chapters that follow, we describe the engineering of a novel human 
methionine degrading enzyme (hMGL) that overcomes the limitations of the bacterial 
therapeutic. We have shown that hMGL is capable of degrading methionine at a 
therapeutically useful rate and inducing extensive cell killing in a variety of neoplasms. 
This enzyme is expected to have low immunogenicity in patients and a high therapeutic 
index. We have developed a high throughput screen for methionine degrading activity 
that we can utilize to further engineer the enzyme based on the results of additional 
preclinical development. We have found that hMGL is also capable of degrading cystine 
to operate as a dual amino acid depletion treatment that is expected to be more potent 
than methionine depletion alone. Due to the wide array of neoplasms sensitive to 
methionine and cystine starvation, the engineered enzyme holds a great deal of promise 
as a unique and powerful cancer therapeutic. 
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Chapter 1: Introduction and Background 
 
1.1 ENZYMATIC DEPLETION OF SERUM AMINO ACIDS IN CANCER TREATMENT 
 
Many cancers exhibit significant metabolic deviations from normal cells, 
including a higher demand for particular amino acids, and depend on the availability of 
these metabolites in the serum pool for survival. The modulation of amino acid levels in 
serum has been investigated as a treatment strategy with a variety of human cancers (1-
4). The clinical administration of an enzyme that catalyzes the degradation of a target 
amino acid efficiently and with high specificity can selectively drive malignancies to 
experience metabolic imbalances, inhibition of protein synthesis, irreversible cell cycle 
arrest, and ultimately, cell death.  
Among enzyme therapies in cancer, asparaginase is one of oldest and most 
successful. Its inclusion has led to a > 90% cure rate for standard risk Childhood Acute 
Lymphoblastic Leukemia (5).  Currently, only bacterial enzymes derived from E. coli and 
Erwinia chrysanthemi are available (6). Since bacterial asparaginase is highly 
immunogenic (7), antibody response in patients inactivates the enzyme, shortens its half-
 2 
life and induces anaphylaxis. Despite clinical success, asparaginase therapy remains 
limited by its immunogenicity (4).   
1.2 L-METHIONINE DEPLETION FOR CANCER THERAPY 
 
Methionine depletion has long been studied as a potential treatment for cancer, as 
many malignant human cell lines have a substantially higher requirement for this amino 
acid than normal tissues (8-15).  L-Met cannot be synthesized de novo and is essential in 
all cells for protein synthesis, oxidative stress protection as a precursor to glutathione, 
polyamine synthesis for nuclear and cell division, and as a major source of methyl groups 
for the methylation of DNA and other molecules (Figure 1). The abnormally high 
demand of malignancies has been attributed to deviations in these functions as well as 
defects in expression of critical enzymes in the metabolic cycle of methionine. The high 
rate of cell growth and division in malignant cells demands greater supplies of raw 
materials for protein and polyamine synthesis. Polyamines themselves have been shown 
to contribute to tumorigenesis and proliferation (16-18). Some cancers have diminished 
or non-existent levels of expression of methylthioadenosine phosphorylase (MTAP) 
which cleaves methylthioadenosine to 5-methylthioribose-1-phosphate that is further 
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metabolized to recycle L-Met (19, 20). Additionally, L-Met dependent cancer cells often 
express low levels of L-Met synthase or produce an enzyme with markedly lowered 
activity (21-24). L-Met synthase is responsible for recycling homocysteine back into L-
Met so dependent malignant cells that are unable to utilize this precursor must instead 
scavenge L-Met from their environment.  
The absolute requirement of neoplasms for L-Met presents an attractive 
opportunity for treatment.  When L-Met levels decrease from the normal human serum 
concentration of ~ 30 µM  to a threshold around ~ 5 µM L-Met dependent tumors are 
unable to survive  (25, 26). Even partial depletion through nutritional deprivation has 
been shown to have an effect on tumor growth in both a rat model and human patients 
(27-29). However, an L-Met free diet alone is insufficient to achieve sufficiently low 
amino acid levels due to replenishment through protein degradation and homocysteine 
conversion by normal cells (levels drop by ~40% (10)). In an effort to overcome this 
limitation, enzymatic L-Met depletion has been investigated in a number of animal model 




Figure 1: Overview of the role of L-Met in cell metabolism and the effects of its depletion on 
cancer. 1) Depletion of an essential amino acid halts protein synthesis.   2) Abrogated polyamine 
synthesis stalls tumorigenesis & proliferation.  3) DNA & protein methylation is halted.              
4) Tumor cells are often compromised in the remethylation of  L-homocysteine back to L-Met.  
5) We engineered the human CGL enzyme to accept L-Met as a substrate 
 
1.3 METHIONINE--LYASE AS A CANCER THERAPEUTIC 
 
L-Methionine-ɣ-lyase (MGL) catalyzes the ,-elimination of L-Met to 
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methanethiol, α-ketobutyrate, and ammonia (Figure 4). It is a tetrameric pyridoxal-5’-
phosphate-dependent (PLP) enzyme present in many species, but absent in mammals (38, 
39). Numerous bacterial enzymes (including MGL from Pseudomonas putida) have been 
purified and tested for L-Met degrading activity and efficacy against various cancer cell 
lines. The P. putida MGL was cloned and expressed in E. coli with high protein yield (~ 
1 g/L) (30, 40) and displayed fast Michaelis-Menten kinetics including a low value of KM 
(~1 mM) and a high value of kcat (~50 s
-1) in comparison to other sources (41, 42).  
The structure of the MGL enzyme was has been defined by crystallization (43). 
Each segment of the tetramer is composed of three regions: an extended N-terminal 
domain (residues 1-63) that includes two helices and three beta-strands, a large PLP 
(vitamin B6) binding domain (residues 64-262), and a C-terminal domain (residues 263-
398). Amino acids thought to be critical for specificity have also been identified based on 
structure. Tyr59 and Arg61 of neighboring subunits, which are also strongly conserved in 
other ɣ-family enzymes, contact the phosphate group of PLP. These residues serve as the 
main anchor for the cofactor within the active site. Lys240, Asp241 and Arg61 of one 
partner monomer and Tyr114 and Cys116 of the other monomer form a hydrogen-bond 
network in the MGL active site that confers specificity to the enzyme (Figure 2).  
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Figure 2:  Structure of MGL (PDB 1E5E) tetramer (a) with PLP cofactor bound to inhibitor. (b) 
Active site detail showing residues discussed and hydrogen bond network  
 
In vivo studies using MGL for L-Met depletion initially yielded promising results 
in animal models. Human lung, colon, kidney, brain, prostate, and melanoma neoplasms 
were all shown to be sensitive to recombinant MGL in a mouse xenograft model (30). 
Additionally, no toxicity was detected at effective doses (determined by absence of 
weight loss). However, the enzyme half-life was determined to be only ~2 hours in vivo 
and in pooled human serum (44). 
Yang et al. investigated the pharmacokinetics, L-Met depletion, antigenicity, and 
toxicity of MGL in a non-human primate model (36). A 90 mg/kg dose was able to 
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reduce plasma L-Met to less than 0.5 M within 30 minutes of injection and the L-Met 
level remained undetectable for 8 hr. Pharmacokinetic analysis showed that MGL was 
eliminated with a half-life of 2.5 hr. Administration of that dose every 8 hr for 2 weeks 
resulted in a steady-state depletion of plasma L-Met to less than 2 M. Mild toxicity was 
observed through decreased food intake and slight weight loss. However, re-challenge on 
day 28 resulted in anaphylactic shock and death in one animal. Anti-MGL antibodies 
were also detected after the first challenge, and increased in concentration for the 
duration of treatment.  
To reduce renal clearance and shield the bacterial enzyme from the primate 
immune system, MGL was conjugated to methoxypolyethylene glycol succinimidyl 
glutarate (MEGC-PEG-5000). A 90 mg/kg dose of MGLPEG was sufficient to reduce 
plasma L-Met to target levels and was administered every 12 hours over the course of 7 
days. Anaphylactic shock was not observed upon re-challenge, but anti-MEGC-PEG-
MGL antibody concentration was comparable to that elicited by unmodified MGL. 
Finally, although the serum longevity improved significantly by PEGylation (36 hrs vs. 2 
hrs), the L-Met levels were only kept below detection for one third longer than with the 
unPEGylated enzyme (12 hrs vs. 8 hrs) (45).  
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Phase I clinical trials were performed on patients with advanced cancers, 
including: breast, lung, renal, and lymphoma, by a single injection of MGLPEG (31, 37). 
The patients experienced no significant toxicity and plasma L-Met levels were 
immediately dramatically reduced. However, the authors did not assess the antitumor 
efficacy of this treatment and to date no other clinical trials have been reported. 
Additionally, these studies did not provide any information regarding immunogenicity 
over the course of multiple injections nor enzyme half-life and duration of L-Met 
depletion.  
MGL has also been shown to have extensive synergistic effects in combination 
with chemotherapeutic agents such as 5-fluorouracil and vincristine (46). The capacity of 
pMGL to reduce L-Met serum levels and lead to neoplastic cell death suggests the 
promise of enzyme-mediated serum amino acid depletion as a potential cancer treatment. 
However, pMGL is highly immunogenic and elicits a response even upon shielding by 
PEG. In fact, any bacterially-derived biotherapeutic runs the high risk of adverse immune 
response, as demonstrated by asparaginase ALL treatment described above. Additionally, 
the short half-life of the MGL enzyme exacerbates its immunogenicity. In order to 
maintain a therapeutically relevant level of L-Met in serum, the patient would have to 
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receive larger or more frequent doses of the enzyme subjecting them to a greater risk of a 
catastrophic immune response.  
1.4 CYSTATHIONINE--LYASE 
 
To circumvent the significant limitations of bacterial MGLs for human therapy, 
we developed a human methionine--lyase by protein engineering. Cystathionine--lyase 
is the last enzyme in the mammalian trans-sulfuration pathway and aids in the conversion 
of L-Met to L-Cysteine (Figure 1) (47, 48). In combination with a PLP cofactor, it 
catalyzes the ,-elimination of L-Cystathionine to L-Cysteine, α-ketobutyrate, and 
ammonia (Figure 4). CGL displays 61% amino acid similarity and extensive structural 
homology with the P. putida MGL (Figure 3) (49). CGL has previously been cloned, 
expressed in E. coli, and determined to convert L-Cyst with a KM of 0.5 mM and a kcat of 
7.5 s-1 (50).  
Structurally, CGL is a tetramer composed of two active dimers (51). Close contact 
between monomers of the tetramer are maintained by several hydrogen bonds and 
extensive hydrophobic interactions. Each CGL monomer consists of two domains, a 
larger PLP-binding domain and a smaller domain from the neighboring monomer. PLP is 
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anchored in position by strong hydrogen bonds between the phosphate moiety and 
surrounding residues from both chains: chain A (G90, L91, S209, and T211) and chain B 
(Y60 and R62). The cofactor is covalently bound to K212 by an internal Schiff base and 
is further stabilized by aromatic π-stacking interactions between its pyridine ring and the 
neighboring Y114. 
The enzyme has been complexed and crystallized with the inhibitor DL-
propargylglycine (PAG) (PDB:1E5E) and an overlay of the solved structures of CGL and 
MGL is presented in Figure 3. The comparison of their active sites highlights key amino 
acid differences that were used to guide the rational design of the first phase of 
engineering (Chapter 2). The structure also shows the additional α-helix at the N-terminal 
domain of MGL that covers the cysteine binding pocket in CGL and is thought to interact 
with the  hydrophobic distal end of L-Met (52).  Due to an appreciable kinetic rate, 
availability of crystal structures, and structural homology to the bacterial MGL, CGL was 
determined to be a promising candidate for protein engineering. 
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Figure 3: Overlay of two structures: MGL (PDB 1E5E) in magenta and CGL (PDB 3COG) in green. 
Full enzyme tetramer view (a) and active site detail with: complex of MGL with inhibitor bound 
to PLP, CGL complexed with an L-Cyst analog inhibitor, specific residues of CGL discussed and 
their corresponding amino acids in MGL, α-helical “lid” of MGL and lack thereof of CGL. 
 
Figure 4:  Reactions catalyzed by MGL and CGL with their natural substrates. 
 
 12 
Chapter 2: De Novo Engineering of a Human Cystathionine-γ-Lyase for 
Systemic L-Methionine Depletion Cancer Therapy1 
 
2.1 CHAPTER SUMMARY 
 
It has been known for nearly a half century that human tumors, including those 
derived from the nervous system such as glioblastomas, medulloblastoma, and 
neuroblastomas are much more sensitive than normal tissues to methionine starvation.  
More recently, systemic L-Met depletion by administration of Pseudomonas putida 
methionine--lyase (MGL) could effectively inhibit human tumors xenografted in mice.  
However, bacterial-derived MGLs are unstable in serum (t1/2 =1.9 ±0.2 hr) and highly 
immunogenic in primates.  Since the human genome does not encode a human MGL 
enzyme, we created de novo a methionine degrading enzyme by re-engineering the 
structurally homologous pyridoxal phosphate-dependent human enzyme cystathionine--
lyase (hCGL).  hCGL degrades L-cystathionine but displays no promiscuous activity 
towards L-Met.  Rational design and scanning saturation mutagenesis led to the 
generation of a variant containing three amino acid substitutions (hCGL-NLV) that 
degraded L-Met with a kcat/KM of 5.6 x 10
2 M-1s-1 and displayed a serum deactivation t1/2 
                                                          
1 Stone, E., Paley, O., Hu, J., Ekerdt, B., Cheung, N. K., and Georgiou, G. (2012) De novo engineering of a 
human cystathionine-gamma-lyase for systemic (L)-Methionine depletion cancer therapy, ACS Chem Biol 
7, 1822-1829. 
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=78 ± 5 hr (non-PEGylated).  In vitro, the cytotoxicity of hCGL-NLV towards 14 
neuroblastoma cell lines was essentially indistinguishable from that of the P. putida 
MGL.  Intravenous administration of PEGylated hCGL-NLV in mice reduced serum L-
Met from 123 M to <5 M for over 30 hours.  Importantly, treatment of neuroblastoma 
mouse xenografts with PEGylated hCGL-NLV resulted in near complete cessation of 
tumor growth.  Since the mode of action of hCGL-NLV does not require breaching the 
blood-brain barrier we believe this enzyme may be well suited for the treatment of 
sensitive tumors that arise from or metastasize to the central nervous system. 
2.2 INTRODUCTION 
 
As discussed in the Introduction in Chapter 1, L-methionine (L-Met) depletion has 
long been studied as a potential treatment for cancer, as many malignant human cell lines 
and tumors have a substantially higher requirement for L-Met than normal cells and 
tissues (13-15, 54, 55).  In particular, neuroblastomas, glioblastomas, and 
medulloblastomas are extremely sensitive to L-Met depletion (56, 57) and their use is so 
high that C11-methionine positron emission tomography (MET-PET) is used to image 
metastases in the brain (58). Depletion of any essential amino will disrupt protein 
synthesis, but L-Met is also required for polyamine synthesis (59-61) and methylation of 
DNA and other molecules (62). Most non-malignant cells can grow on 
homocysteine/homocystine, whereas malignant cells must scavenge L-Met directly from 
their extracellular environment (Chapter 1).  When serum L-Met levels decrease from the 
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normal ~ 30 µM (63) to below ~ 5 µM these tumors are unable to survive (64).  In vivo, a 
significant decrease in serum L-Met can be achieved by the systemic application of 
methionine--lyase from Pseudomonas putida (pMGL) resulting in drastic retardation of 
tumor growth in a variety of animal models (30, 33, 37, 46, 65-68).  However, pMGL is 
rapidly inactivated in vitro (This work) and in vivo (69, 70) and has proven to be highly 
immunogenic in primate models (65). 
To circumvent the significant limitations of bacterial MGLs for human therapy, 
we developed a human methionine--lyase by engineering methionine lyase activity into 
the human enzyme cystathionine--lyase (CGL, Chapter 1).  These enzymes are structural 
homologues (Figure 1a, structural alignment of hCGL and MGL from Trichomonas) and 
belong to the -family of pyridoxal phosphate (PLP) dependent enzymes.  Although 
MGL and CGL are related in their reaction chemistry (Figure 1b), CGL catalyzes the ,-
elimination of L-cystathionine to L-cysteine, -ketobutyrate, and NH3 but shows no 
detectable catalytic activity with L-Met.   Using rational design and scanning saturation 
mutagenesis, coupled with a novel screen for methionine--lyase activity, we engineered 
an hCGL variant containing 3 amino acid substitutions (hCGL-NLV) that displayed 
therapeutically significant rates of L-Met degradation.  
As hCGL-NLV is an engineered human protein, it is expected to be subject to 
immune tolerance, and moreover, computational predictions indicate that the 3 amino 
acid substitutions are unlikely to generate a T cell neo-epitope. While, as with any protein 
therapeutic candidate, it is impossible to rule out the possibility that hCGL-NLV could 
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elicit antibody responses in some patients, the extensive clinical data with approved 
engineered antibodies (71, 72) supports the notion that the introduction of a small, 
carefully selected  number of amino acid substitutions into engineered human proteins 
does not generally result in an adverse immunogenicity profile.  
2.3 RESULTS AND DISCUSSION 
 
2.3.1 Construction of Synthetic Genes, Protein Expression and Purification 
 
A synthetic hCGL gene utilizing optimal E.coli codons was synthesized and 
expressed from the T7 promoter in E.coli BL21(DE3). The codon-optimized gene led to 
very high protein yields in rich media exceeding 350 mg/L shake flask culture with >95 
% of the protein present in the soluble fraction and could be purified to > 98% 
homogeneity (as assessed by SDS-PAGE) in a single IMAC step (Figure 1).  By 
comparison, expression of the human hCGL gene from the same promoter was reported 
to yield <5 mg/L shake flask with the protein found almost exclusively in inclusion 
bodies (73).  
 16 
 




In addition to their native substrates, both hCGL and pMGL exhibit appreciable 
activity towards L-cysteine and DL-homocysteine (Table 1). However, L-Met is not a 
substrate of hCGL and likewise, pMGL has no activity with L-cystathionine as substrate, 
within the detection limit of our assay (Table 1).  Thus,  hCGL does not exhibit 





P. putida methionine--lyase 
Substrate  kcat  ( s
-1) KM (mM) kcat/KM (s
-1 mM-1) 
L-methionine  20 ± 0.4 0.34 ± 0.03 59 ± 6 
L-cystathionine nd nd nd 
L-cysteine   6.5 ±  0.2 1.1  ±  0.1     6 ± 0.7 
DL-homocysteine 86 ±  3 2.9  ±  0.2 30 ±  3 
Substrate 
Human cystathionine--lyase 
L-methionine nd nd nd 
L-cystathionine 3.7 ± 0.2 0.40 ± 0.07 9  ± 2 
L-cysteine 0.15 ± 0.02 0.79 ± 0.30 0.2  ± 0.1 
DL-homocysteine 0.35 ± 0.02   1.7 ± 0.30 0.21 ± 0.04 
Substrate Human cystathionine--lyase-NLV 
L-methionine 7.9 ± 0.4 
(≥106 *) 
 14 ± 1.5 0.56 ± 0.07 
 
L-cystathionine 0.54 ± 0.02    0.83 ± 0.1 0.65 ± 0.07 
(-14) 
L-cysteine 2.7 ± 0.1 0.84 ± 0.1 3.2 ± 0.3 
(16) 
DL-homocysteine 2.6 ± 0.1 0.9 ± 0.1 2.8 ± 0.3 
(13) 
  nd = not detected, ( ) = fold change from hCGL.  
* estimated from DTNB assay limits.   
All reactions were performed at 37 ºC with the MBTH assay. 
Table 1: Kinetic parameters of MGL, CGL, and NLV with various substrates  
 
Structural overlays of hCGL and an MGL from Trichomonas revealed that in 
hCGL the side-chains of residues E59, R119, and E339 are important for the orientation 
of the cysteine terminus of its substrate, L-cystathionine, while in MGL the corresponding 
positions are occupied by amino acids with hydrophobic side chains, namely I55, A116, 
and V337 (Figure 2a).  
 18 
 
Figure 2: CGL and MGL structure and function (a) Structural overlay of human CGL and MGL 
from Trichomonas vaginalis (PDB 3COG:1E5E) with the inhibitor propargylglycine (PAG) 
bound in two different orientations. (b) Reactions catalyzed by CGL and MGL 
 
Positions 59, 119 and 339 in hCGL were subjected to combinatorial pairwise 
saturation mutagenesis and the resulting clones were screened for methionine--lyase 
activity using a novel high throughput plate assay that relies on the colorimetric detection 
of the -ketobutyrate product of the reaction using 3-methylbenzothiazolin-2-one 
hydrazone (MBTH)(75).  Clones expressing mutagenized hCGL were grown in 
microtiter well plates to mid-log phase, the cells were lysed chemically, incubated with 5 
mM L-Met at pH 7.3 and 37 ○C followed by MBTH and the Abs320 was determined 
spectrophotometrically.   
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Screening of > 2,000 colonies (2x theoretical diversity) from a saturation library 
(library A) at positions 119 and 339 gave 14 unique clones (Table 2, Library A) capable 
of producing -ketobutyrate from L-Met.  The active clones encoded hCGL with Pro or 
Val substitutions at position 339 with the latter resulting in higher product formation.  
The clone with the highest activity, hCGL(R119L, E339V), was used as a template to 
randomize the E59/R119L codons.  
 




Pos.  119 
 




pMGL  L V 1 
 L V 0.58 
 C V 0.29 
 Q V 0.29 
 F R 0.15 
 S V 0.11 
 L P 0.08 
 V P 0.07 
 G P 0.07 
 A Q 0.06 
 M P 0.05 
 R P 0.05 
 G V 0.05 
 Q P 0.05 
 V T 0.04 
hCGL R E 0 
MBTH assay 
Table 2: Relative activity of clones from Library A. 
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Screening of an additional 2,000 clones led to the isolation of 31 clones exhibiting 
greater -ketobutyrate formation in the 96 well format than the hCGL(R119L, E339V) 
(Table 3, Library B).   The respective enzymes were produced and purified by IMAC in 
small scale and then rank-ordered with respect to their relative 2nd order rate constants 
(apparent kcat/KM when [S] is << KM) in a reaction with 0.1 mM L-Met and continuous 
monitoring of methanethiol formation with 5,5'-dithiobis-2-nitrobenzoic acid  (Table 4). 
This was done to minimize possible expression effects in the screen signal.  The highest 
apparent kcat/KM was obtained with hCGL (E59N, R119L, E339V) designated hCGL-














 Library B 
 
Pos.  E59 
 




A L 1.00 
N L 0.58 
S P 0.56 
V L 0.49 
A S 0.41 
S L 0.40 
H L 0.38 
S A 0.36 
M L 0.35 
S S 0.32 
Q L 0.32 
A V 0.32 
A A 0.31 
V A 0.29 
S Q 0.28 
H S 0.27 
V S 0.25 
M A 0.24 
A E 0.24 
H Q 0.23 
A H 0.22 
H A 0.20 
P Q 0.17 
L L 0.17 
L Q 0.16 
T A 0.13 
F Q 0.13 
I S 0.12 
Y A 0.11 
T S 0.06 
V Q 0.04 
MBTH assay 








Table 4: Relative V/K of select clones from Library B 
 
Steady state Michaelis-Menten parameters for pMGL, hCGL, and hCGL-NLV 
with L-Met, L-cystathionine, L-cysteine or DL-homocysteine were determined in 100 mM 
phosphate buffer, pH 7.3 at 37 C (Table 1). hCGL-NLV displayed significant 
methionine--lyase activity as well as increased activity towards L-Cys and DL-
homocysteine.  However, this enzyme had approximately 15-fold lower kcat/KM for L-
cystathionine, the physiological substrate of hCGL, suggesting that its methionine--lyase 
activity is not simply a consequence of broader substrate specificity, a rather common 
outcome in enzyme engineering.  For comparison, the kinetics of hCGL-E339V, hCGL-
E339P, hCGL-R119Q-E339V, hCGL-E339V-R119L and hCGL-E59A-R119S- E339V 
(hCGL-ASV) for the degradation of L-Met and L-cystathionine were also determined 
(Table 5).  Consistent with the results of the screening assay, hCGL-NLV displayed 
better kinetics than either the single or the double mutant enzymes above.   
 
Library B Ranked 
Pos. E59 Pos. R119 Pos. E339 Relative V/K 
N L V 1 
A L V 0.87 
V L V 0.84 
S P V 0.73 




Kinetic comparison of select hCGL variants                                                      
kcat/KM  mM
-1s-1 








L-Cysta 2.90 ± 
0.02 
0.37 ± 0.03 0.09 ± 0.01 0.043 ± 0.016 0.10 ± 0.02 0.08 ± 0.01 0.034 ± 0.01 




0.003 ± 0.001 0.013 ± 0.004 0.036 ± 
0.003 
0.041 ± 0.01 
Steady-State Kinetics determined at 25 ○C  with DTNB 
Table 5: Kinetics (kcat/KM) of hCGL, and variants E339V, E339P, R119Q-E339V, R119L-E339V, 
and hCGL-NLV. 
 
2.3.3 Serum Inactivation 
 
Of importance to therapeutic applications, (non-PEGylated) hCGL-NLV 
displayed substantially greater stability in pooled human serum at 37 °C relative to the P. 
putida MGL with t1/2 deactivation of 78 ± 5 hr in contrast to 1.9 ± 0.2 hr for the bacterial 




Figure 3: Stability of enzymes incubated in pooled human serum at 37 ○C.  (●) hCGL-NLV had 




Although hCGL-NLV has activity in vitro with other plasma metabolites (eg L-
cystathionine, L-Cys, and L-homocysteine) it is not expected that this will greatly affect 
their homeostasis in vivo. Plasma L-Cystathionine is excreted in the urine at a rate of 38.5 
μM/day and maintained in the serum at concentration of 0.24 ± 0.06 μM  (76) at which 
concentrations hCGL-NLV would have the negligible turnover rate of 1.5 x 10-4 s
-1 on its 
degradation.  In humans plasma L-Cys, and L-homocysteine exist either as the free amino 
acids, the (mixed) disulfide form, or bound to serum proteins at concentrations around 
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170 μM (54% free) and 6 μM (31% free) respectively (77).  Consistent with the existence 
of a protected fraction of L-Cys and L-Hcys, mice injected with pMGL  were shown to 
have a 90 % reduction in L-Met, but only a 46 % reduction in L-Hcys and no effect on L-
Cys levels(12).  hCGL-NLV is 2–and 10-fold  less active towards L-Cys and L-
homocysteine respectively relative to pMGL and therefore its effect on these metabolites 
would be expected to be significantly lower. 
2.3.5 Methionine Inhibition of hCGL   
 
It was surprising that we could not detect any L-Met hydrolysis with hCGL at any 
concentration despite its smaller size compared to L-cystathionine.  DL-homocysteine is 
also smaller than L-cystathionine yet it is degraded by hCGL, though with a 40-fold 
lower kcat/KM.  We examined the hypothesis that DL-homocysteine is a substrate of hCGL 
whereas L-Met is not due to leaving group effects. Degradation of homocysteine leads to 
H2S (pKa = 7)(78) whereas L-Met degradation leads to methanethiol (pKa = 10.3 (78)).  
The possibility that L-Met binds to the active site but the -lyase activity is disfavored by 
the high pKa of methanethiol could be ruled out since we found that even 20 mM L-Met 
did not inhibit L-cystathionine degradation by hCGL.  This observation raised the 
possibility that the relatively hydrophobic L-Met molecule is unable to partition into the 
hydrophilic active site of hCGL.   
2.3.6 Hydropathy Studies  
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The LogP values of the active-site residues unique to hCGL were summed ( 
LogP) to yield a value  = -19.7 (hydrophilic) while the  LogP value of the pMGL unique 
active-site is -2.87 (hydrophobic).  These values correlate well with the LogP values of 
their respective substrates (L-cystathionine = -5.82, L-Met = -2.19).  Consistent with this 
hypothesis, comparison of the active-site hydropathy values ( LogP) of hCGL, hCGL-
E339V,  hCGL-E339P, hCGL-E339Q-R119L, hCGL-E339V-R119L, hCGL-ASV and 
hCGL-NLV with the Log kcat/KM values (log10 value of kcat divided by KM values found 
from fits to the Michaelis-Menten equation) for L-Met and L-cystathionine hydrolysis 
revealed a positive linear relationship for the turnover of L-Met and a negative linear 
relationship for the turnover of L-cystathionine (Figure 4). This appears to hold true for 
DL-homocysteine and L-Cys as well which have intermediate hydropathy values, LogP = -
2.58, and -2.79 respectively.  DL-homocysteine and L-Cys are substrates that can partition 
into the hCGL active-site and hCGL-NLV with a more hydrophobic active site ( LogP = 
-7.64) increases the kcat/KM for these substrates 13 and 6-fold respectively.  It should be 
noted that in previous studies , when E339 of hCGL was mutated to either Lys, Ala or 
Tyr the kcat/KM for L-Cys increased by 2-, 3-, and 7-fold respectively, results that are also 
consistent with the effect of active site hydrophobicity as a key determinant of CGL 




Figure 4. Plot of the sum of the calculated LogP values of residues in the active sites of hCGL, 
hCGL-E339P, hCGL-E339V, hCGL- R119L-E339Q, hCGL-R119L-E339V, hCGL-ASV and hCGL-NLV 
versus their Log kcat/KM values for the hydrolysis of L-Met (●) and L-Cystathionine (○). 
 
2.3.7 Immunogenicity Assessment   
 
To assess the likelihood that the three point mutations (E59N-R119L-E339V) in 
hCGL could generate a novel T cell epitope (i.e. generate a peptide fragment with affinity 
to MHC II) we compared the computationally predicted MHC(II) binding scores 
(consensus method) for  peptides containing each mutated residue relative to the 
corresponding wild type sequence for 8 of the most common HLA alleles that 
collectively cover nearly 95% of the human population (80) The consensus percentile 
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rank (CPR) score ratios indicated no significant change in predicted MHCII binding  
suggesting that the E59N-R119L-E339V  mutations are unlikely to introduce neo-









Table 6: Computational comparison of T-Cell epitopes. 
 
2.3.8 Pharmacological Optimization  
 
To investigate the therapeutic efficacy of hCGL-NLV in vivo, the enzyme was 
PEGylated by conjugation to methoxy PEG succinimidyl carboxymethyl ester, MW 
5,000 Da at an 80:1molar ratio (80 PEGs per subunit).  Initial tests using PEG:enzyme 
ratios of 10:1, 20:1, 40:1, and 80:1 showed the greatest homogeneity at an 80:1 ratio 
(Figure 5). PEGylation has been extensively exploited to increase the hydrodynamic 
radius of proteins, preventing renal filtration and in turn markedly increasing circulation 
Computational comparison of T-cell epitopes in WT hCGL and 
the hCGL-NLV variant by IEDB consensus method 
 Allele WT:E59N WT:R119L WT:E339V 
HLA-DRB1*01:01 1.1 1.2 1.3 
HLA-DRB1*03:01 0.8 0.7 1.4 
HLA-DRB1*04:01 1.6 1.2 1.2 
HLA-DRB1*07:01 1.4 1.0 1.9 
HLA-DRB1*08:01 1.1 1.4 1.0 
HLA-DRB1*11:01 1.3 0.7 1.0 
HLA-DRB1*13:01 1.0 1.0 2.1 
HLA-DRB1*15:01 1.1 1.4 1.9 
Average 1.2 1.1 1.5 
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persistence; note that PEGylation significantly increased the circulation t1/2 of the 
structurally homologous pMGL in mice and primates (65).  To prevent inactivation 
during PEGylation it was essential to pre-incubate the enzyme with 10 mM pyridoxal 
phosphate (PLP), to avoid conjugation of K212 to the PEG succinimidyl ester. Analytical 
size exclusion chromatography of the resulting PEG-hCGL-NLV gave a single 
homogeneous peak with an apparent MW of 1,300 KDa per tetramer, a 6-fold increase 
from unmodified tetramer (Figure 6).  PEG-hCGL-NLV displayed L-Met degradation 
kinetics identical to those of the unmodified hCGL-NLV with kcat = 7.8 ± 0.4 s
-1, KM = 
13.5 ± 1.5 mM and a t1/2 = 39 ± 2 hrs in pooled human serum (Figure 7).  The specific 
activity of PEG-hCGL-NLV was 10 U/mg protein at 37 ºC and pH 7.3 and had an 
endotoxin level of ≤ 12.5 EU/mg as assessed by Limulus Amebocyte Lysate assay (The 
endotoxin received by the mice was >> 2 orders of magnitude fold lower than doses 





Figure 5: SDS-PAGE gel of PEGylation. hCGL-NLV ( Lane 1), Lanes 2-5: hCGL-NLV  after 




Figure 6: (a) Analytical size exclusion chromatography of MW standards (●), hCGL-NLV (□) 
and PEGylated hCGL-NLV (○).  (b) Pharmacodynamics of PEG-hCGL-NLV in balb/c mice 
maintained on a Met(-)Hcyss(-)Chl(-) diet.   Mice (n=5) were treated with 200 U PEG-hCGL-
NLV administered by tail-vein injection and blood methionine level (○) was monitored by HPLC. 
(c) In vivo activity of PEG-hCGL-NLV (○) and unPEGylated hCGL-NLV (●) in serum as a function 




Figure 7: Stability of (o) PEG-hCGL-NLV incubated in pooled human serum at 37 ○C with an 
apparent     t1/2 = 39 ± 2 hrs. 
 
2.3.9 In Vitro Cytotoxicity & In Vivo Half Life of PEG-hCGL-NLV    
 
The cytotoxicity of PEG-hCGL-NLV towards 14 neuroblastoma (NB) lines 
established to be L-Met dependent (46) was compared to that of pMGL 
(The myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN) 
amplification (83) status, anaplastic lymphoma kinase (ALK) mutation (84) status, and α-
thalassemia/mental-retardation-syndrome-X-linked (ATRX) mutation (85) status and IC50 
values are summarized in Table 7).  While PEG-hCGL-NLV has a lower kcat/KM than 
pMGL for L-Met, its much higher stability  in serum and in growth media led to nearly 
 33 
identical IC50 values with an average of 0.091 ± 0.043 U and 0.086 ± 0.037 U, 
respectively.  In Balb/c mice (n=5) maintained on a L-Met(-)Homocysteine(-)Choline(-) 
diet, tail vein administration of 200 U PEG-hCGL-NLV led to a decrease in the serum L-
Met concentration from 124  37 μM (pretreatment) to 3.9 ± 0.7 µM at 8 hr post-
injection.   Maintaining the animals on a Met(-)Hcyss(-)Chl(-) diet during treatment is 
necessary due to the high metabolic rate of mice which leads to rapid replenishment of 
the serum L-Met pool following depletion(46, 64).  (It is not yet known if L-Met 
depletion therapy in humans will necessitate that the patients are placed on L-Met-
deficient diet. The serum L-Met replenishment rate in man is estimated to be roughly 2 
µM/hr (est. from Ref (37)) compared to ~ 4 µM/hr in mice (est. from Ref (86)) . An L-
Met deficient diet would likely augment a treatment regimen but may not be necessary 
with an enzyme displaying a good PK/PD profile).   In mice treated with PEG-hCGL-
NLV, the serum L-Met was maintained at a therapeutically relevant level for at least 30 hr 
(Figure 6b).  This is on par with various formulations of  PEGylated-pMGL which have 
been reported to maintain serum L-Met levels in mice at <5 M for 8 hrs in one study 
(86) to 48 hrs in an earlier report (69). The PEG-hCGL-NLV activity in the blood of the 
injected mice decreased with a t1/2 of 30 ± 3 hr (Figure 6c), much longer than non-




Table 7: Inhibition of in vitro proliferation of various neuroblastoma cell lines. 
 
2.3.10 Therapy of established NB Xenografts 
 
Athymic mice bearing LAN-1 neuroblastoma tumor xenografts were treated with 
100 Units PEG-hCGL-NLV, administered via tail vein injection once daily for 3 times a 
week for 4 weeks.  Met(-)Hcyss(-)Chl(-) diet was fed to the animals on the days of PEG-
hCGL-NLV administration.   Xenografted control mice were either fed a constant normal 
diet or a Met(-)Hcyss(-)Chl(-) diet 3 times a week for 4 weeks using an identical schedule 
as in the treatment group.  24 hr after the third PEG-hCGL-NLV injection during the last 
(4th) week of treatment, plasma methionine concentration was 6  2 μM among PEG-
hCGL-NLV-treated mice fed Met(-)Hcyss(-)Chl(-) diet, in contrast to 124  37 μM 
before treatment (n=10).  Mice fed Met(-)Hcyss(-)Chl(-) diet exhibited a 10 - 15% 
PEG-hCGL-NLV pMGL
Cell lines MYCN  amplification
ALK or ATRX 
mutations
IC50 (U) Average of 2 exp. IC50 (U) Average of 2 exp.
BE(1)N Amplified Wild type 0.039± 0.009 0.042 ± 0.007
BE(2)N Amplified Wild type 0.076 ± 0.004 0.074 ± 0.008
BE(2)S Amplified Wild type 0.076 ± 0.035 0.075 ± 0.038
BE(2)C Amplified Wild type 0.063 ± 0.004 0.061 ± 0.005
SK-N-LD Amplified Wild type 0.074 ± 0.021 0.100 ± 0.050
NMB-7 Amplified Wild type 0.067 ± 0.018 0.080 ± 0.021
SH-EP-1 Not amplified F1174L 0.151 ± 0.054 0.174 ± 0.086
IMR32 Amplified Wild type 0.051 ± 0.002 0.043 ± 0.005
CHP-212 Amplified Wild type 0.175 ± 0.077 0.137 ± 0.065
SKN-MM Not amplified K1329* 0.161 ± 0.052 0.111 ± 0.054
LAN-1 Amplified Wild type 0.075 ± 0.020 0.053 ± 0.006
LAI-66N Amplified Wild type 0.068 ± 0.003 0.088 ± 0.025
LAI-55N Amplified Wild type 0.073 ± 0.004 0.072 ± 0.003
LAI-5S Amplified Wild type 0.123 ± 0.035 0.099 ± 0.012
Table S6: Inhibition of in vitro  proliferation of NB cells   
IC50 (half maximal inhibitory concentration) was expressed as mean ± SD
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reversible weight loss (Figure 9). While control mice on Met(-)Hcyss(-)Chl(-) diet only 
had no significant reduction in tumor growth, the administration of PEG-hCGL-NLV 
completely inhibited the growth of the LAN-1 tumors during the treatment period 
(p<0.01, Figure 8).  Even three weeks after the last round of treatment with PEG-hCGL-
NLV, rebound tumor volume was small (0.5 fold increase), whereas in the control groups 
tumor growth increased 3- and 4-fold in mice maintained on Met(-)Hcyss(-)Chl(-) or on 
normal diet, respectively.   
 
Figure 8:  Evaluation of PEG-hCGL-NLV in athymic mice bearing LAN-1 xenografts. (□) Control 
animal group maintained on normal diet (N=10); (■) Animals maintained on                          
Met(-)Hcyss(-)Chl(-) diet (N=10); (○) animals treated with 100 U PEG-hCGL-NLV in 
combination with Met(-)Hcyss(-)Chl(-) mouse feed (N=10).  Treatment days are designated by 
(▲). Tumor growth rate was expressed as mean ± SEM (standard error of the mean) for each 
group.  * p<0.01 for the PEG-hCGL-NLV treated group relative to the two untreated groups. 
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Figure 9: Toxicity as assessed by body mass. (□) Control with normal diet (N=10);                   
(●) Met(-)Hcyss(-)Chl(-) mouse feed (N=10); (○) 100 U PEG-hCGL-NLV in combination with 





The differential susceptibility of malignant and non-malignant cells to L-Met 
starvation provides a useful therapeutic window for cancer therapy.  Even partial 
depletion solely through L-Met omission in a parenteral nutrition (TPN) regimen has been 
shown to result in tumor reductions in gastric cancer in both the rat model and in humans 
(27, 87, 88).  However, dietary restriction alone only results in ~ 40 % decrease in serum 
L-Met levels (89).  A much more significant reduction in the serum L-Met concentration, 
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resulting in drastic inhibition of tumor growth in a number of animal models (12, 68, 90, 
91), has been achieved by the administration of MGLs.  Humans do not encode an MGL 
and consequently, bacterial enzymes have been investigated as agents for L-Met depletion 
therapy.  In particular, the P. putida MGL was found to display the most favorable 
catalytic properties, having a low KM and a relatively high kcat (41, 42).  Administration 
of pMGL was shown to drastically affect the growth of human neuroblastoma, lung, 
colon, and brain tumors in mouse xenografts maintained on L-Met restricted diet (30, 33, 
46, 92).  Unfortunately, both in mice and in the non-human primate model, pMGL was 
shown to be deactivated very rapidly with a half-life of approximately 2 hr due to the loss 
of the PLP cofactor(67).   Nonetheless, pMGL given at a 90 mg/kg dose every 8 hr for 2 
weeks resulted in a steady-state depletion of plasma methionine to less than 2 µM in 
animals maintained on L-Met restricted diet.  Only mild toxicities were observed, 
manifested as decreased appetite and slight weight loss.  However, anti-MGL antibodies 
were detected after administration and an additional round of treatment with pMGL 
resulted in anaphylactic shock and death in some animals(67).   Yang et al. sought to 
increase the pharmacokinetic half-life and reduce the immunogenicity of MGL by amine 
conjugation to polyethylene glycol (PEGylation).  PEGylation of pMGL drastically 
improved circulatory persistence (≥ 36 fold) in primates and attenuated severe 
immunological responses (with anti-MGL antibody titers increasing upon repeated 
treatments), however only a marginal improvement in pharmacodynamics was observed 
(serum L-Met was maintained at <5 M for 12 hrs vs 8 hrs for the unPEGylated enzyme) 
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(65, 70).   PEGylation of bacterial and even of mammalian proteins appears to delay but 
not eliminate immune responses as evident in clinical studies of PEGylated M. arginii 
arginine deiminase (93) or pegloticase (94). 
To augment the anti-neogenic potential of systemic L-Met depletion and 
overcome the disadvantages observed with pMGL we engineered hCGL into a 
pharmacologically efficacious human methionine -lyase. Although the overall structures 
of hCGL and pMGL align with a RMS deviation of 0.8 Å they only share a 61 % aa 
sequence similarity.  Many of the differences are seen in the degree of hydrophobicity in 
the active sites which correlates with the relative hydrophobicities of their substrates. The 
hCGL-NLV is engineered  from a native human enzyme and thus it is likely to be much 
less immunogenic than pMGL circumventing problems with adverse immune responses, 
including neutralizing antibodies and anaphylactic reactions observed in earlier studies.  
L-Met depletion may be particularly attractive for the treatment of brain tumors, a 
hypothesis we plan to test in future studies using orthotopic glioblastoma mouse models 
(90).  The paucity of chemotherapeutics that can target tumors from across the blood-
brain barrier makes systemic L-Met depletion an appealing strategy for the treatment of 
tumors that arise from or metastasize to the central nervous system, both significant 
challenges in cancer treatment.    
 
2.5 MATERIALS AND METHODS 
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Construction of Synthetic Genes 
 
Overlapping oligonucleotides (IDT) comprising the coding sequence of a 6X 
histidine tag and human cystathionine-gamma-lyase or p. putida methionine-gamma-
lyase were designed to be codon-optimized for expression in E. coli. Human CGL 
contains mutiple rare E. coli codons that can interfere with expression.  Thus, in order to 
optimize protein expression in E. coli, the hCGL gene was assembled with codon 
optimized oligonucleotides designed with DNA-Works software (95). These were 
combined with dNTPs, buffer and DNA polymerase (Finnzymes) and allowed to react for 
30 cycles of 98C for 30 s, 61C for 30 s, and 70C for 1 min. A 1 µL aliquot of this 
mixture was then used as a template along with specific end primers (Forward `5-     
gatataccATGGGAGGCCATCACCACCATCATCATGGCGGGCAGGAAAAGGATGC
G and Reverse `5-
CTCGAATTCTCAACTGTGGCTTCCCGATGGGGGATGGGCCGCTTTCAGCGCCT
GATCC in another PCR reaction to amplify the full length gene.  The product was 
cleaned on a micro-column (Zymo), digested with NcoI and EcoRI, ligated into a pET28a 
vector (Novagen) and transformed into E. coli (MC1061).   
Saturation Mutagenesis Libraries 
 
Codons from the synthetic hCGL gene corresponding to AA positions E59, R119, 
and E339  were randomized using overlap extension PCR with complementary 
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oligonucleotides containing an  NNS codon scheme (N = A,C,T,G,  and S = G ,C).  
Library (A) was constructed by randomizing positions corresponding to R119 and E339 
using the previously mentioned specific end primers and the following mutagenic 
oligonucleotides, R119-For- `5-gtatggtgggaccaatNNStatttccgtcaggtggcg, R119-Rev- `5-
CGCCACCTGACGGAAATASNNATTGGTCCCACCATAC, E339-For `5-
ctgaaactgtttaccctggca-NNSagcttgggcggctttg, E339-Rev`5-
CAAAGCCGCCCAAGCTSNNTGCCAGGGTAAACAGTTTCAG, and the synthetic 
gene as a template.  Library (B) was constructed by randomizing positions corresponding 
to R119 and E59 using a new template gene that had incorporated a codon for Val at 
position 339, specific end primers, the aforementioned R119 mutagenic primers and 
mutagenic oligonucleotides E59-For `5-ggccagcatagcggttttNNStatagccgtagcggc and E59-
Rev `5-GCCGCTACGGCTATASNNAAAACCG-CTATGCTGGCC. Following 
digestion with NcoI and EcoRI restriction enzymes, the randomized genes were ligated 
into pET28a previously digested with NcoI and EcoRI.  After ligation, plasmids were 
transformed into E. coli BL21 and transformants were screened as described above.  
Clones displaying activity were identified by sequencing, re-transformed into E. coli 
BL21, purified and kinetically characterized.  
Construction of hCGL-E339V variant 
 
In order to characterize the effect of an individual mutation on the ability to 
degrade L-Met we generated a singly mutated clone with the E339V mutation. (We only 
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isolated doubly mutated variants through our screens such as hCGL-R119L-E339V.) 
Overlap extension PCR was used to replace the mutated 119 codon for the wild-type 




were combined with dNTPs, buffer and DNA polymerase (Finnzymes) and allowed to 
react for 30 cycles of 98°C for 30 s, 61°C for 30s, and 70°C for 1 min. A 1 μL aliquot of 
this mixture was then used as a template along with specific end primers (Forward `5-  
gatataccATGGGAGGCCATCACCACCATCATCATGGCGGGCAGGAAAAGGATGC
G and Reverse `5-
CTCGAATTCTCAACTGTGGCTTCCCGATGGGGGATGGGCCGCTTTCAGCGCCT
GATCC) in another PCR reaction to amplify the full length gene. The product was 
cleaned on a micro-column (Zymo), digested with NcoI and EcoRI, ligated into a pET28a 
vector (Novagen) and transformed into E. coli (MC1061). 
Protein Expression and Purification-  E. coli (1 L scale) 
 
 E.coli-BL21 cells harboring plasmids with a given enzyme gene were grown in 
TB media containing 50 g/ml kanamycin at 37C to an OD600 of ~ 0.5 upon which time 
IPTG was added to a concentration of 1 mM.  After an additional  ~ 12 hr of incubation 
at 25C, cells were collected by centrifugation, re-suspended in immobilized metal 
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affinity chromatography (IMAC)  buffer (10 mM NaPO4/10 mM imidazole/300 mM 
NaCl, pH 8) and lysed by a French pressure cell.  The lysates were centrifuged at 14,000 
x g for 30 min at 4C, the resulting supernatant applied to a nickel IMAC column, 
washed with 10-20 column volumes of IMAC buffer, and eluted with IMAC elution 
buffer (50 mM NaPO4/ 250 mM imidazole/ 300 mM NaCl, pH 8). All chromatography 
was performed at 4○C.  Eluted enzyme was then incubated with 10 mM pyridoxal-5’-
phosphate (Sigma) for 30 min to 1 hr at 25C.  Using a 10,000 MWCO centrifugal filter 
device (Amicon), protein was then buffer exchanged into a solution comprised of 1X 
Phosphate Buffered Saline (PBS), 10 % glycerol, pH 7.4.  Aliquots of purified enzyme 
were then flash frozen in liquid nitrogen and stored at -80C.   
To determine protein concentrations, extinction coefficients, were calculated 
based on amino acid sequence  (280 = 29,870 M
-1cm-1 for hCGL, 22,330 M-1cm-1 for 
pMGL) (96).  All protein concentrations were determined from the absorption at 280 nm 
(A280) in 6 M guanidinium hydrochloride, 20 mM phosphate buffer, pH 6.5.  
Protein Expression and Purification-  E. coli (50 mL scale) 
 
Cultures (50 ml) of E.coli expressing hCGL variants were grown in 125 ml shake 
flasks and induced for protein synthesis as described previously(5 ml scale purification). 
5 ml aliquots were centrifuged and the resulting cell pellets were lysed with 400 L of B-
PER protein extraction reagent (Pierce, Rockford IL) and centrifuged. (50 ml scale 
cultures had better expression levels, and the remaining 45 ml culture pellets were frozen 
 43 
for later use) The soluble fractions were then mixed with 500 L IMAC lysis buffer and 
100 L of IMAC beads (Talon, Mountain View CA) in a 1.5 ml Eppendorf tube.  After a 
2 min incubation, the suspensions were centrifuged at 3000 rpm for 20 s in a table top 
centrifuge.  The supernatants were discarded and enzyme-bound beads were washed with 
4 x 1 ml lysis buffer by mixing/centrifuging and discarding the supernatant.  Proteins 
were then eluted from the beads by addition of 300 L of IMAC elution buffer followed 
by another centrifugation step. The elutions were quantified by measuring A280, and 
purity was assessed by SDS-PAGE.  This method allows purification of 12–16 proteins in 
~ 2 hrs with a yield of 50 – 300 g protein with the purity varying between 80 – 95 % as 
assessed by SDS-PAGE. 
Kinetic Assays 
 
Kinetic analyses were performed as described elsewhere (75) to measure α-
ketobutyrate production by reaction with 3-methyl-2-benzothiazolone hydrazone 
hydrochloride (MBTH) to generate a chromophore with a max of ~ 320 nm. Eppendorf 
tubes (1.5 ml) containing 220 L of substrate in a 100 mM sodium phosphate buffer, 1 
mM EDTA (pH 7.3), and 10 µM PLP were incubated at 37°C in a heat block.  Reactions 
were started by adding 20.3 L of enzyme solution and quenched with 26.7 L of 50% 
trichloroacetic acid after a set length of time (without shaking).  Reactions and blanks 
were then mixed with 733 L of MBTH solution (2.2 ml: 1.6 ml of 1 M acetate buffer pH 
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5.0 and 0.6 ml of 0.1% MBTH in same) and incubated at 50°C for 40 minutes. After 
cooling, the samples were transferred to cuvettes and the A320 nm was determined. The 
assay was shown to be linear between 0 - 320 M α-ketobutyrate with a lower detection 
limit of 15 M.  One unit of MGL activity was defined as the amount of enzyme that 
produced 1 mol of -ketobutyrate per minute at infinite concentration of L-methionine.  
We also followed enzyme reactions in a continuous assay by detection of product 
methane-thiol with 5,5'-Dithiobis(2-nitrobenzoic acid) (DTNB) using 96-well plates and 
a microtiter  plate reader set at 405 nm.  
96-well plate screen 
 
  Both MGL and CGL produce -ketobutyrate from their respective substrates.  
The aforementioned colorimetric assay was adapted to a 96-well plate scale for screening 
small libraries and for ranking clones with the greatest L-Met degrading activity.  Single 
colonies of E. coli BL21(DE3), containing plasmids encoding either wild-type (pMGL of 
hCGL control) or variant hCGL enzymes were picked into 96-well culture plates 
containing 75 L of TB media/well and 50 g/ml kanamycin.  Cells were grown at 37 °C 
on a plate shaker to an OD600 of ~0.8–1, cooled to 25 °C, whereupon an additional 75 L 
of media containing 50 g/ml kanamycin, and 2 mM IPTG were added and incubation 
with shaking was continued for 2 hrs at 25 °C.   Subsequently, 100 L of culture/well 
were transferred to a fresh 96 well plate (assay plate).  The assay plates were centrifuged 
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(10 min x 3,500 g) to pellet the cells, the media was removed, and the cells were 
chemically lysed by addition of 50 L/well of B-PER protein extraction reagent (Pierce, 
Rockford IL) and mixing for  5 min on a plate shaker.  Then 20 uL of 5 mM L-Met at pH 
7.3 was added to the lysates and incubated at 37○C for approximately 12 hours. The -
keto acid reaction product is then derivatized by addition of 146 L of MBTH solution to 
54 L of reaction and heated for 40 min at 50°C. The absorbance at 320 nm was 
determined spectrophotometrically using a microtiter plate reader.  Variants exhibiting 
high absorbance values and indicative of production can thus be identified and selected 
for further characterization. 
L-Met Inhibition of hCGL 
 
We measured the rate of L-cystathionine (1 mM) hydrolysis by hCGL in the 
presence of varying concentrations of L-Met ( 0-20 mM).  The reactions were conducted 
at 25°C by mixing 5 μL enzyme (20 µM) with 95 μL of a solution of 1 mM cystathionine 
and either 0 or 20 mM L-Met in 100 mM sodium phosphate buffer with 1 mM EDTA and 
10 µM PLP at pH 7.3.  Ellman’s reagent was used to quantify product formation by the 




We used software from the Immune Epitope Database (IEDB) (consensus method 
for MHC(II) binding) (97) to evaluate peptides spanning 9 residues on either side of  the 
WT or the mutated position (i.e. pos. 59,119, 339).  Using the averaged consensus 
percentile rank (CPR) scores for the 8 most common HLA alleles as reported previously 
(98) we then calculated the ratio of the predicted CPR scores for each WT:mutant peptide 
for each HLA allele.  
WST8 Assay for NB Cell Proliferation 
 
In vitro proliferation of NB cell lines was assayed in 96-well plates (BD 
Biosciences, Bedford, MA). Twenty-four hours after seeding at a density of 3000-6000 
cells/well, PEG-hCGL-NLV and pMGL were added.  After 3 days of culture, PEG-
hCGL-NLV and pMGL were removed and  fresh medium  was added for another 36 hr 
incubation because methioninase activity interferes with WST8 assay). WST8 (Dojindo 
Molecular Technologies, MA) was added to culture wells at volume ratio of 1:10. After 
4-6 hr of reaction, optical density (OD) was read at 450 nm. Cell proliferation was 
calculated as follows: % Cell Growth = (OD450 of experimental well - OD450 of medium-
only well)/(OD450 of control well - OD450 of medium-only well)  100%.  IC50 (half 
maximal inhibitory drug concentration) was calculated using SigmaPlot 8.0 (Systat 
Software, Inc., San Jose, CA). 
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In vitro half lives 
 
In vitro half– life of PEG-hCGL-NLV activity was assayed by incubating PEG-
hCGL-NLV in RPMI medium containing 10% calf serum at 37C. Additionally purified 
enzymes were also added to pooled human serum (Innovative, Novi MI) at a 
concentration of 20 M and incubated at 37C.  At various time points, aliquots were 
withdrawn and tested in triplicate for their ability to hydrolyze L-Met (10 mM).  Data 
were plotted as observed reaction rate vs. time and fit to a single exponential equation to 
calculate t1/2 values. 
Serum Stability 
 
Purified enzymes were added to pooled human serum (Innovative, Novi MI) at a 
concentration of 20 M and incubated at 37C.  At various time points, aliquots were 
withdrawn and tested in triplicate for their ability to hydrolyze L-Met (10 mM).  Data 
were plotted as observed reaction rate vs. time and fit to a single exponential equation to 
calculate t1/2 values. 
Pharmacological Optimization of hCGL Variants 
 
Human CGL variants were conjugated to lysyl residues using methoxy PEG 
succinimidyl carboxymethyl ester of MW 5000 (PEG-5K) (JenKem, Inc.).   Purification 
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was performed as described above, with inclusion of an additional on column wash step 
using 100 column volumes of IMAC buffer containing 0.1% Triton X114 (Sigma, MO) 
in order to remove endogenous endotoxin. Purified proteins were then buffer exchanged 
into 1X PBS using a 10,000 MWCO filtration device (Amicon).  PEG-5K was added at 
an 80:1molar ratio to enzyme and allowed to react for one hour at 25° C in glass vials 
with gentle stirring.  PEGylated hCGL variants were extensively buffer exchanged using 
a 100,000 MWCO centrifugal filter device (Amicon) into storage buffer (PBS made 10% 
v/v with glycerol).  Aliquots of PEGylated enzyme were flash frozen in liquid nitrogen 
and stored at -80C.  All PEGylated enzymes were analyzed for lipopolysaccharide (LPS) 
content using a Limulus Amebocyte Lysate (LAL) kit (Cape Cod Incorporated). 
Methionine Depletion in mouse plasma 
 
Methionine levels were measured according to the method of Sun et al (99) with 
minor modifications. 15 μl acetonitrile was added to 5 μl plasma samples, mixed, and 
centrifuged at 14000 rpm for 2 min at 4C. 10 μl supernatant was transferred to an 
Eppendorf tube. 5 μl OPA (o-phthaldialdehyde)  solution (Sigma-Aldrich) was added, 
mixed, and incubated at room temperature for 90 sec. 150 μl 0.1 M sodium acetate (pH 
7.2) was added. After mixing, the OPA–derivatized samples were loaded (50 μl sample 
volumes) immediately on a SupelcosilTM LC-18 DB column (particle size 5mm, 25cm  
4.6mm, 120 Å pores) for HPLC analysis. Solution A for HPLC was prepared with 
tetrahydrofuran/methanol/0.1M sodium acetate (pH 7.2) at volume ratios of 5/95/900. 
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Solution B for HPLC was methanol. The elution gradient for HPLC was as follows: (1) 0 
- 5 min: 40% solution B; (2) 5 - 10 min: 40-46% solution B; (3) 10 - 20 min: 46-48% 
solution B; (4) 20 - 25 min: 48-60% solution B; (5) 25 - 26 min: 60-100% solution B; (6) 
26 - 30 min: 100% solution B; (7) 30 - 31 min: 100-40% solution B; and (8) 31 - 35 min: 
40% solution B.  At a flow rate of 1 ml/min, total running time was 35 min. Fluorescence 
detection by in-line spectrophotometer (Waters, Milford, MA) was set at the wavelength 
of 350-450 nm and Gain = 1. Amino acid standard H solution (Pierce Chemicals) was 
used for methionine quantification and methionine from Sigma-Aldrich was used to 
characterize the methionine peak.  
Mouse Feed 
 
The Met(-)Hcyss(-)Chl(-) mouse feed, purchased from Dyets (Bethlehem, PA) 
was methionine, choline and DL-homocystine deficient. 
Hydropathy Calculations 
 
Using structural alignments of hCGL (3COG) and pMGL (2O7C) as a guide we 
identified residues in the active site within 5-6 Å of a covalently bound inactivator, 
propargylglycine.  We found that F58, L62, C116, A119, and V339 were unique to the 
pMGL active-site whereas in hCGL these residues correspond to E59, S63, G116, R119, 
and E339 respectively.  By convention, the relative hydropathy of a solute is described by 
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the logarithm of its octanol water partition coefficient (LogP).  Using ChemAxon 
software we calculated the LogP values of each of the aforementioned residues with their 
 amino and carboxy termini in the amide form (100). (We used this method because the 
LogP values are in good agreement with available experimental values and allowed us to 
estimate LogP values for compounds without known reference values like L-
cystathionine) We also calculated the active site LogP values for three hCGL variants, 
hCGL-E339V, hCGL-R119L -E339V, and hCGL-E59N-R119L-E339V - (hCGL-NLV).  
These LogP values were summed for each enzyme to calculate an overall hydropathy 
value for each active site and plotted against the Log kcat/KM values for each enzymes 
ability to hydrolyze L-Met and L-cystathionine (This is similar to an analysis of lipase 
performed by Hirata et.al. (101)). We also calculated the LogP values for the substrates 
L-Met, L-homocysteine, L-Cys, and L-cystathionine. 
Tumor Cell Lines    
 
NB cell line LAN-1 was obtained from Dr. Robert Seeger (Children’s Hospital of 
Los Angeles; Los Angeles, CA), NB cell line NMB-7 from Dr. Liao of McMaster 
University (Hamilton, ON, Canada). SK-N-BE(1)N, SK-N-BE(2)C, SK-N-BE(2)N, SK-
N-BE(2)S, LAI-5S and SH-EP-1, 55N and 66N were kindly provided by Dr. Robert Ross, 
Fordham University (New York, NY).  NB cell lines SK-N-LD and SK-N-MM were 
established at Memorial Sloan-Kettering Cancer Center (MSKCC, New York, NY).  
IMR-32 and CHP-212 were purchased from American Type Culture Collection 
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(Manassas, VA). Cells were cultured in RPMI with 10% fetal calf serum (F10) as 
previously described (102). 
In vivo half-lives   
 
hCGL-NLV and PEG-hCGL-NLV activity was assayed on sera following 
injection of 50 U of enzyme in nude mice.  Serum samples were obtained at 1, 2, 4, 8, 24, 
50, and 120 hours after injection. Half-lives of enzymatic activity was calculated by 
SigmaPlot using the exponential decay equation (y = ae-bx).   
Therapy of established NB Xenografts 
 
All animal experiments were carried out according to an Institutional Animal 
Care and Use Committee (IACUC) approved protocol at Memorial Sloan-Kettering 
Cancer Center, following institutional guidelines for the proper and humane use of 
animals in research. Athymic female nude mice were purchased from the National 
Cancer Institute.  Mice with 5-10 mm established tumors were randomly separated into 
groups of 10 mice each.  In mice xenografted with LAN-1 neuroblastoma, 100 Units of 
PEG-hCGL-NLV was given iv three times a week for 4 weeks. 0.5 cm -1 cm tumors are 
generally regarded as standard for tumor therapy studies since Institutional Animal Care 
and Use Committee (IACUC) requirement stipulates that mice with tumor that is >15% 
body weight (or 2 cm maximal tumor diameter) causes undue distress and animals have 
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to be sacrificed.  Tumor volume was calculated as (a2b)/2 where a is the width of the 
tumor (small diameter), and b the length (large diameter), both in millimeters (103).  All 
of the tumors were growing at the time when the treatment was started and all of the mice 
finally died of tumor when the treatment was stopped.  There were no spontaneous 
regressions in this experiment and in this tumor model.  Met(-)Hcyss(-)Chl(-) diet was 
fed to the animals on the days of PEG-hCGL-NLV administration.  Mice were bled 24 hr 
after the third PEG-hCGL-NLV injection during the last week of treatment. The weight 
of mice was measured twice weekly and normalized to the weight at day 0 (start of 
experiment) and used as an index of toxicity.  A 20% maximum weight loss was used as 
a guideline in designing PEG-hCGL-NLV dosing, and none of the mice required 
sacrificing because of toxicity.  Tumor size was measured twice per week and expressed 
as mean ± SEM (standard error of the mean) for each group.  Mice were sacrificed when 
their tumor sizes exceeded 20 mm in diameter. 
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Chapter 3: Augmenting hMGL Activity through Phylogenetic Analysis 
 
3.1 CHAPTER SUMMARY 
 
Many decades of research support the cancer treatment strategy of L-Met 
depletion. When the serum pool of this amino acid is enzymatically degraded, many 
tumors are unable to survive. Normal cells, however, are generally able to withstand the 
absence of L-Met and the differential requirements between normal tissues and cancer 
present an attractive therapeutic opportunity. We have previously shown that the human 
CGL can be engineered into a proficient L-Met degrading enzyme with the addition of 
three mutations established by rational design and saturation mutagenesis (CGL-NLV 
kcat/KM 0.56 s
-1mM-1). The resulting enzyme was able to induce cell death in a variety of 
neuroblastoma cell lines and retard Lan-1 neuroblastoma tumor growth in a mouse 
xenograft. The dosage required to achieve the efficacy result, however, was impractically 
high and helped define the threshold activity necessary for a viable therapeutic as 10 
times faster than CGL-NLV. We describe the utility of phylogenetic analysis as a method 
to identify critical residues for engineering a variant with improved L-Met degradation 
kinetics. The resulting enzyme “Variant 9” has a kcat/KM 5.3 s
-1mM-1 and a selectivity that 
is 9 fold higher for L-Met than for the wild-type substrate cystathionine.  This second-
generation enzyme also displays improved structural stability and a slow rate of 
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inactivation in serum. Finally, mice treated with a therapeutically useful dose of Variant 9 




3.2.1 Phylogenetic Analysis as a Tool of Protein Engineering 
 
We had previously engineered an enzyme with novel L-Met-degrading activity by 
analyzing structural overlays of a bacterial methionine--lyase and the human 
cystathionine--lyase to identify residues critical for substrate binding (Chapter 2, (53)). 
The resulting “first generation” engineered enzyme degraded L-Met with a kcat/KM of 
0.56 s-1mM-1 (NLV).   However, the catalytic activity of this enzyme was 100 fold slower 
than the kcat/KM of the P. pseudomonas MGL that had been used earlier for L-Met 
depletion in animal studies, but had the significant advantage of a 15 fold better half-life 
in vivo and in vitro. The improved half-life in turn translated into lower IC50 values in 
vitro with several cell lines. Treatment with NLV also reduced serum L-Met levels to < 5 
µM and had a significant (p < 0.01) effect on retardation of tumor growth of Lan-1 
neuroblastoma xenografts. The mice received a dose of 500 mg/kg and were fed a L-Met-
free diet on treatment days to minimize resupply of L-Met. Murine metabolism is much 
faster than human (37, 57, 64) so L-Met resupply from the diet can be expected to play a 
less significant role in the clinic. Nonetheless, the dose required is impractically high and 
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would pose a challenge in both formulation and cost as a therapeutic. We therefore set 
out to improve kinetics by additional engineering and set a benchmark of 10 fold higher 
kcat/KM against L-Met as the target catalytic proficiency activity. 
  The Ellington group has extensive experience engineering proteins based on 
phylogenetic analysis. We evaluated this approach in collaboration with Dr. Wayne Lu. 
Phylogenetic analysis takes advantage of the evolutionary history of two or more paralog 
enzymes that likely originated from a single ancestral protein. Though these paralogs 
may have evolved different substrate specificities, we expect them to have similar protein 
folds, defined amino acid conservations, and notable residue differences at key positions 
across sub-families (104-106). The human CGL shares 61% amino acid similarity and a 
high degree of structural homology with the P. putida bacterial MGL (Chapter 2). MGL 
and CGL both belong to the -family of pyridoxal phosphate (PLP) dependent enzymes 
and can be assumed to have shared an ancestor in their evolutionary history. We aligned 
the sequences of a set of both eukaryotic cystathionine--lyases and bacterial methionine-
-lyases from a variety of organisms. As shown in Figure 1, residues can fall into four 
different categories in the alignment: conserved across both sub-families shown in the 
phylogenetic tree, not conserved, conserved within each sub-family but different between 
them, and conserved within just one sub-family or the other. Conservation across all 
enzymes at a given position identifies that residue as necessary for structure or for 
general -lyase reaction activity. Alignment categories 2-4 in Figure 1 identify residues 
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that are specific to L-Met or cystathionine activity and represent an opportunity for 
targeted mutagenesis.  
 
Figure 1: Overview of phylogenetic analysis based on the assumption that paralog enzymes 
derive from the same ancestral protein; definitions of 5 possible cases of alignment. 
 
3.2.2 Experimental Approach 
 
The application of phylogenetic analysis to the engineering of a human L-Met-
degrading enzyme consisted of four phases. In the first, a proof of concept alignment of 
the active site-associated C-terminal domain of the enzymes identified 11 target residues 
of interest. These were of the type defined as “2” in Figure 1: residues that were 
conserved within each sub-family yet different between them. Such differences likely 
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govern substrate specificity, making these positions an obvious first choice for 
mutagenesis. Individual clones with each respective mutation were generated by 
substituting the MGL residue at each position and screened by the 96 well plate method 
discussed in Chapter 2 and in the Methods section. Although variants were found with 
greater than NLV baseline activity, this simplified method of screening did not take into 
account potential cooperative interactions between different mutations. 
To account for cooperation between residues, the second phase in the protein 
engineering campaign consisted of the construction of a combinatorial library on top of 
the NLV variant by overlap extension PCR. Each residue position was allowed to be 
occupied by either the wild type CGL amino acid or the MGL consensus substitution. 
The identity of the residues was limited to these two options in order to keep the library 
size small enough to be screened by hand (211 = 2048 possible variants vs. 2011 variants 
in the case of a full saturation mutagenesis library). This library was screened by the 96 
well plate method described previously. “Winners” from the screen were sequenced, re-
transformed, expressed, purified, and tested for kinetic activity against L-Met. 
In the third phase of engineering, the scope of the alignment was extended to 
encompass the entire sequence as well as to include the identification of residues falling 
into classes 2, 3 and 4 as defined in Figure 1. This resulted in 20 additional positions 
identified and a larger library constructed and screened by the same method as in phase I.  
Finally, the fourth phase of engineering involved revisiting the previously 
mutated 59 and 119 positions by the same method of analysis. In the initial stages of this 
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project N59, L119, and V339 were selected as conferring the best L-Met degrading 
activity to the enzyme, but were chosen within the context of wild-type residues 
everywhere else in the active site. Given the changes in the active site environment 
caused by additional mutations, we investigated whether altering residues at these 
positions may enhance activity further. We generated variants with point mutations to the 
MGL equivalent residue at each position (I59, A119, V339 remained unchanged) and 
measured their Michaelis-Menten kinetics against L-Met.  
 
3.3 RESULTS  
 
3.2.1 Phase I: Proof of Concept 
 
The 11 positions initially determined to be conserved within each sub-family but 
different between them are presented in Figure 2. Variants with the mutations T311G and 
I353S were identified individually for their improved activity and were subsequently 
combined to yield a variant with 2.3 fold improved activity against L-Met as compared to 
NLV (Table 1). In the cases of all three variants (T311G, I353S, and T311G + I353S) the 
improvement in kcat/KM stemmed from a dramatic decrease in KM. The magnitude of kcat 
was reduced as well, but that reduction was insufficient to negate the KM effect. As a 
proof of concept experiment, this approach confirmed phylogenetic analysis as a 
powerful tool for further enzyme optimization.  
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Figure 2: (W. Lu) Alignment used to identify the 11 critical positions for the proof of concept 
library (red arrows). All meet Alignment Condition 2 as defined by Figure 1. 
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Figure 3: Identification of Variants 1-9 and their respective mutations. 
 
 
Table 1: Kinetic parameters for reaction with L-Met for Variants 1, 2, 3 (as defined by Figure 3) 




Table 2: Kinetic parameters for Variants 1-9 with L-Met and cystathionine. 
 
3.2.2 Phase II: Combinatorial Library 
 
The 11 positions which were found to be occupied by two different amino acids in 
the phylogenetic analysis were introduced in a combinatorial fashion to construct a 
library to investigate cooperative interactions. After screening ~4000 clones, 34 were 
identified as having a detectable signal in the screen, the top 10 of which were chosen for 
subsequent purification and characterization. From these, one variant was selected for the 
best kinetic parameters. This variant contained both the T311G and I353S mutations 
identified previously as well as the additional mutation K268R (variant 5 in Table 2). 
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Interestingly, the small improvement in kcat/KM for this enzyme came exclusively from a 
doubling of kcat, with this variant having a slightly worse KM than the previous.  
3.2.3 Phase III: Comprehensive Alignment  
 
The new NLRGVS variant served as the starting point for the next round of 
engineering. A comprehensive phylogenetic analysis was performed on the full-length 
eukaryotic CGLs (16 enzymes), bacterial MGLs (18), as well as a collection of bacterial 
CGL enzymes (8). Sixty seven positions were initially identified as potential mutagenesis 
targets and were further narrowed down by proximity to the active site to reduce the 
theoretical library to a more manageable size. The twenty positions ultimately chosen 
were: Q49F, P52A, G53E, H55G, S63L, L91M, A92G, T94S,D112T, G116C, W155Y, 
T160A, S218G, M222A, Q240K, N241D, O247L, Y317E, E349Q, and A357S. In order 
to rule out expression effects in a 96-well plate screen, these variants were generated 
individually and their respective enzymes expressed and directly purified by Ni-NTA 
chromatography. At low substrate concentrations, Michaelis-Menten kinetics are linear 
and the slope of a line through the data should be equivalent to the value of kcat/KM for the 
enzyme. Therefore, these variants were tested at a range of low L-Met concentrations and 
compared. Three of these mutations resulted in improved activity:  S63L, L91M and 
Y317E. These three variants were further subjected to detailed kinetic analysis to 
determine their kcat and KM values against L-Met and Y317E was discarded as having 
worse kinetics. In the case of S63L (NLLRGVS), the mutation slightly elevated KM but 
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significantly improved kcat while the L91M mutation (NMLRGVS) improved KM at the 
expense of kcat (Table 3). When these two mutations were combined, the resulting variant 
(NLMLRGVS) exhibited the benefits of both a lowered KM and an increased kcat, 
resulting in an overall improvement of 6.4 fold in kcat/KM over NLV.  
 
 
Table 3: Kinetics parameters with L-Met of Variants 1, 5, 6, 7 and NMLRGVS (Variant 5 NLRGVS 
+ L91M) 
 
3.2.4 Phase IV: Reevaluating Previous Residues 
 
In the initial stages of this project N59, L119, and V339 were selected for the best 
L-Met degrading activity, but were chosen within the context of wild-type residues 
elsewhere in the active site. Given the changes to the active site environment introduced 
by additional mutations, we questioned whether different residues at these positions 
would yield greater activity. Sequence alignment defined the most common equivalent 
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MGL residue at the 59, 119, and 339 positions (Figure 4). As evident from this 
alignment, the 339 position residue in NLV had already been optimized. Isoleucine and 
alanine at positions 59 and 119, respectively, were significantly different from the 
asparagine and leucine previously identified in our selection, motivating the investigation 
of these variants.  We found that these two mutations did improve kcat/KM to a small 
degree individually and significantly improved it when combined (Table 4). The 
asparagine to isoleucine substitution in particular served to lower the KM of the enzyme 
by ~20%. The resulting Variant 9 had a kcat/KM of 5.3 + 0.5 s
-1mM-1, 10 fold greater than 
the first generation NLV enzyme (Table 2). 
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Figure 4: (W. Lu) Sequence alignment at the three positions previously identified by structural 
alignment and mutated in Variant 1 NLV (59, 119, 339) used to identify target residues. Bacterial 
CGL sequences were included to identify and rule out bacteria-specific (rather than enzyme-
specific) residues.  
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3.2.5 Evaluating Mutation Requirement  
 
A human enzyme was initially chosen as a scaffold for engineering due to its low 
immunogenicity risk. Through engineering a variant that met kinetic criteria for use, we 
had introduced a total of eight mutations to the parent enzyme. With each additional non-
human residue we run the risk of generating immunogenic epitopes within the protein. 
We wanted to investigate whether we could trade an insignificant drop in activity for a 
significant reduction in the number of mutations. We therefore generated two revertant 
variants based on Variant 7 (Figure 3): M91L and R268K. Michaelis-Menten steady state 
kinetics confirmed that both mutations are required for activity within the desired range 
(Figure 5).  
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Figure 5: Michaelis-Menten kinetics for Variant 7 and its revertants at positions 91 and 268. 
*Note: Kinetic parameters for Variant 7 differ slightly from those previously reported in Table 2 
due to experimental variability. Each set of kinetic values compared for best variant identification 




Table 4: Kinetics parameters with L-Met of Variants 1, 7, 8, 9 and NLMARGVS (Variant 7 
NLRGVS + L119A) 
 
3.2.6 Enzyme Selectivity/Promiscuity 
 
In their native form, both CGL and MGL have high activity against their “target 
substrates”- cystathionine and L-Met, respectively. Although CGL catalyzes the gamma 
elimination of cystathionine and is capable of accepting the smaller cysteine and 
homocysteine as substrates, it shows no detectable activity with L-Met (Chapter 2). 
MGL, likewise, is incapable of accepting cystathionine as a substrate. An ideal 
engineered enzyme therapeutic should degrade L-Met with high selectivity in relation to 
cystathionine to mitigate any physiological side effects during treatment. We tested the 
Michaelis-Menten kinetics of a selection of variants against cystathionine (Table 2 and 
Figure 6). Mutagenesis to alter substrate specificity initially yielded highly promiscuous 
variants, but the introduction of almost every additional mutation improved the L-Met to 
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cystathionine selectivity, as defined by the ratio of their kcat/KM values (inset Figure 6). 
Particularly, with the addition of the S63L mutation (Variant 6) the cystathionine lyase 
activity fell by 70% and the selectivity for L-Met over cystathionine increased by > 3 
fold. Variant 9 ultimately had a 9 fold higher selectivity for L-L-Met over L-
cystathionine.  For comparison, the first generation Variant 1 NLV mutant only showed a 
selectivity of 0.25 resulting in an increase in selectivity of 36 fold through engineering. 
Two other substrates known to be degraded by both CGL and MGL are cysteine 
and homocysteine (structures in Chapter 2). We measured the Michaelis-Menten kinetics 
for both substrates with the same collection of variants as above (Table 6) and found that 
the activity tracked with the evolution from a wild-type cystathionine--lyase to an 
enzyme with methionine---lyase character and a higher rate of turnover of both of these 
amino acids. Notably, Variant 9 kcat/KM for cysteine is ultimately higher than that of the 




Figure 6: Activity of each significant variant with and cystathionine as defined by kcat/KM. Inset: 









In order to better understand the effects of specific mutations, we collaborated 
with the Zhang crystallography group to solve the structure of Variant 9. Important 
features of this structure aligned with the wild-type CGL (PDB file: 3COG) are presented 
in detail in Figures 7-11. The overall quaternary and tertiary structures of the engineered 
variant align with the parent enzyme.  As discussed in Chapter 2, the introduction of N59, 
L119, and V339 residue mutations increases hydrophobicity of the active site substrate-
binding pocket thus enabling the more hydrophobic L-Met to be a substrate for the 
mutant enzyme.  A reduction in the number of charged side chains around the 
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hydrophobic methyl group of are expected to further improve L-Met docking into the 
correct orientation for catalytic gamma elimination, enhance the reaction rate at the 
exclusion of the charged cystathionine substrate, and improve selectivity (Chapter 2). The 
Variant 9 mutations N59I and L119A are shown in Figures 7a and 7b, confirming the 
orientation of these new residues and their proximity to the distal end of the substrate 
analog.  
The mutations identified in the engineering campaign described in this chapter 
fall into three categories: 1st shell active site residues that are close enough to the 
substrate to directly interact with it (E/N59I, S63L, L91M, R/L119A, E339V), 2nd shell 
residues several angstroms further away from the active site (I353S), and other residues 
distant from the active site (T311G, K268R).    
 
Figure 7a: Alignment of the active site of the solved structure of Variant 9 and CGL with 
substrate analog bound (PDB: 3COG). 
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Figure 8: Additional view of mutation T311G showing its distance from the active site. 
 
 
Figure 9: Variant 9 structure details of the L91M mutation and proximity of the sulfur to both 




Figure 10: Alignment of CGL and Variant 9; I353S mutation in the context of the flexible loop 
showing conformational change. 
 






Figure 11b: Variant 9 structure details of the K268R mutation, its proximity to residues of the 
neighboring monomer chain, and its potential for hydrogen bonding. 
 
3.2.8 Structural Stability  
 
In order to ascertain that the engineering of CGL to increase catalytic activity 
towards L-Met did not negatively impact the structural stability of the enzyme, we 
determined the Tm of the most active variant isolated from the engineering campaign 
(Variant 9) by Circular Dichroism Spectroscopy and compared it to that of NLV (Figure 
12).  Variant 9 had a Tm that was 8 degrees higher than that of NLV (81C vs. 73C).  
We note that the K268R mutation introduced a guanidinium group on an extended side 
chain at this position that is in the correct orientation to hydrogen bond with the E267 
carboxylic acid functional group and the backbone carbonyl oxygens of H263 and V264 
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on the neighboring chain (Figure 11b). Arginine has been previously reported to form 
more stable surface ionic interactions than lysine due to its capability to form a larger 
number of these interactions as well as its higher pKa (107). We therefore hypothesize 
that the K268R mutation and the more stable salt bridge that results increase the overall 
structural stability and Tm of the tetrameric enzyme.  
 
 
Figure 12: Melting curves of NLV and Variant 9 (labeled IAV). The calculated Tms were: NLV 
73C, Variant 9 81C. 
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3.2.9 Serum Inactivation  
 
We evaluated whether the additional mutations in Variants 7, 8, and 9 relative to 
the NLV variant reported in Chapter 2 impact the rate at which the enzyme become 
inactivated in the presence of serum. We have previously shown that supplementation of 
additional PLP cofactor in the pooled serum/enzyme incubation significantly extended 
the half-life of the NLV variant. In the first step of the gamma elimination reaction, the 
PLP cofactor forms an external Shiff base with the substrate. Without a covalent bond to 
the enzyme, the PLP-substrate and PLP-intermediate complexes have some probability of 
diffusing out of the active site. Since serum contains significant concentrations of 
potential substrates for the enzyme, we hypothesize that an important mechanism of 
inactivation in serum is the loss of the externally bound cofactor from the active site. 
Additionally, serum albumin has been implicated in binding PLP and inactivating the 
bacterial MGL enzyme (108). It stands to reason that mutagenesis of residues around the 
PLP cofactor within the active site may have an effect on the probability of its escape. 
We have previously shown that NLV-PEG half-life in the mouse was effectively the 
same as in pooled human serum (Chapter 2).  Thus the deactivation stability of CGL 
variants in serum is likely to correlate well with stability in vivo. It was important to 
modify the enzyme with methoxy PEG succinimidyl carboxymethyl ester for in vivo 
experiments to increase the hydrodynamic radius and reduce renal clearance of the drug 
(described in the Pharmacological Optimization section of Chapter 2). We had found that 
unmodified enzyme had a much longer half-life and could not be used as a 
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physiologically representative model for the rate of inactivation in vivo. Consequently, 
purified enzyme Variants 7, 8, and 9 were modified by PEG, added to pooled human 
serum at 37C, and tested for activity at various time points. The calculated half-lives 
were compared to previously determined t1/2 values for NLV and NLV-PEG (Figure 13 
and Table 7). The apparent half-life of the variants tested was > 100 hours, significantly 




Figure 13: Serum inactivation of Variant 1 NLV with and without conjugation to PEG, PEG-
modified Variant 7 (8mutPEG), Variant 7 + N59I (8mutPEG59I), Variant 7 + L119A 
(8mutPEG119A), and Variant 9 (8mutPEG59I119A) as measured by activity against L-Met and 














Table 7: Calculated t1/2 values based on fitting the curve to exponential decay equation. 
 
3.2.10 In Vivo Pharmacodynamics 
 
In order to test how well the new drug candidates reduced L-Met levels in vivo, 
we performed a small scale PK/PD experiment in mice with PEG modified Variant 7. 
This experiment was performed before the final phase of engineering and identification 
of Variants 8 and 9. The animals were dosed once at 50 mg/kg by intraperitoneal (IP) 
injection at time zero and groups of three mice were sacrificed at 8, 24, and 48 hours 
each. Throughout the experiment, the animals had access to complete feed. Blood was 
drawn from each sacrificed mouse and allowed to clot. The serum was then drawn off 
and filtered through a 3000 Da cutoff membrane. This assures that any enzyme (active or 
otherwise) present in the sample is separated from the filtered fraction and all possible 
enzyme L-Met degradation had ceased. The filtered serum was then analyzed for L-Met 
content by reversed-phase High-Performance Liquid Chromatography. The L-Met 
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concentrations obtained were compared to the depletion achieved previously with 
NLVPEG.  
The resulting time course for both enzyme injections is compared in Figure 14. 
The mice previously treated with NLVPEG were also fed a full diet and received one 
dose of 250 mg/kg of enzyme at time zero, with L-Met levels determined at set times 
thereafter. At the 8 hour time point, the L-Met levels were an average of 18 M- much 
higher than the < 5 M target level. By 24 hours, L-Met levels had rebounded to 
approximately 60% of untreated, and by 48 hours had effectively returned to normal. In 
addition to insufficient degradation of L-Met, an obvious concern was the extremely high 
dose necessary to achieve even this modest effect.  
In vivo efficacy data in Chapter 2 was obtained with still a higher dose of 500 
mg/kg with animals maintained on a diet restricted for L-Met, homocysteine, and choline 
on treatment days (Figure 6b in Chapter 2). At this dose, an average 70 kg human being 
would have to receive a prodigious 35 grams of enzyme per injection. This is not only 
impractical to administer but would be prohibitively expensive. This rationale ultimately 
defined the criteria used in engineering the enzyme further.  
Based on the preliminary PD data, Variant 7 has sufficient activity to deplete L-
Met to desirably low levels for a useful amount of time. At a dose of only one fifth of the 
250 mg/kg tested previously for NLVPEG, the L-Met levels drop to < 5 M by hour 8, 
recover to about 15% of untreated at hour 24, and are still only 50% of untreated by 48 
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hours after injection. Experiments are ongoing to determine if Variant 9 has even better 
in vivo performance.  
 
Figure 14: Mouse serum L-Met levels after enzyme treatment at time 0 at the defined doses of 
CGL-NLV (Variant 2) and Variant 7 as measured by HPLC. The animals were fed a complete diet 
in both cases. 
 
3.3 DISCUSSION AND SUMMARY 
 
Through iterative rounds of phylogenetic analysis, mutagenesis, and selection, we 
have identified an efficient L-Met-degrading enzyme which, upon administration at a 
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dose that can be translated to a practical human therapeutic, can reduce serum L-Met to a 
level that can potentially impact tumor growth. The second generation hMGL enzymes 
(Variants 7 and 9) developed here display 7-10 fold better L-Met degrading activity than 
the first generation NLV as well as up to a 36 fold improvement in selectivity over the 
wild-type substrate cystathionine. We have shown that this enzyme is stable and capable 
of reducing murine serum L-Met levels to a therapeutically useful range without dietary 
restriction. 
3.3.1 Phylogenetic Analysis   
 
Phylogenetic analysis is a powerful tool to engineer desired characteristics into an 
enzyme by taking advantage of the observation that during evolution residues that are 
critical to function are conserved (104-106). Since protein paralogs in the same family 
share a common ancestor, residues that are conserved within their respective sub-families 
but different between them may point to positions that correspond with enzyme 
phenotype such as substrate specificity, pH optimum, temperature optimum, etc. (106, 
109-111). Identifying such  positions provides an important route to generating mutations 
that confer improved or altered protein function. 
Phylogeny based mutagenesis and protein engineering offers some important 
advantages over structure-based mutagenesis . First, many more protein sequences are 
known than structures currently available. This allows a deeper evaluation at each 
possible position by permitting the alignment of many more sequences than would be 
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available for structural analysis. Second, a structure by nature traps an enzyme in one 
static state (such as bound to inhibitor, substrate or intermediate analog, etc.). 
Phylogenetic analysis however, can identify residues important in other interactions not 
observable in the static enzyme, such as those that contribute to protein dynamics. Third, 
structural analysis is generally limited to a small sphere of residues in the immediate 
vicinity of the active site.  Phylogenetic analysis expands the search to the entire 
sequence and enables the identification of second shell and even distant positions of 
importance. Finally, phylogenetic analysis provides an opportunity to substitute residues 
in a more targeted manner by limiting the mutations to amino acids suggested by the 
alignment (rather than sampling all 20 amino acids at each position). This allows us to 
sample multiple positions concurrently and still restrict the library to a manageable size, 
directly probing possible synergistic effects between positions. 
Starting with a scaffold of CGL with three mutations (NLV) we applied 
phylogenetic analysis as a guide to iterative mutagenesis and screening to generate a 
more active enzyme. The kcat/KM of Variant 9 was 5.3 s
-1mM-1 compared to a kcat/KM  of 
0.56  s-1mM-1 displayed by the first human methionine-γ-lyase, i.e. the CGL-NLV variant 
of Chapter 2.  This second generation variant satisfied the protein engineering goal of 10 
fold improvement in kcat/KM  relative to the NLV variant. Notably, Variant 9 displays a 
slight increase in kcat (9.8 s
-1 Variant 9 vs. 7.9 s-1 NLV), and thus the main consequence of 
the protein engineering campaign was to achieve a marked decrease in KM (1.8 mM 
Variant 9 vs. 14 mM NLV). The cystathionine degrading activity of the enzyme was also 
 85 
significantly reduced resulting in a 36 fold improvement in enzyme specificity for L-Met 
over the wild-type substrate.  
These results underscore the power of phylogenetic analysis as an engineering 
technique and the advantages of what is effectively iterative mutagenesis and screening 
by evolution to arrive at residues suited for the chemistry of interest. Evolution is not a 
process with a definitive endpoint, nor can we assume that the enzymes in each sub-
family have evolved to their greatest specific substrate degrading potential (particularly 
since their selection pressures likely involve numerous other factors). Therefore, 
additional engineering and enzyme improvement should be possible, especially since the 
MGL residues grafted into CGL now exist in the context of a different environment.  
3.3.2 Active Site Residues  
 
It is possible to infer possible explanations for the activity and specificity of a 
number of the beneficial amino acid substitutions identified in the protein engineering 
campaign by examination of the alignment of the crystal structures of CGL and Variant 
9.  For example, the S63L mutation is approximately 4 Å away from the distal end of the 
substrate and the replacement of the polar serine with the very hydrophobic leucine 
renders the active site more hydrophobic and favors the binding of L-Met over 
cystathionine (Figure 7b, see also Chapter 2).  The introduction of the leucine at position 
63 results in a dramatic reduction of kcat/KM with cystathionine (from 2.1 s
-1mM-1 to 0.61 
s-1mM-1) and an increase of the selectivity of the enzyme for target vs. wild-type substrate 
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from 0.86 to 3.3. Up to this point in engineering Variants 2-5 the activity with the wild-
type substrate had remained relatively unchanged, even as the kcat/KM for L-Met 
incrementally improved. Therefore, the addition of just one hydrophobic residue in this 
section of the binding pocket appears to result in markedly improved exclusion of the 
highly polar cystathionine.  
While the S63L mutation alters the specificity of the enzyme by affecting the 
relative partitioning of the substrates into the active site, the introduction of L91M 
corresponds to an increase in activity with all amino acids tested (L-Met, cystathionine, 
cysteine, and homocysteine). It appears that this mutation increases the enzyme rate of 
chemistry indiscriminately. Inspection of the structure of the Variant 9 enzyme indicates 
that the L-Met sulfur may be in a good position to interact with both PLP and the 
substrate. Since the activity enhancement effect occurs for both gamma elimination and 
cysteine beta elimination, we hypothesize that the sulfur atom plays a role in positioning 
the PLP in an improved orientation for faster chemistry (Figure 9 and ref. (112)). 
The N59I and L119A mutations incrementally increased activity against L-Met 
and improved selectivity by also diminishing cystathionine activity. In the case of L-Met 
as substrate, the effect of the N59I substitution was to decrease KM. This may be due to 
an increase in the hydrophobicity of the binding pocket effects discussed above. The 
effect of the L119A mutation was primarily to increase the kcat. In the initial stages of 
engineering a human L-Met-degrading enzyme, the leucine at position 119 played an 
important role in modulating hydrophobicity of the binding pocket of NLV.  With the 
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introduction of additional mutations, including those also conferring greater 
hydrophobicity to the active site (N58I, S63L), the need for a hydrophobic residue at this 
position diminished (Figure 7b). Instead, we hypothesize that the removal of the bulky 
leucine side chain improves L-Met reaction kinetics by minimizing steric hindrance and 
facilitating leaving group escape.  
3.3.3 Second Shell I353S 
 
I353S is a second shell residue that is positioned somewhat further from the 
substrate binding pocket than the 1st shell residues. The introduction of this mutation 
reduces the KM and produces a twofold improvement in kcat/KM of NLV. This residue is 
part of a flexible loop and based on the solved Variant 9 crystal structure appears to 
introduce a slight twist that results in a shift in the overall loop orientation and a flip of 
another serine at the 358 position away from the entrance of the active site (Figure 10). In 
the wild-type CGL enzyme this S358 is positioned less than 5 angstroms away from the 
substrate and its repositioning may be significant for the way the substrate approaches 
and docks into the active site. However a caveat in any structural interpretation of 
mutational effects is that all crystallographic structures are static whereas enzyme flexible 
loops in solution are not, by definition.  
3.3.4 Long Distance Positions 
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T311G has the effect of reducing the KM of the enzyme by 5 fold.  While it also 
affects the kcat with a 2.5 fold reduction, the net effect is a twofold improvement in 
catalytic turnover of L-Met (kcat/KM).  The activity against cystathionine remains 
effectively unchanged. The structure of CGL and that of Variant 9 reveal that the 311 
position is too far away from the active site and substrate binding pocket to directly 
participate in static binding interactions or chemistry and must therefore be important for 
conformational effects (Figure 8). The discovery of this mutation encapsulates the power 
of the phylogenetic analysis approach since it would not have been identified without the 
sequence alignment. When combined with the I353S mutation, the resulting modest 
increase in activity suggests a small degree of synergy between the two positions. 
The K268R mutation was shown to reproducibly double the kcat, but to also 
slightly increase the KM of the enzyme. Based on structure, this residue is well positioned 
to participate in the formation of a stronger salt bridge between two monomers and has 
been implicated in the increase of the thermodynamic stability of the enzyme (Figure 
11b, and section 2.2.8, ref. (113) ). The mechanism by which this distant residue affects 
the reaction rate remains to be elucidated. 
 
3.4 METHODS  
 
Kinetic analysis using MBTH  
 
 89 
Kinetic analyses were performed as described in Chapter 2 to measure 
ketobutyrate production by reaction with 3-methyl-2-benzothiazolone hydrazine 
hydrochloride (MBTH) to generate a chromophore with a λmax of ~320 nm. Eppendorf 
tubes (1.5 ml) containing 220 μL of substrate in a 100 mM sodium phosphate buffer, 
1mM EDTA (pH 7.3), and 10 uM PLP were incubated at 37°C in a heat block. Reactions 
were started by adding 20.3 L of enzyme solution and μ quenched with 26.7 μL of 50% 
trichloroacetic acid after a set length of time (without shaking). Reactions and blanks 
were then mixed with 733 μL of MBTH solution (2.2 ml: 1.6 ml of 1M acetate buffer pH 
5.0 and 0.6 ml of 0.1% MBTH in same) and incubated at 50°C for 40 minutes. After 
cooling, the samples were transferred to cuvettes and the A320 nm was determined. The 
assay was shown to be linear between 0 - 320 μM α-ketobutyrate with a lower detection 
limit of 15 μM. One unit of MGL activity was defined as the amount of enzyme that 
produced 1 μmol of α-ketobutyrate per minute at infinite concentration of L-Met. 
96-well plate screen 
 
This screen was performed the same way as discussed in Chapter 2. Both MGL 
and CGL produce -ketobutyrate from their respective substrates.  The aforementioned 
colorimetric assay was adapted to a 96-well plate scale for screening small libraries and 
for ranking clones with the greatest L-Met degrading activity.  Single colonies of E. coli 
BL21 containing plasmids encoding either wild-type (pMGL or hCGL control) or variant 
hCGL enzymes were picked into 96-well culture plates containing 75 L of TB 
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media/well and 50 g/ml kanamycin.  Cells were grown at 37 °C on a plate shaker to an 
OD600 of ~0.8–1, cooled to 25 °C, whereupon an additional 75 L of media containing 50 
g/ml kanamycin, and 2 mM IPTG were added and incubation with shaking was 
continued for 2 hrs at 25 °C.   Subsequently, 100 L of culture/well were transferred to a 
fresh 96 well plate (assay plate).  The assay plates were centrifuged (10 min x 3,500 g) to 
pellet the cells, the media was removed, and the cells were chemically lysed by addition 
of 50 L/well of B-PER protein extraction reagent (Pierce, Rockford IL) and mixing for  
5 min on a plate shaker.  Then 20 uL of 5 mM L-Met at pH 7.3 was added to the lysates 
and incubated at 37○C for approximately 12 hours. The -keto acid reaction product is 
then derivatized by addition of 146 L of MBTH solution to 54 L of reaction and heated 
for 40 min at 50°C. The absorbance at 320 nm was determined spectrophotometrically 
using a microtiter plate reader.  Variants exhibiting high absorbance values and indicative 
of production can thus be identified and selected for further characterization. 
Site-Directed Mutagenesis  
 
QuickChange Site-Directed Mutagenesis kit (Agilent Technology) was utilized to 
generate single site-mutated hCGL variants. All oligonucleotides were optimized by the 
constraints of the kit protocol and ordered from Integrated DNA Technologies. After the 
PCR thermal cycling, the gene product was treated with Dpn I (New England BioLabs) at 
37oC for 1 hour. Finally, 4 ul of reaction was used for heat-shock transformation on 
BL21(DE3) competent cells.  
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Combinatorial Library Construction 
 
Phylogenetic analysis was performed as described within the chapter. Geneious 
analysis software was used for the sequence alignment and the source organisms for the 
enzyme sequences were as follows: eukaryotic cystathionine--lyases - human, cattle, rat, 
mouse, zebra, bacterial methionine--lyases - Ruegeria, Pseudomonas, Ferrimonas, 
Porphyromonas, Shewanella, Bacillus. Positions were identified as potentially important 
to conferring substrate specificity. Overlapping PCR was used to generate combinatorial 
library containing either the wild-type or MGL residue at each position using 
“DNAWorks” software-designed oligonucleotides (16 total). These were obtained from 
Integrated DNA Technologies and were additionally further purified by PAGE gel 
electrophoresis. After the initial PCR reaction the gene product was amplified by thermal 
cycling with gene-specific end primers. Following digestion with NcoI and EcoRI 
restriction enzymes, the randomized genes were ligated into pET28a previously digested 
with NcoI and EcoRI.  After ligation, plasmids were transformed into E. coli BL21 and 
transformants were screened as described above.  Clones displaying activity were 
identified by sequencing, re-transformed into E. coli BL21, purified and kinetically 
characterized. 
Circular Dichroism Spectroscopy 
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A 5 M sample of enzyme in a 100 mM phosphate buffer, pH 7.3 was analyzed 
on a Jasco J-815 CD spectrometer.  The change in molar ellipticity at 222 nm ( 222) was 
monitored from 25 – 90°C.  The fraction of denatured protein at each temperature was 
calculated by the ratio of [ 222]/[ 222]d where [ 222]d is the molar ellipticity of the 
completely unfolded protein.  The resulting data was fit to a modified logistic equation to 
determine the thermal transition midpoint. 
Serum Stability 
 
Purified enzymes were added to pooled human serum (Innovative, Novi MI) at a 
concentration of 20 M and incubated at 37C.  At various time points, aliquots were 
withdrawn and tested in triplicate for their ability to hydrolyze L-Met (10 mM).  Data 
were plotted as observed reaction rate vs. time and fit to a single exponential equation to 







Chapter 4: GFP Reporter Screens for the Engineering of Amino Acid 
Degrading Enzymes From Libraries Expressed in Bacteria2 
  
4.1 CHAPTER SUMMARY 
 
There is significant interest in engineering human amino acid degrading enzymes 
as non-immunogenic chemotherapeutic agents.  We have designed a high-throughput 
fluorescence activated cell sorting (FACS) assay for detecting the catalytic activity of 
amino acid degrading enzymes in bacteria, at the single cell level.  This assay relies on 
coupling the synthesis of the GFP reporter to the catalytic activity of the desired amino 
acid degrading enzyme in an appropriate E.coli genetic background.   The method 
described here allows facile screening of much larger libraries (106-107) than was 
previously possible.  We demonstrate the application of this technique in the screening of 





                                                          
2 Paley, O., Agnello, G., Cantor, J., Yoo, T. H., Georgiou, G., and Stone, E. (2013) GFP reporter 
screens for the engineering of amino acid degrading enzymes from libraries expressed in 




The screening of large libraries of enzyme variants for improved or altered 
catalytic function  generally presents a daunting challenge.  Unlike the screening of 
protein libraries for ligand binding, which can be accomplished using the same assay 
format regardless of the identity of the ligand, enzymes catalyze a plethora of reactions 
which in turn, necessitates the use of specific individualized activity assays.  Many, if not 
most, enzyme-catalyzed reactions are not easily amenable to high-throughput assays. 
This in turn limits the size of the sequence space that can be practically sampled in 
directed evolution experiments (115). 
As discussed in Chapters 1 and 2, the engineering of desired activity into human 
enzymes can yield potent therapeutics with low immunogenic response risk to patients. In 
recent years we have demonstrated the use of protein engineering strategies to develop 
human enzymes with the requisite properties for cancer therapy (116-119). High 
throughput screens target activities can greatly aid the engineering of therapeutic 
enzymes by directed evolution of human enzymes that catalyze similar reactions.  The 
development of such screens necessitates the engineering of unique E. coli strains that are 
dependent on a metabolite generated by the chemistry of interest. In this chapter we 
discuss the example of a human methionine degrading enzyme that rescues an E. coli 
strain engineered to be auxotrophic for L-isoleucine by the enzymatic degradation of L-
Met to produce -ketobutyrate (a metabolite required for synthesis of L-Ile) . In turn, this 
reaction can complement the auxotrophic strain enabling the synthesis of GFP.  Thus a 
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very active enzyme allows GFP to be translated at levels commensurate with non-
selective conditions whereas a less active or inactive enzyme results in reduced GFP 
expression due to the depleted amino acid pool in the auxotroph. FACS can then be used 
to isolate individual clones based on their fluorescence profile from large libraries of 
enzyme variants expressed in E.coli.  Employing several rounds of FACS sorting we can 
attain thousands of fold enrichment of clones with desired activity and then use a 
secondary assay method to analyze a handful of clones for the rank ordering of enzyme 
variants and assessment of kinetics. Figure 1 shows the general scheme and workflow of 





Figure 1: General method 1) Engineer E.coli strain that can no longer make a metabolic 
intermediate needed for growth. 2) Create mutagenized libraries of enzymes that have the 
potential to make the missing metabolic intermediate. 3) Co-transform auxotrophic strain with 
library and GFP plasmids that have mutually exclusive promoters. 4) Culture under non-selective 
conditions and induce expression of enzyme plasmids. 5) Shift culture to selective conditions and 
induce expression of GFP. If an enzyme variant can rescue the auxotrophy, that cell will express 
greater levels of GFP. 6) Use rounds of FACS sorting to select cells with high GFP fluorescence. 
7) Use secondary screen/assay to rank order clones and if necessary repeat mutagenesis on 
variants with increased activity. 
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4.3 BACKGROUND AND MATERIALS METHIONINE--LYASE SCREEN 
 
The non-mammalian enzyme methionine--lyase (MGL) catalyzes the ,-
elimination of L-methionine to methanethiol, -ketobutyrate, and ammonia (Chapter 1).  
MGL from P. putida has shown efficacy in controlling tumor growth in a variety of 
xenograft models (30, 32, 33, 37, 46, 65, 67, 68) but unfortunately has proven to be 
highly immunogenic in primates (45). We employed rational design and scanning 
saturation mutagenesis to convert the structurally related human enzyme cystathionine--
lyase (CGL) into a human L-Methionine γ-lyase (MGL) that catalyzes the ,-
elimination of L-Methionine to methanethiol, -ketobutyrate, and ammonia but does not 
accept L-Met as a substrate. The assay previously available to screen this class of 
enzymes is a 96-well plate colorimetric assay for -ketobutyrate production.  
4.3.1 Engineering an Isoleucine Auxotroph Rescued by Methionine Lyase Activity  
 
E.coli produces -ketobutyrate as an intermediate metabolite in the de novo 
production of L-isoleucine (L-Ile) by action of threonine deaminase (ilvA).  We thus 
deleted ilvA to create an L-Ile auxotroph that could be rescued by -ketobutyrate 
produced from L-Met degradation by MGL (Figure 2a). Additionally, because CGL can 
also produce -ketobutyrate from L-cystathionine and L-homocysteine which are 
metabolites in the E.coli pathway for L-Met production, we also deleted the metA gene 
(Figure 2b).   
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The gene deletions were performed by bacteriophage P1 transduction (120, 121). 
Keio collection donor strains (122) were incubated with P1 phage. The resulting lysate 
contained a small percentage of phage capsids carrying the bacterial chromosome. The 
DNA was transduced into the host cells and selected for successful gene knockout on 
plates with the appropriate resistance marker. The antibiotic resistance cassette 
introduced at the gene site was then removed by site-specific recombination and the 
resulting scar sequence fragment was confirmed by PCR (9). The ilvA gene deletion was 
performed first, and the resulting BL21(DE3) ΔilvA strain was used as the host for the 
second round of transduction. E.coli [BL21(DE3) ΔilvAΔmetA] was named E.coli MI-aux 





Figure 2: Metabolic pathways a) Summary of the pathway and gene deleted in E.coli needed to 
create an -ketobutyrate auxotrophic strain that can be rescued by recombinant methionine--
lyase activity.  b) Summary of the pathway and gene deleted needed to create an L-methionine 
auxotroph to prevent parental cystathionine--lyase activity from rescuing -ketobutyrate 
auxotrophy.  
4.3.2 Plasmids   
 
We used the arabinose inducible pBAD-GFP with a chloramphenicol 
acetyltransferase marker as a reporter plasmid coupled with the IPTG inducible 
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pET28a with a kanamycin resistance marker as an expression plasmid for parental 
hCGL and pMGL. 
4.3.3 Media/plates/buffer 
 
1. Non Selective Media: Enzyme expression media; M9 minimal medium 
supplemented with 0.4% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 150 μg∕mL of 
the amino acids L-Met and L-Ile, 75 μg∕mL of the remaining amino acids 
excluding L-Leu and L-Val (see Note 6), 50 μg∕mL kanamycin, and 34 μg∕mL 
chloramphenicol. 
2. Selective Media: GFP Expression Media;  M9 medium supplemented with 0.4% 
glucose, 1 mM MgSO4, 0.1 mM CaCl2, 150 μg∕mL of L-Met, 75 μg∕mL of the 
remaining amino acids (excluding L-Ile,  L-Leu and L-Val), 50 μg∕mL kanamycin, 
34 μg∕mL chloramphenicol, and 2 % arabinose. 
3. General Media: LB supplemented with 50 µg/mL kanamycin and 34µg/mL 
chloramphenicol. 
4. Plates: 2xYT agar supplemented with 50µg/mL kanamycin and 34µg/mL 
chloramphenicol. 
5. Competent cells: E.coli MI-aux harboring pBAD-GFP. 
6. Buffers/reagents: filter sterilized 0.9% NaCl (4○C), filter sterilized 1X phosphate 
buffered saline at 4 ○C (PBS), filter sterilized solution of L-Ile (250mM) in PBS, 
filter sterilized solution (1M) of isopropyl--D-1-thiogalactopyranoside (IPTG).  
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7. Culture tubes (5 ml), 1.5 mL Eppendorf tubes, 15 mL Falcon tubes, FACS tubes 
etc.  
4.3.4 Flow cytometric analyses 
 
A FACSAria (BD Biosciences) using a 488-nm solid state laser for the excitation 
of GFP. A 530/30 band pass filter was used for the detection.  
4.4          METHODS METHIONINE--LYASE SCREEN 
 
4.4.1 Cell growth and GFP expression  
 
Use your laboratories favorite methods for library construction, competent cells, 
transformations etc. 
1. Grow an overnight culture (5 mL) of E.coli BL21(MI-aux) co-transformed with 
pBAD-GFP and plasmids either a library or a single mutant in 2xYT (see Note 2). 
2. Inoculate 1 ml of Non Selective Media in a sterile culture tube with E. coli 
BL21(MI-aux) cells harboring plasmids of pBAD-GFP reporter and pET28a 
containing gene of interest to a final OD600 of 0.1. The cell source for the 
inoculation can be previously frozen aliquots or overnight cultures of either a 
single mutant or a library of variants. Make sure to include tubes for a positive 
and negative control (1 ml each) for each round if planning to sort a library.  
 102 
3. Grow cultures with shaking at 250 rpm at 37 °C to an OD600 of 0.3-0.4. 
4. Add 1M IPTG solution to a final concentration of 1 mM and shift the cultures to 
25 °C for 2 hours with shaking at 250 rpm for enzyme expression (See Note 7).  
5. Harvest the cells by centrifugation (7,000 rpm, 3 min, 4○C).  Wash the cells twice 
with cold 0.9% NaCl by re-suspending and centrifuging at 7,000 rpm, for 3 min at 
4 °C (See Note 8). Use sterile 1.5 ml Eppendorf tubes to harvest the cells and at 
least 1 ml of the 0.9% NaCl solution for each wash. 
6. Re-suspend the washed cells in 1 ml of GFP Expression Media (containing 
arabinose inducer for GFP expression). Split each 1 ml sample into two small 
culture tubes (500 L per tube) and add 250 mM L-Ile solution to a final 
concentration of 1 mM in one of the two tubes. This will serve as a control for 
each sample (See Note 9).  
7. Continue to grow at 25 °C for an additional 2 hours (shake at 250 rpm).  
8. Harvest the cells by centrifugation (7,000 rpm, 3 min) and re-suspend in PBS to a 
final OD600 ∼ 0.05–0.1 for flow cytometric analysis and cell sorting. 
 
4.4.2    Cytometric analysis and cell sorting 
 
1. Perform flow cytometric analysis with a FACSAria (BD Biosciences) or an 
equivalent system.  Adjust the throughput rate of cells to 4,000–5,000 events per 
second. 
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2.  Perform all rounds of sorting in single cell mode, except for the initial sort, which 
should be in purity mode. 
3. Set a gate in the fluorescence channel to recover the 4–5% most highly 
fluorescent cells. Additionally, set gates based on both the forward- and side-
scatter channels to exclude sorting non-single cell events (See Note 10).  
4. Sort 10-fold the number of cells expected to cover the diversity for each round. 
5. Collect the sorted cells in 0.5 mL of 2xYT medium and plate onto pre-warmed 
2xYT medium supplemented with 50 μg∕mL kanamycin and 34 μg∕mL 
chloramphenicol (See Note 11).  
6. Following overnight growth at 30 °C, pool the clones and store aliquots in 15% 
glycerol at −80 °C. At this step, you may also use the pool to inoculate the next 
round.  
 
4.4.3     Enrichment Experiment with Controls 
 
1. Inoculate two culture tubes of Non Selective Media with E. coli BL21(MI-aux) 
containing pBAD-GFP/pET28-pMGL for a positive control and pBAD-
GFP/pET28-hCGL for a negative controls. Follow the protocols from section 
4.4.1 (steps 1-7) keeping the controls separate. 
2. After GFP expression, measure the OD600 of the cultures and make several 100 
μL aliquots of negative controls in 1.5 mL Eppendorf tubes. 
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3. Through serial dilution of your positive control into your negative control 
aliquots, generate a pool that contains the negative control in a 10,000-fold 
excess.  
4. Dilute this mixture in PBS to a final OD600 ~ 0.05–0.1 for flow cytometric 
analysis and cell sorting.  
5. Follow the remaining steps of the protocol described in section 4.4.2. 
6. Continue additional rounds of sorting until the fluorescence signal of your pool is 
either: i) equivalent to that of the positive control alone, or ii) no longer changing 
from one sort round to the next. 
7. Sequence at least 20 random clones from the last round plate to verify identity of 
gene in the pET28a expression plasmid. Alternately, you can perform a 
secondary 96-well plate screen for methionine--lyase activity (75) to determine 
the makeup of the pooled sample. 
8. Calculate the fold of enrichment achieved and note the number of sort rounds 
necessary to achieve the enrichment.  
9. A successful Enrichment Test should yield results similar to Figure 3. We 
achieved a 5,000-fold enrichment within 3 rounds (Additional rounds may be 




Figure 5.  Histogram showing enrichment of positive enzyme control out of a mixed pool of 
10,000:1 hCGL to pMGL over the course of four rounds, as well as the signals of a positive 
enzyme control alone (pMGL -Ile).  Inset) A histogram of a positive and negative control 
experiment using hCGL in the presence or absence of L-Ile (+/- Ile). 
4. 5         ADDITIONAL NOTES 
 
1. The amount of enzyme required to rescue the auxotrophy depends on the catalytic 
activity and level of “leaky” expression. In the case of the sufficient parental 
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enzyme leaky expression, uninduced culture is suitable for the analyses.  For a 
poorly expressed enzyme one can supplement with IPTG.  
2. We find it is easiest to prepare competent cells harboring the reporter plasmid 
pBAD-GFP and then transform with the expression plasmids of interest.  
3. The multiple wash steps with PBS ensure removal of the selective expression 
media for the subsequent cytometric analysis.  
4. L-Val and L-Ile are excluded from the Non Selective Growth Media and Selective 
Growth Media because these branched-chain amino acids are known to inhibit the 
L-Ile biosynthesis pathway (123, 124). The addition of these two amino acids to 
the Selective Growth Media without L-Ile in our experiments resulted in 
undetectable GFP expression in all variants tested. 
5. Some enzymes express better at lower temperatures thus this parameter can be 
adjusted on a case by case basis. 
6. The multiple wash steps ensure that L-Ile is removed from the media. 
7. In the positive control for each sample the expression of GFP will be independent 
from the enzymatic activity, as the medium is non-selective and supplemented 
with L-Ile. In the sample the expression of GFP will be dependent on the L-Met 
degrading activity of the single mutant or of the library, as the medium is 
selective and deprived of L-Ile. 
8. During flow cytometric analysis the applied voltage may be adjusted to improve 
the signal separation of the controls. A higher voltage will result in higher signals 
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for both the positive and negative samples, but will also improve the signal to 
noise ratio when the positive control signal is at the lower end of the optimal 
dynamic range for the instrument and the negative control is near 0 (FITC-A 0-
10,000).  
9. When plating cells collected from a round of sorting, optimal recovery is achieved 
if the agar plate is pre-warmed for 30 minutes to 1 hour at 37C. 
10. Various parameters may be adjusted to optimize the process. Optimization should 
maximize the fluorescence signal difference between the positive and negative 
control variants. The expression of enzyme can be tuned by changing the IPTG 
inducer concentration, altering the expression temperature and time, as well as by 
choosing a different OD600 reading to initiate expression. GFP expression can be 
similarly controlled by altering the arabinose concentration in the Selective Media 
and varying expression time and temperature.  
 
4.6     CONCLUSION 
 
We have developed a high throughput FACS- based method of screening libraries of 
upwards of 107 clones for the catalytic optimization of enzymes. By coupling the 
synthesis of GFP to catalytic activity in a cell line engineered to be dependent on a 
product of the target chemical reaction, we can selectively enrich for the population 
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expressing enzymes with greater catalytic activity. In the specific example of a 
methionine degrading enzyme, we coupled GFP production to the generation of α-
ketobutyrate in an isoleucine auxotroph host. Applying this screen, were able to enrich 
the population expressing positive control pMGL 5,000 fold over the course of only three 
rounds of screening (1 in 10,000 to 1 in 2).  
At the time of protocol development, we also tested this method with a mixed 
population of 1:1000 Variant 1 NLV to wild-type CGL (Chapter 2), but were unable to 
see any enrichment after 7 rounds of screening. Variant 1 has a methionine degrading 
activity (as measured by kcat/KM) that is only 1% the activity of the bacterial MGL, and 
we concluded that this rate of α-ketobutyrate production is insufficient to generate 
detectable (above background) levels of GFP in the absence of isoleucine. A 10 fold 
faster enzyme (10% of MGL activity) has now been engineered through the application 
of phylogenetic analysis and iterative lower throughput 96 well plate screens (Chapter 3). 
Future work will test whether enrichment in the FACS based assay is possible with the 







Chapter 5: In vitro Effects of Enzyme-Mediated L-Met Depletion on the 
Melanoma and Prostate Carcinoma Cell Lines  
 
5.1 CHAPTER SUMMARY 
 
Various malignant cells experiencing starvation stress in response to methionine 
deprivation are known to undergo processes that arrest cell division and ultimately lead to 
cell death. The study of the mechanisms of the death response and other processes 
induced by treatment with the engineered human L-Met degrading enzyme serves to aid 
in the selection of appropriate cancer targets, prediction of effects on other neoplasms and 
normal tissues, and identification of effective combination therapies. We have shown that 
treatment with CGL-NLV is correlated with an induction of autophagy and cell death by 
apoptosis in A375 melanoma cell line. Prostate cancer cell line DU145 treated with 
Variant 7 also responds by undergoing extensive cell death, though the precise 
mechanism of the process remains unclear. The mouse prostate model HMVP2 treated 
with Variant 7 arrests in the G2 phase and experiences a buildup of reactive oxygen 
species. The newly engineered human enzyme Variant 9 (Chapter 3) is capable of 
inducing extensive cell killing of a variety of neoplasms at therapeutically useful doses. 
Finally, we have shown that hMGL is also capable of degrading cystine to operate as a 





Melanoma and prostate carcinoma neoplasms have both been shown to have an 
absolute requirement for methionine and to undergo cell cycle arrest and death upon the 
degradation of this amino acid by the bacterial pMGL (62, 125-130). Melanoma is a 
highly aggressive malignancy of the pigment producing melanocytes in the skin, and 
though it is the least common form of skin cancer, is has the greatest rates of mortality 
(75% of all skin carcinoma deaths) (131). The 10 year survival rate for patients whose 
melanoma has metastasized is less than 10%. The current standard of care for treatment 
remains highly toxic chemotherapeutic treatment along with surgical interventions and 
radiation (132). Prostate carcinoma is the most common form of sub-cutaneous cancer 
and the second leading cause of male cancer mortality globally (World Cancer Report 
2014). Though many prostate neoplasms are slow growing, they are often asymptomatic 
until later stages of the disease precluding early detection, and other forms of the cancer 
are significantly more aggressive (133). Though prostate cancer generally responds well 
to traditional therapies (such as androgen deprivation and chemotherapy), a subset of 
patients will experience a recurrence of the malignancy that is resistant to standard 
treatment (134). The unfavorable outcomes of advanced melanoma and prostate 
carcinoma as well as the general toxicity associated with chemotherapeutic treatment 
demonstrate the need for an effective and better-tolerated therapeutic against these 
neoplasms. Characterization of the mechanism of action of such a therapeutic supports 
the selection of appropriate models of efficacy, prediction of effects on normal tissues, 
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and identification of effective combination therapies. We therefore investigated the in 
vitro effects of methionine depletion with our engineered human enzyme.     
Since both melanoma and prostate carcinoma are known to be methionine 
auxotrophs (125), we expect treatment to result in extensive cell death. Neoplasm death is 
a complex group of processes that are initiated by stress to the cell (135) and can occur in 
multiple overlapping forms in a given cell population (136). The various processes 
associated with cell death can be loosely classified into “types”, and the three most 
relevant to our studies were: apoptosis (caspase dependent and independent), necrosis, 
and autophagic cell death. For simplicity, Figure 1 presents only the key features of each 
type.  
 
Figure 1: Three mechanisms of cell death considered in melanoma and prostate cancer 
methionine depletion. 
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Apoptosis, a process of programmed cell death, has been previously studied as a 
response to methionine starvation of cancer (137). The apoptotic process is generally 
defined by the presence of activated caspase proteases that participate in a signaling 
cascade, ultimately resulting in nuclear degradation and the packaging of cellular 
contents into blebs that can be phagocytosed and degraded by neighboring cells such as 
macrophages (138). Caspases are or cysteine-dependent aspartate-specific proteases that 
are activated by cleavage and play a central role in the transduction of apoptotic signals 
and execution of proteolytic degradation within the cell. Apoptosis can be initiated both 
extrinsically in response to external stress, or intrinsically by internal factors such as 
DNA damage, oxidative stress, and many others (135). Though the vast majority of 
research has focused on the caspase-dependent process, caspase-independent apoptosis 
does exist as some cells die with a similar morphology even after caspase proteolysis is 
irreversibly inhibited (139).  
Due to the absence of defined morphological traits associated with apoptosis or 
autophagy, necrosis has traditionally been considered an accidental cell death mechanism 
that results from external trauma to the cell (140). It is now known that necrosis can 
occur in both a regulated and unregulated manner, and that regulated necrosis can be 
triggered by intracellular causes (135).    
Finally, autophagy is a well regulated process that can play dual roles in the 
survival of a cell. During nutrient deprivation and other stress, autophagy can serve a 
protective role by catabolically recycling unnecessary proteins and other cell components 
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to regenerate the raw materials critical to survival (141). The general mechanism of 
autophagy is shown in Figure 2. Autophagosomes initially engulf cytoplasm along with 
the components to be degraded. The autophagosomes then proceed to fuse with 
lysosomes carrying hydrolytic enzymes to form autolysosomes in which cellular proteins 
and organelles are degraded. The recycled raw materials are then transported back into 
the cytoplasm. Though in most known cases autophagy constitutes a protective response 
(135), large scale autophagy has also previously been shown to result in the elimination 








Figure 2: Schematic showing the general process of autophagy 1) an early autophagosome 
precursor (phagophore) begins to form; 2) the phagophore extends and surrounds the cytosolic 
material to be degraded 3) the complete autophagosome is formed around target components 4) 
the autophagosome fuses with a lysosome containing hydrolytic enzymes to form an 
autolysosome 5) the now degraded contents of the autolysosome are transported back into the 
cytoplasm and the autolysosome is itself degraded 
 
5.3 RESULTS  
 
The effects of hMGL administration and the ensuing L-Met depletion on cancer 
cells were studied in vitro (i.e. in tissue culture).  These studies were conducted while the 
protein engineering process described in Chapter 3 was ongoing, and hence involved the 
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use of enzymes at different points along the engineering path. The experiments described 
below were conducted using  NLV, Variant 7 (NLV + 5 additional mutations), or Variant 
9 (Variant 7 + N59I, L119A). Though the kinetic details differ between these variants 
resulting in somewhat different profiles of amino acid degradation, each experiment 
contributes to the understanding of malignant cell response to treatment with an 
engineered human methionine degrading therapeutic. 
5.3.1 Melanoma Cytotoxicity with MGL, NLV, and Variant 7 
 
Numerous melanoma cell lines have been reported to have a high degree of 
dependence on methionine and to undergo cell cycle arrest and programmed cell death in 
its absence(125-128, 130). We sought to determine the sensitivity of an A375 melanoma 
cell line to treatment with NLV (Chapter 2) and Variant 7 (Chapter 3) and to compare the 
results to treatment with bacterial MGL (Figure 2 and Table 1).  Cells were treated for 5 
days and their viability was measured by an MTS Cell Proliferation Assay as a percent of 
untreated control. The MTS assay detects viable cells by their ability to convert a 
chromogenic substrate with active cellular oxidoreductase enzymes. The calculated EC50 
value for the bacterial enzyme was 580 nM. While NLV has a much lower kcat/KM than 
pMGL for methionine, its much higher stability in serum and in growth media resulted in 
an EC50 value that was lower than pMGL (400 nM). Variant 7 kinetic constants with 
methionine are 7 fold greater than NLV (Table 2, Chapter 3) and the increased activity 
results in an EC50 of 80 nM, or more than 7 fold better than pMGL. The improved 
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cytotoxicity of the human variants underscores the importance of their longer half-lives 
and the benefits of enhancing kcat/KM through engineering.  
 
 
Figure 3: Effect of enzyme engineering on cytotoxicity with A375 melanoma cell line. Bacterial 
enzyme is denoted “pMGL”, Variant 1 “NLV”, and Variant 7 “8mut” 
 






Table 1: Calculated EC50 values for treatment in Figure 3. 
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Along with enzyme concentration, the exposure time necessary for a therapeutic 
to have a desired cytotoxic effect in vitro provides important drug potency information 
that may be extrapolated to future in vivo experiments. We therefore determined the time 
dependence of A375 melanoma cell death in response to Variant 7 treatment over the 
course of three days (Figure 3). Most of the cell killing effect occurs very rapidly within 
the first 24 hours, with diminishing drops in viability over the course of the next two 
days.   
 
 
Figure 4: Cytotoxicity time course with Variant 7 (8mut) and A375 melanoma cell line. 
 
5.3.2 Melanoma Apoptosis 
 
Apoptosis is a well-defined process of programmed cell death (138) and it is well 
established that L-Met depletion triggers apoptosis  in a variety of cancer cell lines (8, 57, 
126, 128). One of the key features of apoptosis is the activation of caspases, or cysteine-
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dependent aspartate-specific proteases, that are activated by cleavage and play a central 
role in the transduction of apoptotic signals and execution of proteolytic degradation of 
intracellular proteins- ultimately resulting in cell death.  
In order to understand what role apoptosis plays in the killing of A375 cells by 
treatment with a human methionine degrading enzyme, we decided to directly probe for 
the presence of activated caspases within the cell (135) using FITC-VAD-FMK, a cell 
permeable, irreversible pan-caspase inhibitor conjugated to a fluorescein isothiocyanate 
group (143).  Cells were seeded on day 0, and on day 1 cultures received either fresh 
media or fresh media with NLV enzyme at 500 nM or 1000 nM. On day 2, camptothecin 
was added to a previously untreated culture as a positive control.  Camptothecin is a 
quinoline alkaloid that triggers apoptosis in cells by inhibiting their topoisomerase I DNA 
enzyme. Finally, on day 3 the cells were collected, washed and incubated with FITC-
VAD-FMK as well as propidium iodide, a fluorescent intercalating molecule that is only 
capable of permeating dead or dying cells that have lost integrity (144). The samples 
were then analyzed by flow cytometry. 
The results of the experiment are presented as two-dimensional scatter plots in 
Figure 5.  Cells falling into Q3 correspond to those that are FITC negative and PI 
negative, which means they do not have detectable activated caspases and thus are alive 
with full membrane integrity. Cells falling in Q1 quadrant after staining are FITC 
negative but PI positive indicating they may be necrotic or dying via other caspase 
activation-independent mechanisms (Introduction, (136)). Cells in the second quadrant, 
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Q2, stain for both FITC and PI, a staining pattern consistent with “dead by apoptosis” in 
that they have lost integrity in the presence of activated caspase enzymes. Finally, Q4 
cells are ones in which apoptosis has been induced and in which active caspases are 
present, but these cells have not yet become permeable to PI. This population can be 
expected to shift into Q2 given additional time.  
For comparison, cells that were not treated with enzyme were overwhelmingly 
FITC and PI negative, and almost exclusively contained in the Q3 quadrant. The positive 
camptothecin-treated control is assumed to be representative of a population of cells in 
the process of undergoing apoptosis, with 44% of cells FITC and active caspase positive. 
Additionally, 26% of active caspase positive cells are also positive for PI and are dead or 
dying. The enzyme treated sample shows a similar distribution of cells. Additionally, a 
doubling in treatment enzyme concentration results in a slight decrease in the number of 
live non-apoptotic cells and a slight increase in the FITC positive cell population. For all 
treatment conditions, Q1 contains 1% or less of total cells. This population can be defined 
as dead by a non caspase-dependent process. These results imply that the primary 
response to enzyme treatment for melanoma A375 is to undergo programmed caspase-
mediated cell death. 
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Figure 5: Flow cytometric analyses showing cell integrity and presence of activated caspases. 
(-) Top left: negative untreated control. (+) Top right: positive control treated with camptothecin. 
Bottom left: treated with 0.5 µM Variant 1 NLV. Bottom right: treated with 1.0 µM Variant 1 
NLV. FITC positive (right two quadrants for each) correspond to presence of activated caspases. 
PI positive (top two quadrants for each) correspond to dead cells. 
 
Two additional experiments were performed to confirm apoptosis as the 
mechanism of A375 melanoma cell death in response to treatment with the methionine-
depleting enzyme NLV. First, the flow cytometry experiment was repeated in the 
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presence of the Z-VAD-FMK apoptosis inhibitor. This pan caspase inhibitor irreversibly 
binds to the catalytic site of initiator caspases and prevents the induction of the signaling 
cascade that activates effector caspases and results in apoptosis (145). Two A375 aliquots 
were treated with media and enzyme. One of these cultures was also pre-incubated for 30 
minutes with Z-VAD-FMK (unlabeled) inhibitor before enzyme was added. In order to 
assure extensive killing, the cells were treated for a total of 4 days. Results are presented 
in Figure 6. Untreated cells were alive and stained negative for active caspase while the 
positive control and cells treated with enzyme without caspase inhibitor show a high 
percentage of apoptosis. Notably, in the presence of the inhibitor during treatment the 
percent of apoptotic cells is drastically reduced and the percentage of “live cells” in Q3 
approaches that of the untreated control. Since inhibiting the apoptotic cascade modulates 
cell killing so effectively, we can conclude that apoptosis is indeed the dominant 




Figure 6: A375 flow cytometric analyses showing cell integrity and presence of activated 
caspases with apoptosis inhibitor. (-) Top left: negative untreated control. (+) Top right: positive 
control treated with camptothecin. Bottom left: treated with Variant 1 NLV. (I) Bottom right: pre-
treated with apoptosis inhibitor and then treated with Variant 1 NLV. FITC positive (right two 
quadrants for each) correspond to presence of activated caspases. PI positive (top two quadrants 
for each) correspond to dead cells. 
 
We also performed a Western Blot for the activated Caspase-3. Caspase-3 is a 
critical effector caspase associated with the “death cascade” and therefore a specific 
marker for the initiation of the apoptotic signaling pathway (139). Upon initiation of 
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apoptosis, the inactive protoenzyme of Casp-3 undergoes proteolytic processing to 
produce two subunits that dimerize to form the active enzyme (139). The smaller 17 kDa 
subunit produced can be detected directly with  an antibody specific to the cleaved 
fragment (146). Using this active Casp-3 specific antibody, we detected the active 
fraction present in the cells after treatment with the apoptosis-inducing positive control 
camptothecin discussed above, or the NLV enzyme therapeutic. We also included a 
caspase inhibitor test by pre-incubating one of the samples with another pan caspase 
inhibitor prior to enzyme treatment (Q-VD-Oph). The treated cells were collected, 
counted, and diluted to a consistent cell density before being denatured and separated by 
SDS-PAGE.  The GAPDH housekeeping gene was also detected as a loading control 
since the levels of this protein are not expected to vary with treatment (147). In support of 
the results obtained from flow cytometry, both positive control and uninhibited enzyme 
yielded detectable cleaved Casp-3 (Figure 7). Addition of the inhibitor also prevented 
activation. Finally, increase in the enzyme treatment concentration was correlated with 
decreased survival and a more extensive activation of apoptosis as defined by a brighter 
cleaved Casp-3 band in the Western Blot (Figure 8).  
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Figure 7: Western Blot for activated caspases (band at blue arrow) for (lanes left to right): 
untreated, positive control treated with camptothecin, treated with Variant 1 NLV, and pre-
incubated with apoptosis inhibitor and then treated with Variant 1 NLV. GAPDH band used as 
standard for number of loaded cells.  
 
Figure 8: Western Blot for activated caspases (band at blue arrow) for several treatment 
concentrations of Variant 1 NLV. GAPDH band used as standard for number of loaded cells.  
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5.3.3 Melanoma Autophagy 
 
Nutritional deprivation based cancer treatment lends itself to the study of the 
malignancy autophagic response. Autophagy is the catabolic mechanism response to 
starvation stress that recycles unnecessary components in a cell to regenerate raw 
materials and funnel them into pathways necessary for survival (148). As discussed in the 
introduction, this mechanism has been implicated as both protective and as a possible 
mechanism of cell death (142). In order to confirm an autophagic response to methionine-
degrading enzyme treatment in A375 melanoma, we performed a Western Blot for LC3-
II.  
Microtubule-associated protein light chain 3 (LC3) is a soluble protein that exists 
ubiquitously in the cell (149). When the autophagic response is triggered, 
autophagosomes engulf cytoplasm along with its components. The cytosolic form of 
LC3, LC3-I is conjugated to a phosphatidylethanolamine to form LC3-II. This modified 
protein is then incorporated into autophagosomal membranes. The autophagosomes 
proceed to fuse with lysosomes to form autolysosomes in which cellular proteins and 
organelles are degraded. Therefore, the detection and quantification of LC3-II correlates 
with the amount of autophagic activity present within the cells (149). 
The results are presented in Figure 9. Staurosporine is a known activator of 
autophagy and was used as a positive control (150). A375 cells were treated at three 
different concentrations of NLV for three days. Higher enzyme concentration during 
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treatment correlates with a greater detectable LC3-II signal, confirming that treatment 
with NLV induces an autophagic starvation stress response in A375 melanoma cells. 
 
Figure 9: Western Blot for LC3-II (~17 kDa) for positive staurosporine control, negative untreated 
control, and several treatment concentrations of Variant 1 NLV. GAPDH band used as standard 
for number of loaded cells.     
 
5.3.4 Normal Cell Cytotoxicity 
 
The effect of enzyme treatment on human skin melanocytes was compared to the 
response of the A2058 melanoma cell line. An equivalent number of cells were seeded on 
day 0 and treated for four days in the presence of the specified amount of Variant 7 
(Figure 10). At the end of treatment the dead cells were washed away and the remaining 
adherent living cells were counted. At the end of day 4, treatment resulted in almost 
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complete killing of the malignant cells. The normal cells treated at the same 
concentration retained 75% viability. At a lower enzyme concentration the melanocyte 
viability remained closer to 100%, but monitoring for any adverse effects in normal 
tissues remains a priority for future in vivo experiments. 
 
 
Figure 10: Cytotoxicity of normal melanocytes and melanoma A2058 with Variant 1 NLV as 
measured by live cell counting. 
 
5.3.5 Prostate Carcinoma Cytotoxicity  
                        
Prostate cancer is the second leading cause of death in men and the most common 
neoplasm outside skin cancer (World Cancer Report 2014). DU145 is a “classical” cell line 
of human prostate cancer with moderate metastatic potential (151). To evaluate the 
therapeutic potency of Variant 7 against this cancer target, we performed a cytotoxicity 
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time course experiment, evaluating the EC50 daily (Figure 11). DU154 is less sensitive to 
treatment than A374 melanoma evaluated previously with a somewhat higher EC50 (210 
nM vs. 80 nM) and a slower response (more than two days of treatment were necessary 
for extensive cell killing). Greater than 98% killing is ultimately observed at day 5 with > 
0.9 M enzyme.        
 
 
Figure 11: Cytotoxicity time course with Variant 7 (8mut) and DU145 prostate carcinoma cell 
line.  Calculated IC50 values for each day inset. 
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5.3.6 Prostate Carcinoma Apoptosis 
 
The DU145 cell line was also tested for a caspase-dependent apoptotic response 
to treatment by flow cytometry and FITC labeling of activated caspases. Experiments 
were conducted in the same way as described for A375 melanoma and results are 
presented in Figure 12. The positive control for apoptosis was again camptothecin. The 
scatter plot for this sample shows that only 14.9% of the total cells are FITC and active 
caspase positive, and only 1.6% are also permeable to PI.  Prostate cancer cells treated 
with Variant 7 for two days behaved similarly to the positive control with 19.4% FITC 
and active caspase positive and 1.7% also permeable to PI. Almost all of the PI positive 
“dead” cells from enzyme and camptothecin treated samples were in Q1 and did not have 
a detectable FITC active caspase signal. This cell distribution suggests that though a 
subpopulation of treated cells has activated the apoptotic pathway, the dead cells present 
are active caspase free and therefore likely died by a mechanism other than caspase 
dependent apoptosis. It is possible that given additional time the Q4 active caspase 
positive/PI negative cells would lose their membrane integrity and shift into Q2, but it is 
notable that even the positive control lacks this population. Possible mechanisms of 




Figure 12: DU145 flow cytometric analyses showing cell integrity and presence of activated 
caspases. (-) Top left: negative untreated control. (+) Top right: positive control treated with 
camptothecin. Bottom left: treated with Variant 7 (8mut). FITC positive (right two quadrants for 
each) correspond to presence of activated caspases. PI positive (top two quadrants for each) 
correspond to dead cells.  
 
5.3.7 Prostate Carcinoma Cell Cycle Arrest 
 
To further explore the effects of hMGL treatment, we collaborated with Dr. John 
DiGiovanni from the UT Austin College of Pharmacy and Dr. Stefano Tiziani from the 
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School of Human Ecology. The DiGiovanni lab has extensive experience with a variety 
of prostate cancer cell lines, including human and mouse derived prostate carcinomas. 
The HMVP2 mouse prostate cancer cell line in particular has been previously defined as 
a valid model of human prostate cancer (153). Allograft efficacy experiments in the 
mouse with HMVP2 neoplasms can be uniquely useful because they are often more 
representative of the local tumor environment, vascularization, and immune system 
response than xenografts (154).  
Many cancer cell types respond to methionine starvation by undergoing cell cycle 
arrest in the G2 phase (3). We tested the effect of treatment at three different 
concentrations of Variant 7 on the cell cycle parameters of HMVP2 cells by DNA 
fluorescent labeling and flow cytometry (Figure 13). The 3 day EC50 of these cells with 
Variant 7 was previously determined to be 100 nM. With increasing enzyme 
concentration, the malignant cell response becomes more pronounced and the cells cease 





Figure 13: Percent of HMVP2 murine prostate cancer cells in each phase of the cell-division 
cycle as a function of Variant 7 (MGL) treatment concentration.  
 
5.3.8 Direct Measurement of Amino Acid Levels   
 
In collaboration with Dr. Tiziani, we tested the extracellular and intracellular 
levels of methionine post treatment with Variant 7. HMVP2 cells were incubated with 
several concentrations of enzyme and the media and cells were both analyzed by NMR 
spectroscopy for metabolite content (Figure 14). 
Treatment resulted in complete degradation of methionine in the extracellular 
medium. Intracellularly, the methionine levels decreased with increasing enzyme 
concentration, confirming that treatment is capable of affecting the levels of the amino 
acid in the cytoplasm. Since this malignant cell line is expected to be incapable of 
recycling homocysteine back into methionine (127), all methionine present in the cell 
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must be imported from the medium or derived from autophagic degradation of cell 
components. 
 
Figure 14: NMR spectroscopy results for extracellular and intracellular methionine content as 
a function of Variant 7 (MGL) treatment concentration with HMVP2 murine prostate cancer 
cells. Extracellular methionine was below detection at all concentrations. 
 
We observed that Variant 7 treatment was also associated with a dramatic 
decrease in the extracellular cystine concentration (Figure 15). Cysteine is a non-essential 
amino acid that exists predominantly as its oxidized cystine form in serum (155). The 
depletion of cystine was either due to an increased uptake by malignant cells or direct 
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degradation by the enzyme therapeutic. hMGL is known to have appreciable kinetics 
with cysteine (Table 6, Chapter 3). We therefore measured the kinetic constants of 
cystine degradation with Variant 7 and found a kcat and KM of 0.74 + 0.3 s
-1 and 0.47 + 
0.4 mM, respectively (kcat/ KM ~ 1.6 s




Figure 15: NMR spectroscopy results for extracellular methionine (right) and cystine (left) 
content in response to Variant 7 (MGL) treatment.   
 
To evaluate the requirement of cystine for cell proliferation in a human prostate 
carcinoma line and to understand what role cystine degradation by Variant 7 may play in 
cytotoxicity we incubated DU145 cells with dropout media supplemented with cystine, 
methionine, or both, as well as full media treated with Variant 7 (Figure 16). Although 
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the absence of methionine results in ~50% decrease in proliferation as measured by the 
MTS assay, the absence of cystine with or without methionine ceases all growth.  
 
 
Column Condition with DU145 cell line 
1 cystine (C), methionine (M), glutamine (G) free RPMI media 
2 + FBS (fetal bovine serum) 
3 + FBS and G 
4 + FBS, G, and M 
5 + FBS, G, and C 
6 + FBS, G, M, and C 
7 + FBS, G, M, C, and 3 µM Variant 7 
 
Figure 16: DU145 cell response to dropout media. The composition for each condition (1-7) is 
listed in the table. 
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5.3.9 Reactive Oxygen Species in Prostate Carcinoma 
 
Reactive oxygen species (ROS) are byproducts of normal aerobic metabolism and 
must be neutralized by glutathione, which acts as the main antioxidant within the cell 
(156). Without sufficient glutathione, ROS levels can rise and lead to oxidative damage 
and cell death (157). Many malignant cells are known to have higher glutathione levels 
than normal tissues, making them less sensitive to oxidative stress (158) and prostate 
cancer specifically has been shown to be associated with a high degree of ROS 
production that correlates with an aggressive phenotype (159). Methionine and cystine 
are both precursors for glutathione synthesis. We therefore expect that depleted levels of 
these amino acids in the treatment media will correspond to lowered intracellular 
glutathione concentrations and a higher level of ROS. 
We analyzed the ROS content of HMVP2 cells with and without treatment with 
Variant 7. The cells were incubated with a cell permeable chemical that reacts with ROS 
to yield a green fluorescent product detectable by flow cytometry. Results are presented 
in Figure 17. Enzyme treatment correlates with an increase in ROS levels, suggesting that 
ROS may be playing a role in treatment-induced cell damage and contributing to the 




Figure 17: Flow cytometry results measuring the Reactive Oxygen Species (ROS) content of 
HMVP2 cells at different Variant 7 (Metase) treatment concentrations. 
 
5.3.10 Cancer Cytotoxicity Assays with Variant 9 
 
Finally, we tested the effect of Variant 9 treatment on the survival and 
proliferation of several cancer cell lines. This enzyme variant has a 10 fold higher 
methionine kcat/KM than NLV and is approximately 30% faster than Variant 7 (Table 2, 
Chapter 3). As discussed in the Introduction to this chapter, melanoma and prostate 
cancer have both been reported to be sensitive to methionine starvation. In addition, we 
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examined the effect of enzyme administration on HPAF-II pancreatic cancer cell line and 
the U138 glioblastoma cell line (160, 161).  All of these cancers are known to be highly 
aggressive and have limited treatment option (132, 133, 162, 163).  
Cells were seeded in a 96 well plate and treated with a range of Variant 9 enzyme 
concentrations on day 0. On day 3, cells were incubated with fresh enzyme-free media. 
The cells were allowed to recover for 24 hours and were tested for viability by the MTS 
assay discussed previously. The EC50 values were calculated and are reported in Table 9 
(curves presented in Figure 18).  
The EC50 values for Variant 9 treatment are at their lowest at 18 nM with 
melanoma cell line A2058, and slightly higher at 63 nM with PC3, a highly aggressive 
line of prostate cancer (164).  In the case of the pancreatic malignant cell line, it appears 
that even though the EC50 is a fairly low 38 nM, even the highest enzyme concentration 
is insufficient to kill > 90% of cells. This response is consistent with a small sub-
population with a diminished methionine starvation sensitivity compared to the rest of the 
population. The evasion of drug treatment induced cell death by a sub-population of 
cancer cells has previously been attributed to the variability of protein dynamics, with the 
resistant cells  exhibiting protein expression profiles conducive to survival (165).  The 
surviving cells can quickly overtake the population and become the new dominant cell in 
the tumor that is now resistant to the therapeutic (166). Drug treatment itself can also 
induce sub-population resistance by applying stress that can provoke adaptive evolution 
of the genome  (167). 
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Figure 18: Cytotoxicity dose dependence of a selection of malignant cell lines treated with 
Variant 9. 
 
Table 2: Calculated EC50 values for treatment in Figure 18. 
 
Cell Line Variant 9 EC50 (nM) 
PC3 Prostate 63 
A375 Melanoma 26 
A2058 Melanoma 18 
HPAF-II Pancreatic 38 
U138 Glioblastoma 35 
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5.4 SUMMARY AND DISCUSSION 
 
We have shown that an engineered human enzyme that degrades methionine has 
cytotoxic effects with a wide variety of cancer cell lines.  An enhancement of this activity 
through engineering correlates with improved cytotoxicity profile across all malignancies 
tested. Variant 9 treatment of melanoma cell lines A2058 and A375 in particular led to 
rapid and extensive cell killing with an EC50 that was < 26 nM at three days. We 
investigated the mechanism of cell death of the A375 cell line and concluded that the 
majority of cells die by caspase-dependent apoptosis. Pretreatment with an inhibitor of 
apoptosis promotes cell survival and supports this hypothesis. Based on the presence of 
LC-II in this cell line after treatment with NLV, we know that the cells initiate an 
autophagic response to starvation stress to recycle the raw materials critical for survival, 
but that any protective effects of this process are insufficient to prevent cell death. 
The prostate cancer cell lines tested (PC3, DU145, HMVP2) were also sensitive 
to treatment, but had somewhat higher EC50 values that melanoma. DU145 also 
exhibited a slower response to the drug than A375 cells. Though active caspases could be 
detected in a subpopulation of DU145 cells, none of the PI permeable dead cells were 
caspase positive, ruling out caspase dependent apoptosis as the dominant cell death 
mechanism. Programmed cell death dysregulation is a well-defined causative factor in the 
development and progression of cancer (168), as well as a resistance to the body’s own 
immune responses and a barrier to efficacy of chemotherapeutics (169). However, even 
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in the absence of a caspase mediated programmed death response, the prostate carcinoma 
cells readily respond to treatment by a yet not well understood mechanism of cell death.   
We determined that in addition to catalyzing the hydrolysis of methionine, the 
engineered enzyme is a potent cystine-lyase. Cysteine (and cystine, its predominant 
disulfide form in serum) is not considered to be an essential amino acid as many tissues 
are capable of synthesizing it through the combination of homocysteine and serine in the 
transsulfuration pathway (170, 171).  Numerous cancer cells, likely due to their increased 
rate of protein synthesis and requirement for antioxidants, have been shown to be 
critically dependent on the serum pool of this amino acid and satisfy their demand 
through xCT(-) antiporter mediated exchange of glutamine for extracellular cystine (172). 
Cysteine is critical for maintaining the correct redox potential of the cell and its 
surrounding environment through two mechanisms. Intracellularly, like methionine, 
cysteine is a precursor in the biosynthesis of glutathione, a potent antioxidant (156). 
Additionally, some tumors may export cysteine back into the extracellular medium as a 
method of modulating their surrounding redox environment (187).  
Based on dropout media experiments, DU145 prostate carcinoma cells have an 
absolute requirement for cystine/cysteine. This has been previously shown by the 
blocking of the xCT(-) antiporter with sulfosalazine and a resulting 100% inhibition of 
growth in vitro (173). It appears that in the case of HVMP2 murine prostate cells, the 
promiscuous activity of the engineered enzyme against methionine, cystine, and cysteine 
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works synergistically to arrest the cells in G2 phase, lead to a buildup of intracellular 
ROS, and ultimately induce cell death.  
The understanding of the mechanisms of cell death and other responses to 
treatment with the human methionine depleting enzyme aids in the selection of 
appropriate targets for the drug, prediction of effects on normal tissues, and identification 
of effective combination therapies. We have shown that treatment with NLV, Variant 7, 
and Variant 9 is correlated with an induction of autophagy and cell death by apoptosis in 
A375 melanoma cell line. Prostate cancer cell line DU145 also responds to treatment by 
undergoing extensive cell death, though the mechanism of the process remains unclear. 
The mouse prostate model HMVP2 displays an arrest in the G2 phase and a buildup of 
reactive oxygen species upon incubation with hMGL. The novel human enzyme Variant 
9 is capable of inducing extensive cell killing of a variety of neoplasms at therapeutically 
useful doses. Finally, we have shown that hMGL is also capable of degrading cystine to 
operate as a dual amino acid depletion treatment that is expected to be more potent than 
methionine depletion alone. 




Androgen insensitive human prostate cancer cell lines DU145 and PC-3, 
Melanoma cell lines A375 and A2058,  human normal cell melanocytes, HPAF-II 
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pancreatic cancer, and U138 glioblastoma cell line were all purchased from ATCC. Cells 
were maintained in either RPMI-1640 medium or DMEM with 10% FBS. The prostate 
tumor cell line, HMVP2, was derived from the ventral prostate of a one year old HiMyc 
mouse (174) and cultured in RPMI-1640 medium containing 10% FBS (Blando, J. Saha, 
A, Kiguchu, K., and DiGiovanni, J., unpublished studies). Cells were cultured in 95% air 
and 5% CO2 incubator at 37C.  
Cytotoxicity of hMGL Variants 
 
The in vitro cytotoxicity of hCGL-NLV, pMGL, Variant 7, and Variant 9 was 
compared in the a variety of cell lines. Typically cells seeded at ~3000 cells/well were 
incubated in 96-well plates and varying amounts of enzyme were added 24 hours later. 
After 3-5 days exposure, proliferation was measured by MTS assay and plotted to 
calculate apparent IC50 values (175). For melanocyte cytotoxicity, cells were counted 
visually with a hemocytometer.  
Cell cycle analysis 
 
HMVP2 cells were treated with various concentrations of hMGL for 24 h. After 
that cells were harvested and washed twice with phosphate buffered saline (PBS) and 
then fixed in ice cold 70% ethanol overnight at 20 °C (PMID 20686221). Following 
fixation, cells were washed and resuspended in PBS containing RNase (250m g/ml) and 
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incubated for 30 min at 37 °C. Cells were then treated with PI (50m g/ml) solution, 
incubated for 30 min in the dark, and distribution of different phase of cell-cycle was 
analyzed by Guava-based flow cytometry (Millipore) 
Apoptosis assay 
 
The percentage of apoptotic cells was determined using CaspACE™ FITC-VAD-
FMK In Situ Marker (Promega) with the pan Caspase (active) FITC Staining Kit (abcam) 
apoptosis detection kit following the recommended protocol. Active caspase positive and 
PI positive cells were detected by a BD LSRFortessa cell analyzer. 
Measurement of Reactive Oxygen Species 
 
The intracellular reactive oxygen species (ROS) was measured by using DCFDA 
fluorescence. Briefly, HMVP2 cells were treated with indicated concentrations of hMGL 
for 24h. After the indicated time point, the cells were washed with PBS twice and then 
stained by H2DCFDA (20 µmol/L, Invitrogen) at 37
oC for 30 min. After washing with 
PBS, fluorescence intensity was measured using a flow cytometer (Guava, Millipore). 
Western Blotting 
 
Cells were treated with indicated concentrations of enzyme or control substance 
for the designated time. After incubation, both adherent (live) and floating (dead) cells 
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were collected, resuspended in PBS, and lysed by incubating them at 95°C for 10 
minutes. Proteins were separated by 12% SDS-PAGE gel and transferred to nitrocellulose 
membrane. After blocking in 5% BSA for 1h, the membranes were probed with specific 
primary antibodies for overnight at 4C. Following secondary antibody incubation, the 
membranes were visualized using commercial chemiluminescent detection kit (Pierce 
Biotechnology).   
NMR acquisition 
 
Frozen extracellular media were thawed on ice and then separated from protein by 
ultrafiltration (Nanosep 3K OMEGA, Pall Corporation, MI) at 4°C (176, 177). An aliquot 
of 160 μL of filtered media was placed in 3 mm MRS tube (Norell, Landisville, NJ, 
USA) containing 40 μL of phosphate buffer (final concentration 100 mM, pH 7.0), 
sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TMSP, 0.1 mM final concentration; 
Cambridge Isotope Laboratories, Andover MA), 0.75% (w/v) sodium azide and 10% D2O 
(final concentration; Cambridge Isotope Laboratories).  
Extraction of intracellular metabolites was performed as described previously 
(178). Briefly, extraction of intracellular metabolites from cell pellets was performed 
using a modified Bligh-Dyer procedure (179). Samples were dried using a refrigerated 
centrifugal vacuum concentrator CentriVap (Labconco, Kansas City, MO). The dried 
polar extracts were redissolved in 90% H2O/10% D2O (99.8 atom%; Cambridge Isotopes 
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Laboratories, Andover MA) prepared as 100 mM phosphate buffer (pH 7.0), containing 
0.1 mM sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TMSP, Cambridge Isotope 
Laboratories, Andover MA) as internal reference. 
One dimensional 1H-MRS spectra were acquired on the extra and intracellular 
metabolite fractions using a 700-MHz Bruker Avance spectrometer equipped with a TCI 
cryoprobe and SampleXpress high-throughput robotics. (Bruker BioSpin Corp., MA, 
USA). Each sample was allowed to equilibrate for 5 min inside the probe before starting 
data acquisition. The acquisition parameters for 1D spectra were a 90° flip angle, 6 kHz 
spectral width, 1 s relaxation delay, 32,000 data points, 8 dummy scans, and 6 kHz 
spectral width. Excitation sculpting pulse sequence was implemented to suppress the 
water signal (180). All the MRS datasets were processed using MetaboLab (181)  in the 
MATLAB programming environment (MathWorks, Inc., Natick, MA). MRS resonances 
were assigned and the metabolites quantified using the Chenomx NMR Suite and other 







Chapter 6: Major Findings and Future Recommendations 
 
6.1 MAJOR FINDINGS 
 
It has been known for nearly half a century that many cancers have an absolute 
requirement for the amino acid methionine (L-Met). Studies have shown that in the 
absence of L-Met, sensitive neoplasms experience cell cycle arrest and perish. Without 
the metabolic deviations that characterize L-Met auxotrophs, normal cells are able to 
grow on precursors such as homocysteine and tolerate L-Met starvation. The differential 
requirement for this amino acid between normal and tumor cells has been exploited 
through enzymatic serum degradation of L-Met by a bacterial methionine-γ-lyase. 
Though MGL was able to deplete L-Met to therapeutically useful levels in animal models 
and exert a significant cytotoxic effect on malignant cell lines in vitro and on tumor 
xenografts in vivo, the clinical implementation of this enzyme is hampered by its short 
serum half-life and potential for catastrophic immune response.  
We have circumvented the limitations of the bacterial MGL by re-engineering its 
human structural homologue cystathionine-γ-lyase to accept L-Met as a substrate. The 
introduction of three critical mutations to the CGL scaffold by the process of rational 
design, saturation mutagenesis, and screening yielded a novel human L-Met degrading 
enzyme CGL-NLV. Due to its human origin, CGL-NLV is unlikely to elicit adverse 
immunological responses in the patient and displays a 15 fold longer serum half-life than 
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bacterial MGL. Furthermore, the human enzyme cytotoxicity against a variety of 
neuroblastoma cell lines was similar to MGL and administration of CGL-NLV in athymic 
mouse Lan-1 neuroblastoma xenografts resulted in complete retardation of tumor growth. 
 In order to decrease the dosage requirement for our therapeutic, we have applied 
the technique of phylogenetic analysis to perform additional enzyme engineering. 
Sequence alignments of paralogs within the gamma lyase family identified positions of 
importance for activity and specificity. Iterative rounds of mutagenesis and screening 
yielded next generation enzymes with up to 10 fold better L-Met degrading activity than 
CGL-NLV (Variant 9). The additional mutations were shown to not negatively impact 
serum stability and an improved variant (Variant 7) was capable of reducing serum L-
Met to target levels in a mouse model at a clinically useful dose. 
We tested human L-Met degrading enzymes against a variety of cancer cell lines 
including neuroblastoma, pancreatic carcinoma, glioblastoma, melanoma, and prostate 
carcinoma. In all cases, treatment led to extensive cell killing. Second-generation 
enzymes with faster L-Met-degradation kinetics displayed EC50 values in the nM range 
with all lines tested.  We also studied the treatment response of melanoma and prostate 
carcinoma in more detail. The melanoma cell line A375 undergoes rapid and extensive 
apoptosis in spite of initiating an (assumed to be protective) autophagic response to 
stress. Prostate cancer was shown to undergo non apoptotic cell death and to experience 
G2 phase cell cycle arrest and a buildup of intracellular reactive oxygen species. Variant 
7 hMGL was also found to have an appreciable activity against cystine that may function 
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synergistically to deprive cancer cells of multiple required sulfur-containing amino acids 
and enhance the potency of the drug. Finally, since the mode of action of hMGL is 
systemic and does not require breaching the blood-brain barrier, we believe this enzyme 
may be particularly well suited for the treatment of sensitive tumors that arise from or 
metastasize to the central nervous system- a target that has historically been limited in 
treatment options.  
We have designed a high-throughput fluorescence activated cell sorting (FACS) 
assay for detecting the catalytic activity of amino acid degrading enzymes in bacteria, at 
the single cell level.  This assay relies on coupling the catalytic activity to the synthesis of 
a GFP reporter in an appropriate E.coli genetic background.  To demonstrate the utility of 
the assay in the case of methionine-γ-lyase engineering, we generated a strain 
auxotrophic for isoleucine that can be rescued by α-ketobutyrate, a product of the L-Met 
degradation reaction. We were able to enrich a 1:10,000 population of MGL:CGL 
expressing clones 5,000 fold in only three rounds of sorting.  
6.2 PROPOSALS FOR FUTURE WORK 
 
Further improvement in enzyme kinetic parameters should be possible through 
additional engineering. The positions of interest identified by phylogenetic analysis can 
be reengineered through saturation mutagenesis to select residues that afford enhanced 
activity in the context of the human enzyme active site and the other mutations. Synergy 
of various positions can be investigated by generating larger libraries and selecting for 
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clones with the greatest activities by the high throughput GFP reporter screen presented 
in Chapter 4.  The screen conditions should be re-optimized for the latest variants by 
adjusting parameters such as expression time, temperature, IPTG inducer concentration, 
and others. We also plan to investigate the potential benefits of using homocysteine in 
place of, or in conjunction with, methionine to achieve necessary rates of α-ketobutyrate 
production. The gamma elimination of homocysteine also produces α-ketobutyrate and 
we have previously reported that for a given enzyme variant, homocysteine hydrolysis 
activity correlates with methionine and is generally significantly higher (Chapters 1 & 3). 
Further exploration of the reaction chemistry and mechanism of different variants 
through the analysis of steady and non-steady state reaction kinetics will be performed 
and should yield important information for both scientific understanding and future 
engineering. 
Forthcoming experiments with numerous cancer cell lines will examine the 
general importance of cystine degradation as a complement to methionine depletion for 
enzyme cytotoxicity and efficacy. Additional studies will be performed to better 
understand the exact mechanism of cell killing of prostate carcinoma and other 
neoplasms that do not die by readily defined caspase-dependent apoptosis. We will also 
investigate the benefits of combining our enzyme therapeutic with other anti-cancer 
drugs. Combination therapies are a powerful tool in the treatment of cancer and we plan 
to identify those drugs that synergize well with the engineered methionine/cystine 
degrading enzyme. We will conduct cytotoxicity experiments with a variety of cancer 
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cell lines in combination with the chemotherapeutic drugs most commonly used as the 
standard of care such as: carmustine(BCNU), cisplatin, cyclophosphamide, etoposide, 
methotrexate, temozolomide, thiotepa and vinblastine/vincristine as well as autophagy 
inhibitors and inducers such as chloroquine and rapamycin. Those combinations that 
show a high degree of synergy as defined by their combination index (CI) will be tested 















1. Shen, L.-J., Beloussow, K., and Shen, W.-C. (2006) Modulation of arginine metabolic 
pathways as the potential anti-tumor mechanism of recombinant arginine deiminase, 
Cancer Lett 231, 30-35. 
2. Wetzler, M., Sanford, B. L., Kurtzberg, J., DeOliveira, D., Frankel, S. R., Powell, B. L., 
Kolitz, J. E., Bloomfield, C. D., and Larson, R. A. (2007) Effective asparagine depletion 
with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic 
leukemia: Cancer and Leukemia Group B Study 9511, Blood 109, 4164. 
3. Cellarier, E., Durando, X., Vasson, M. P., Farges, M. C., Demiden, A., Maurizis, J. C., 
Madelmont, J. C., and Chollet, P. (2003) Methionine dependency and cancer treatment, 
Cancer treatment reviews 29, 489-499. 
4. Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., and Pazdur, R. (2007) FDA drug 
approval summary: pegaspargase (oncaspar) for the first-line treatment of children with 
acute lymphoblastic leukemia (ALL), Oncologist 12, 991-998. 
5. Pui, C. H. (2009) Toward a total cure for acute lymphoblastic leukemia, J Clin Oncol 27, 
5121-5123. 
6. Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., 
Schrappe, M., and Pui, C. H. (2011) L-asparaginase treatment in acute lymphoblastic 
leukemia: a focus on Erwinia asparaginase, Cancer 117, 238-249. 
7. Avramis, V. I., and Panosyan, E. H. (2005) Pharmacokinetic/pharmacodynamic 
relationships of asparaginase formulations: the past, the present and recommendations 
for the future, Clin Pharmacokinet 44, 367-393. 
8. Breillout, F., Antoine, E., and Poupon, M. F. (1990) Methionine dependency of malignant 
tumors: a possible approach for therapy, J Natl Cancer Inst 82, 1628-1632. 
9. Datsenko, K. A., and Wanner, B. L. (2000) One-step inactivation of chromosomal genes 
in Escherichia coli K-12 using PCR products, Proc Natl Acad Sci U S A 97, 6640-6645. 
10. Durando, X., Thivat, E., Farges, M., Cellarier, E., D Incan, M., Demidem, A., Vasson, M., 
Barthomeuf, C., and Chollet, P. (2008) Optimal methionine-free diet duration for 
nitrourea treatment: a Phase I clinical trial, Nutrition and cancer 60, 23-30. 
11. Halpern, B., Clark, B., Hardy, D., Halpern, R., and Smith, R. (1974) The effect of 
replacement of methionine by homocystine on survival of malignant and normal adult 
mammalian cells in culture, Proceedings of the National Academy of Sciences of the 
United States of America 71, 1133. 
12. Kokkinakis, D. M., Schold, S. C., Hori, H., and Nobori, T. (1997) Effect of long-term 
depletion of plasma methionine on the growth and survival of human brain tumor 
xenografts in athymic mice, Nutrition and cancer 29, 195-204. 
13. Kreis, W. (1979) Tumor therapy by deprivation of L-methionine: rationale and results, 
Cancer treatment reports 63, 1069. 
14. Kreis, W., Baker, A., Ryan, V., and Bertasso, A. (1980) Effect of nutritional and enzymatic 
methionine deprivation upon human normal and malignant cells in tissue culture, 
Cancer research 40, 634. 
 153 
15. Kreis, W., and Goodenow, M. (1978) Methionine requirement and replacement by 
homocysteine in tissue cultures of selected rodent and human malignant and normal 
cells, Cancer research 38, 2259. 
16. Thomas, T., and Thomas, T. J. (2003) Polyamine metabolism and cancer, J Cell Mol Med 
7, 113-126. 
17. Megosh, L., Gilmour, S. K., Rosson, D., Soler, A. P., Blessing, M., Sawicki, J. A., and 
O'Brien, T. G. (1995) Increased frequency of spontaneous skin tumors in transgenic mice 
which overexpress ornithine decarboxylase, Cancer Res 55, 4205-4209. 
18. Auvinen, M., Paasinen, A., Andersson, L. C., and Holtta, E. (1992) Ornithine 
decarboxylase activity is critical for cell transformation, Nature 360, 355-358. 
19. Frau, M., Feo, F., and Pascale, R. M. (2013) Pleiotropic effects of methionine 
adenosyltransferases deregulation as determinants of liver cancer progression and 
prognosis, J Hepatol 59, 830-841. 
20. Bertino, J. R., Lubin, M., Johnson-Farley, N., Chan, W. C., Goodell, L., and Bhagavathi, S. 
(2012) Lack of expression of MTAP in uncommon T-cell lymphomas, Clin Lymphoma 
Myeloma Leuk 12, 306-309. 
21. Ashe, H., Clark, B. R., Chu, F., Hardy, D. N., Halpern, B. C., Halpern, R. M., and Smith, R. A. 
(1974) N5-methyltetrahydrofolate: homocysteine methyltransferase activity in extracts 
from normal, malignant and embryonic tissue culture cells, Biochemical and biophysical 
research communications 57, 417. 
22. Halpern, B. C., Clark, B. R., Hardy, D. N., Halpern, R. M., and Smith, R. A. (1974) The 
effect of replacement of methionine by homocystine on survival of malignant and 
normal adult mammalian cells in culture, Proceedings of the National Academy of 
Sciences 71, 1133-1136. 
23. Poirier, L. A., and Wilson, M. J. (1980) The elevated requirement for methionine by 
transformed rat liver epithelial cells in vitro, Annals of the New York Academy of 
Sciences 349, 283-293. 
24. Kenyon, S. H., Waterfield, C. J., Timbrell, J. A., and Nicolaou, A. (2002) Methionine 
synthase activity and sulphur amino acid levels in the rat liver tumour cells HTC and Phi-
1, Biochemical pharmacology 63, 381-391. 
25. Stabler, S. P., Marcell, P. D., Podell, E. R., and Allen, R. H. (1987) Quantitation of total 
homocysteine, total cysteine, and methionine in normal serum and urine using capillary 
gas chromatography-mass spectrometry, Anal Biochem 162, 185-196. 
26. Kokkinakis, D. M., Schold, S. C., Hori, H., and Nobori, T. (1997) Effect of long-term 
depletion of plasma methionine on the growth and survival of human brain tumor 
xenografts in athymic mice, Nutr Cancer 29, 195-204. 
27. Goseki, N., Yamazaki, S., Shimojyu, K., Kando, F., Maruyama, M., Endo, M., Koike, M., 
and Takahashi, H. (1995) Synergistic effect of methionine-depleting total parenteral 
nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical 
trial, Jpn J Cancer Res 86, 484-489. 
28. Epner, D. E. (2001) Can dietary methionine restriction increase the effectiveness of 
chemotherapy in treatment of advanced cancer?, J Am Coll Nutr 20, 449. 
 154 
29. Xiao, H., Cao, W., Yin, H., Lin, Y., and Ye, S. (2001) Influence of L-methionine-deprived 
total parenteral nutrition with 5-fluorouracil on gastric cancer and host metabolism, 
WORLD JOURNAL OF GASTROENTEROLOGY 7, 698-701. 
30. Tan, Y., Xu, M., Tan, X., Wang, X., Saikawa, Y., Nagahama, T., Sun, X., Lenz, M., and 
Hoffman, R. M. (1997) Overexpression and large-scale production of recombinant L-
methionine-a-deamino-g-mercaptomethane-lyase for novel anticancer therapy, Protein 
Expression and Purification 9, 233-245. 
31. Tan, Y., Zavala, J. S. R., Xu, M., Zavala, J. J. R., and Hoffman, R. M. (1996) Serum 
methionine depletion without side effects by methioninase in metastatic breast cancer 
patients, Anticancer research 16, 3937-3942. 
32. Lishko, V. K., Lishko, O. V., and Hoffman, R. M. Depletion of serum methionine by 
methioninase in mice, Anticancer research 13, 1465. 
33. Tan, Y., Xu, M., Guo, H., Sun, X., Kubota, T., and Hoffman, R. M. (1996) Anticancer 
efficacy of methioninase in vivo, Anticancer research 16, 3931-3936. 
34. Yoshioka, T., Wada, T., Uchida, N., Maki, H., Yoshida, H., Ide, N., Kasai, H., Hojo, K., 
Shono, K., and Maekawa, R. (1998) Anticancer efficacy in vivo and in vitro, synergy with 
5-fluorouracil, and safety of recombinant methioninase, Cancer Research 58, 2583-2587. 
35. Yang, Z., Wang, J., Lu, Q., Xu, J., Kobayashi, Y., Takakura, T., Takimoto, A., Yoshioka, T., 
Lian, C., and Chen, C. (2004) PEGylation confers greatly extended half-life and 
attenuated immunogenicity to recombinant methioninase in primates, pp 6673-6678, 
AACR. 
36. Yang, Z., Wang, J., Yoshioka, T., Li, B., Lu, Q., Li, S., Sun, X., Tan, Y., Yagi, S., and Frenkel, 
E. P. (2004) Pharmacokinetics, methionine depletion, and antigenicity of recombinant 
methioninase in primates, pp 2131-2138, AACR. 
37. Tan, Y., Zavala, J. S. R., Han, Q., Xu, M., Sun, X., Tan, X., Magana, R., Geller, J., and 
Hoffman, R. M. (1997) Recombinant methioninase infusion reduces the biochemical 
endpoint of serum methionine with minimal toxicity in high-stage cancer patients, 
Anticancer research 17, 3857-3860. 
38. Sridhar, V., Xu, M., Han, Q., Sun, X., Tan, Y., Hoffman, R. M., and Prasad, G. S. (2000) 
Crystallization and preliminary crystallographic characterization of recombinant L-
methionine--deamino--mercaptomethane lyase (methioninase), Acta Crystallographica 
Section D: Biological Crystallography 56, 1665-1667. 
39. Nakamura, T., Esaki, N., Sugiem, K., Beresov, T., Tanaka, H., and Soda, K. (1984) 
Purification of bacterial L-methionine-lyase, Anal. Biochem 138, 421–424. 
40. Hori, H., Takabayashi, K., Orvis, L., Carson, D. A., and Nobori, T. (1996) Gene cloning and 
characterization of Pseudomonas putida L-methionine-alpha-deamino-gamma-
mercaptomethane-lyase, Cancer Research 56, 2116-2122. 
41. Esaki, N., and Soda, K. (1987) L-methionine gamma-lyase from Pseudomonas putida and 
Aeromonas, Methods in enzymology 143, 459. 
42. Ito, S., Nakamura, T., and Eguchi, Y. (1976) Purification and characterization of 
methioninase from Pseudomonas putida, Journal of Biochemistry 79, 1263. 
43. Kudou, D., Misaki, S., Yamashita, M., Tamura, T., Takakura, T., Yoshioka, T., Yagi, S., 
Hoffman, R. M., Takimoto, A., and Esaki, N. (2007) Structure of the Antitumour Enzyme 
 155 
L-Methionine {gamma}-Lyase from Pseudomonas putida at 1.8 A Resolution, Journal of 
Biochemistry 141, 535. 
44. Takakura, T., Takimoto, A., Notsu, Y., Yoshida, H., Ito, T., Nagatome, H., Ohno, M., 
Kobayashi, Y., Yoshioka, T., and Inagaki, K. (2006) Physicochemical and pharmacokinetic 
characterization of highly potent recombinant L-methionine -lyase conjugated with 
polyethylene glycol as an antitumor agent, Cancer Research 66, 2807. 
45. Yang, Z., Wang, J., Lu, Q., Xu, J., Kobayashi, Y., Takakura, T., Takimoto, A., Yoshioka, T., 
Lian, C., Chen, C., Zhang, D., Zhang, Y., Li, S., Sun, X., Tan, Y., Yagi, S., Frenkel, E. P., and 
Hoffman, R. M. (2004) PEGylation confers greatly extended half-life and attenuated 
immunogenicity to recombinant methioninase in primates, Cancer Res 64, 6673-6678. 
46. Hu, J., and Cheung, N. K. (2009) Methionine depletion with recombinant methioninase: 
in vitro and in vivo efficacy against neuroblastoma and its synergism with 
chemotherapeutic drugs, International journal of cancer 124, 1700-1706. 
47. Rose, W. C., Coon, M. J., Lockhart, H. B., and Lambert, G. F. (1955) The amino acid 
requirements of man. XI. The threonine and methionine requirements, J Biol Chem 215, 
101-110. 
48. Rose, W. C., and Wixom, R. L. (1955) The amino acid requirements of man. XIII. The 
sparing effect of cystine on the methionine requirement, J Biol Chem 216, 753-773. 
49. Inoue, H., Inagaki, K., Sugimoto, M., Esaki, N., Soda, K., and Tanaka, H. (1995) Structural 
analysis of the L-methionine {gamma}-lyase gene from Pseudomonas putida, Journal of 
Biochemistry 117, 1120. 
50. Steegborn, C., Clausen, T., Sondermann, P., Jacob, U., Worbs, M., Marinkovic, S., Huber, 
R., and Wahl, M. C. (1999) Kinetics and Inhibition of Recombinant Human Cystathionine 
?-Lyase TOWARD THE RATIONAL CONTROL OF TRANSSULFURATION, Journal of 
Biological Chemistry 274, 12675-12684. 
51. Sun, Q., Collins, R., Huang, S., Holmberg-Schiavone, L., Anand, G. S., and Tan, C. H. 
(2009) Structural Basis for the Inhibition Mechanism of Human Cystathionine {gamma}-
Lyase, an Enzyme Responsible for the Production of H2S, Journal of Biological Chemistry 
284, 3076. 
52. Messerschmidt, A., Worbs, M., Steegborn, C., Wahl, M. C., Huber, R., Laber, B., and 
Clausen, T. (2003) Determinants of enzymatic specificity in the Cys-Met-metabolism 
PLP-dependent enzymes family: crystal structure of cystathionine gamma-lyase from 
yeast and intrafamiliar structure comparison, Biol Chem 384, 373-386. 
53. Stone, E., Paley, O., Hu, J., Ekerdt, B., Cheung, N. K., and Georgiou, G. (2012) De novo 
engineering of a human cystathionine-gamma-lyase for systemic (L)-Methionine 
depletion cancer therapy, ACS Chem Biol 7, 1822-1829. 
54. Breillout, F., Antoine, E., and Poupon, M. F. (1990) Methionine dependency of malignant 
tumors: a possible approach for therapy, pp 1628-1632, © Oxford University Press. 
55. Halpern, B. C., Clark, B. R., Hardy, D. N., Halpern, R. M., and Smith, R. A. (1974) The 
effect of replacement of methionine by homocystine on survival of malignant and 
normal adult mammalian cells in culture, Proceedings of the National Academy of 
Sciences 71, 1133. 
 156 
56. Poirson-Bichat, F., Goncalves, R. A., Miccoli, L., Dutrillaux, B., and Poupon, M. F. (2000) 
Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-
resistant human tumor xenografts, Clin Cancer Res 6, 643-653. 
57. Hu, J., and Cheung, N.-K. V. (2009) Methionine depletion with recombinant 
methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with 
chemotherapeutic drugs, Int J Cancer 124, 1700-1706. 
58. D'Souza, M. M., Sharma, R., Jaimini, A., Panwar, P., Saw, S., Kaur, P., Mondal, A., Mishra, 
A., and Tripathi, R. P. (2014) 11C-MET PET/CT and Advanced MRI in the Evaluation of 
Tumor Recurrence in High-Grade Gliomas, Clin Nucl Med 17, 17. 
59. Thomas, T., and Thomas, T. J. (2003) Polyamine metabolism and cancer, Journal of 
Cellular and Molecular Medicine 7, 113-126. 
60. Megosh, L., Gilmour, S. K., Rosson, D., Soler, A. P., Blessing, M., Sawicki, J. A., and 
O'Brien, T. G. (1995) Increased frequency of spontaneous skin tumors in transgenic mice 
which overexpress ornithine decarboxylase, Cancer research 55, 4205-4209. 
61. Auvinen, M., Paasinen, A., Andersson, L. C., and Hölttä, E. (1992) Ornithine 
decarboxylase activity is critical for cell transformation. 
62. Lu, S., and Epner, D. E. (2000) Molecular mechanisms of cell cycle block by methionine 
restriction in human prostate cancer cells, Nutrition and cancer 38, 123-130. 
63. Stabler, S. P., Marcell, P. D., Podell, E. R., and Allen, R. H. (1987) Quantitation of total 
homocysteine, total cysteine, and methionine in normal serum and urine using capillary 
gas chromatography-mass spectrometry, Analytical biochemistry 162, 185-196. 
64. Kokkinakis, D. M., Von Wronski, M. A., Vuong, T. H., Brent, T. P., and Schold Jr, S. C. 
(1997) Regulation of O6-methylguanine-DNA methyltransferase by methionine in 
human tumour cells, British journal of cancer 75, 779. 
65. Yang, Z., Wang, J., Lu, Q., Xu, J., Kobayashi, Y., Takakura, T., Takimoto, A., Yoshioka, T., 
Lian, C., Chen, C., Zhang, D., Zhang, Y., Li, S., Sun, X., Tan, Y., Yagi, S., Frenkel, E. P., and 
Hoffman, R. M. (2004) PEGylation confers greatly extended half-life and attenuated 
immunogenicity to recombinant methioninase in primates, pp 6673-6678, Cancer 
Research. 
66. Lishko, V. K., Lishko, O. V., and Hoffman, R. M. (1993) Depletion of serum methionine by 
methioninase in mice, Anticancer research 13, 1465. 
67. Yang, Z., Wang, J., Yoshioka, T., Li, B., Lu, Q., Li, S., Sun, X., Tan, Y., Yagi, S., Frenkel, E. P., 
and Hoffman, R. M. (2004) Pharmacokinetics, methionine depletion, and antigenicity of 
recombinant methioninase in primates, Clinical Cancer Research 10, 2131-2138. 
68. Yoshioka, T., Wada, T., Uchida, N., Maki, H., Yoshida, H., Ide, N., Kasai, H., Hojo, K., 
Shono, K., Maekawa, R., Yagi, S., Hoffman, R. M., and Sugita, K. (1998) Anticancer 
efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant 
methioninase, Cancer research 58, 2583-2587. 
69. Sun, X., Yang, Z., Li, S., Tan, Y., Zhang, N., Wang, X., Yagi, S., Yoshioka, T., Takimoto, A., 
and Mitsushima, K. (2003) In vivo efficacy of recombinant methioninase is enhanced by 
the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate 
supplementation, pp 8377-8383, AACR. 
 157 
70. Yang, Z., Sun, X., Li, S., Tan, Y., Wang, X., Zhang, N., Yagi, S., Takakura, T., Kobayashi, Y., 
Takimoto, A., Yoshioka, T., Suginaka, A., Frenkel, E. P., and Hoffman, R. M. (2004) 
Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose 
dependent on cofactor pyridoxal-5'-phosphate, Cancer research 64, 5775. 
71. Hwang, W. Y. K., and Foote, J. (2005) Immunogenicity of engineered antibodies, 
Methods 36, 3-10. 
72. Magdelaine-Beuzelin, C., Vermeire, S., Goodall, M., Baert, F., Noman, M., Assche, G. V., 
Ohresser, M., Degenne, D., Dugoujon, J. M., and Jefferis, R. (2009) IgG1 heavy chain-
coding gene polymorphism (G1m allotypes) and development of antibodies-to-
infliximab, Pharmacogenetics and genomics 19, 383. 
73. Steegborn, C., Clausen, T., Sondermann, P., Jacob, U., Worbs, M., Marinkovic, S., Huber, 
R., and Wahl, M. C. (1999) Kinetics and inhibition of recombinant human cystathionine 
gamma-lyase. Toward the rational control of transsulfuration, J Biol Chem 274, 12675-
12684. 
74. Khersonsky, O., and Tawfik, D. S. (2010) Enzyme promiscuity: a mechanistic and 
evolutionary perspective, Annu Rev Biochem 79, 471-505. 
75. Takakura, T., Mitsushima, K., Yagi, S., Inagaki, K., Tanaka, H., Esaki, N., Soda, K., and 
Takimoto, A. (2004) Assay method for antitumor L-methionine -lyase: comprehensive 
kinetic analysis of the complex reaction with L-methionine, Analytical biochemistry 327, 
233-240. 
76. Ditscheid, B., Fünfstück, R., Busch, M., Schubert, R., Gerth, J., and Jahreis, G. (2005) 
Effect of L-methionine supplementation on plasma homocysteine and other free amino 
acids: a placebo-controlled double-blind cross-over study, European journal of clinical 
nutrition 59, 768-775. 
77. Araki, A., and Sako, Y. (1987) Determination of free and total homocysteine in human 
plasma by high-performance liquid chromatography with fluorescence detection, 
Journal of Chromatography: Biomedical Applications 422, 43-52. 
78. Serjeant, E. P., and Dempsey, B. (1979) Ionization constants of organic acids in solution, 
IUPAC Chemical Data Series No. 23, Oxford (UK): Pergamon Press. 
79. Huang, S., Chua, J. H., Yew, W. S., Sivaraman, J., Moore, P. K., Tan, C. H., and Deng, L. W. 
(2010) Site-Directed Mutagenesis on Human Cystathionine-[gamma]-Lyase Reveals 
Insights into the Modulation of H2S Production, Journal of molecular biology 396, 708-
718. 
80. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. 
T., Chesnut, R. W., Grey, H. M., and Sette, A. (1998) Several common HLA-DR types 
share largely overlapping peptide binding repertoires, The Journal of Immunology 160, 
3363. 
81. Purswani, M. U., Eckert, S. J., Arora, H. K., and Noel, G. J. (2002) Effect of ciprofloxacin 
on lethal and sublethal challenge with endotoxin and on early cytokine responses in a 
murine in vivo model, Journal of Antimicrobial Chemotherapy 50, 51-58. 
82. Deb, K., Chaturvedi, M. M., and Jaiswal, Y. K. (2005) Gram-negative bacterial LPS 
induced poor uterine receptivity and implantation failure in mouse: Alterations in IL-1b 
 158 
expression in the preimplantation embryo and uterine horns, Infectious diseases in 
Obstetrics and Gynecology 13, 125-134. 
83. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and 
Hammond, D. (1985) Association of multiple copies of the N-myc oncogene with rapid 
progression of neuroblastomas, The New England journal of medicine 313, 1111-1116. 
84. Azarova, A. M., Gautam, G., and George, R. E. (2011) Emerging importance of ALK in 
neuroblastoma, Seminars in cancer biology 21, 267-275. 
85. Cheung, N. K., Zhang, J., Lu, C., Parker, M., Bahrami, A., Tickoo, S. K., Heguy, A., Pappo, 
A. S., Federico, S., Dalton, J., Cheung, I. Y., Ding, L., Fulton, R., Wang, J., Chen, X., 
Becksfort, J., Wu, J., Billups, C. A., Ellison, D., Mardis, E. R., Wilson, R. K., Downing, J. R., 
Dyer, M. A., and St Jude Children's Research Hospital-Washington University Pediatric 
Cancer Genome, P. (2012) Association of age at diagnosis and genetic mutations in 
patients with neuroblastoma, JAMA : the journal of the American Medical Association 
307, 1062-1071. 
86. Takakura, T., Takimoto, A., Notsu, Y., Yoshida, H., Ito, T., Nagatome, H., Ohno, M., 
Kobayashi, Y., Yoshioka, T., Inagaki, K., Yagi, S., Hoffman, R. M., and Esaki, N. (2006) 
Physicochemical and pharmacokinetic characterization of highly potent recombinant L-
methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent, 
Cancer research 66, 2807. 
87. Epner, D. E. (2001) Can dietary methionine restriction increase the effectiveness of 
chemotherapy in treatment of advanced cancer?, Journal of the American College of 
Nutrition 20, 443. 
88. Cao, H., Lin, H., and Ye, S. H. (2001) Influence of L-methionine-deprived total parenteral 
nutrition with 5-fluorouracil on gastric cancer and host metabolism, ( ) 7. 
89. Durando, X., Thivat, E., Farges, M. C., Cellarier, E., D'Incan, M., Demidem, A., Vasson, M. 
P., Barthomeuf, C., and Chollet, P. (2008) Optimal methionine-free diet duration for 
nitrourea treatment: a Phase I clinical trial, Nutrition and cancer 60, 23. 
90. Tan, Y., Sun, X., Xu, M., Tan, X., Sasson, A., Rashidi, B., Han, Q., Wang, X., An, Z., Sun, F., 
and Hoffman, R. M. (1999) Efficacy of recombinant methioninase in combination with 
cisplatin on human colon tumors in nude mice, Clinical Cancer Research 5, 2157-2163. 
91. Kokkinakis, D. M., Wick, J. B., and Zhou, Q. X. (2002) Metabolic response of normal and 
malignant tissue to acute and chronic methionine stress in athymic mice bearing human 
glial tumor xenografts, Chemical research in toxicology 15, 1472-1479. 
92. Kokkinakis, D. M., Hoffman, R. M., Frenkel, E. P., Wick, J. B., Han, Q., Xu, M., Tan, Y., and 
Schold, S. C. (2001) Synergy between methionine stress and chemotherapy in the 
treatment of brain tumor xenografts in athymic mice, Cancer research 61, 4017. 
93. Glazer, E. S., Piccirillo, M., Albino, V., Di Giacomo, R., Palaia, R., Mastro, A. A., Beneduce, 
G., Castello, G., De Rosa, V., Petrillo, A., Ascierto, P. A., Curley, S. A., and Izzo, F. (2010) 
Phase II study of pegylated arginine deiminase for nonresectable and metastatic 
hepatocellular carcinoma, Journal of Clinical Oncology 28, 2220. 
94. Reinders, M. K., and Tim, L. (2010) New advances in the treatment of gout: review of 
pegloticase, Therapeutics and Clinical Risk Management 6, 543. 
 159 
95. Hoover, D. M., Boulegue, C., Yang, D., Oppenheim, J. J., Tucker, K., Lu, W., and 
Lubkowski, J. (2002) The structure of human macrophage inflammatory protein-3alpha 
/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with 
human beta-defensins, J Biol Chem 277, 37647-37654. 
96. Gill, S. C., and von Hippel, P. H. (1989) Calculation of protein extinction coefficients from 
amino acid sequence data, Anal Biochem 182, 319-326. 
97. Wang, P., Sidney, J., Dow, C., Mothé, B., Sette, A., and Peters, B. (2008) A systematic 
assessment of MHC class II peptide binding predictions and evaluation of a consensus 
approach, PLoS Comput Biol 4, e1000048. 
98. Cantor, J. R., Yoo, T. H., Dixit, A., Iverson, B. L., Forsthuber, T. G., and Georgiou, G. (2011) 
Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using 
neutral drift, Proc Natl Acad Sci U S A 108, 1272-1277. 
99. Sun, X., Tan, Y., Yang, Z., Li, S., and Hoffman, R. M. (2005) A rapid HPLC method for the 
measurement of ultra-low plasma methionine concentrations applicable to methionine 
depletion therapy, Anticancer Res 25, 59-62. 
100. MarvinSketch. (2011) 5.5.0.1 edn., ChemAxon. 
101. Hirata, H., Kawanishi, M., Iwata, Y., Sakaki, K., and Yanagishita, H. (2007) Kinetic studies 
on lipase-catalyzed acetylation of 2-alkanol with vinyl acetate in organic solvent, Journal 
of Oleo Science 56, 309-317. 
102. Cheung, N. K. V., Guo, H. F., Modak, S., and Cheung, I. Y. (2003) Anti-idiotypic antibody 
facilitates scFv chimeric immune receptor gene transduction and clonal expansion of 
human lymphocytes for tumor therapy, Hybridoma and hybridomics 22, 209-218. 
103. Sanceau, J., Poupon, M. F., Delattre, O., Sastre-Garau, X., and Wietzerbin, J. (2002) 
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-
alpha or interferon-beta with ifosfamide, Oncogene 21, 7700-7709. 
104. Benner, S. A., and Gaucher, E. A. (2001) Evolution, language and analogy in functional 
genomics, Trends Genet 17, 414-418. 
105. Skovgaard, M., Kodra, J. T., Gram, D. X., Knudsen, S. M., Madsen, D., and Liberles, D. A. 
(2006) Using evolutionary information and ancestral sequences to understand the 
sequence-function relationship in GLP-1 agonists, J Mol Biol 363, 977-988. 
106. Yamashiro, K., Yokobori, S., Koikeda, S., and Yamagishi, A. (2010) Improvement of 
Bacillus circulans beta-amylase activity attained using the ancestral mutation method, 
Protein Eng Des Sel 23, 519-528. 
107. Sokalingam, S., Raghunathan, G., Soundrarajan, N., and Lee, S. G. (2012) A study on the 
effect of surface lysine to arginine mutagenesis on protein stability and structure using 
green fluorescent protein, PLoS ONE 7, 9. 
108. Takakura, T., Takimoto, A., Notsu, Y., Yoshida, H., Ito, T., Nagatome, H., Ohno, M., 
Kobayashi, Y., Yoshioka, T., Inagaki, K., Yagi, S., Hoffman, R. M., and Esaki, N. (2006) 
Physicochemical and pharmacokinetic characterization of highly potent recombinant L-
methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent, 
Cancer Res 66, 2807-2814. 
 160 
109. Gaucher, E. A., Miyamoto, M. M., and Benner, S. A. (2003) Evolutionary, structural and 
biochemical evidence for a new interaction site of the leptin obesity protein, Genetics 
163, 1549-1553. 
110. Perez-Jimenez, R., Li, J., Kosuri, P., Sanchez-Romero, I., Wiita, A. P., Rodriguez-Larrea, D., 
Chueca, A., Holmgren, A., Miranda-Vizuete, A., Becker, K., Cho, S. H., Beckwith, J., 
Gelhaye, E., Jacquot, J. P., Gaucher, E. A., Sanchez-Ruiz, J. M., Berne, B. J., and 
Fernandez, J. M. (2009) Diversity of chemical mechanisms in thioredoxin catalysis 
revealed by single-molecule force spectroscopy, Nat Struct Mol Biol 16, 890-896. 
111. Yuen, C. M., and Liu, D. R. (2007) Dissecting protein structure and function using 
directed evolution, Nat Methods 4, 995-997. 
112. Pal, D., and Chakrabarti, P. (2001) Non-hydrogen bond interactions involving the 
methionine sulfur atom, J Biomol Struct Dyn 19, 115-128. 
113. Borders, C. L., Jr., Broadwater, J. A., Bekeny, P. A., Salmon, J. E., Lee, A. S., Eldridge, A. 
M., and Pett, V. B. (1994) A structural role for arginine in proteins: multiple hydrogen 
bonds to backbone carbonyl oxygens, Protein Sci 3, 541-548. 
114. Paley, O., Agnello, G., Cantor, J., Yoo, T. H., Georgiou, G., and Stone, E. (2013) GFP 
reporter screens for the engineering of amino acid degrading enzymes from libraries 
expressed in bacteria, Methods Mol Biol 978, 31-44. 
115. Farinas, E. T. (2006) Fluorescence activated cell sorting for enzymatic activity, 
Combinatorial Chemistry &# 38; High Throughput Screening 9, 321-328. 
116. Agrawal, V., Woo, J. H., Mauldin, J. P., Jo, C., Stone, E. M., Georgiou, G., and Frankel, A. 
E. (2012) Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of 
supplemental L-citrulline is dependent on decreased argininosuccinate synthetase 
expression in human cells, Anti-Cancer Drugs 23, 51. 
117. Cantor, J. R., Panayiotou, V., Agnello, G., Georgiou, G., and Stone, E. M. (2012) 
Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in 
Cancer, Protein Engineering for Therapeutics 502, 291. 
118. Stone, E., Chantranupong, L., Gonzalez, C., O'Neal, J., Rani, M., VanDenBerg, C., and 
Georgiou, G. (2011) Strategies for Optimizing the Serum Persistence of Engineered 
Human Arginase I for Cancer Therapy, Journal of Controlled Release. 
119. Stone, E. M., Glazer, E. S., Chantranupong, L., Cherukuri, P., Breece, R. M., Tierney, D. L., 
Curley, S. A., Iverson, B. L., and Georgiou, G. (2010) Replacing Mn2+ with Co2+ in human 
arginase I enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines, ACS 
chemical biology 5, 333-342. 
120. Donath, M. J., 2nd, Dominguez, M. A., and Withers, S. T., 3rd. (2011) Development of an 
automated platform for high-throughput P1-phage transduction of Escherichia coli, J 
Lab Autom 16, 141-147. 
121. Barrick, J. E., Yu, D. S., Yoon, S. H., Jeong, H., Oh, T. K., Schneider, D., Lenski, R. E., and 
Kim, J. F. (2009) Genome evolution and adaptation in a long-term experiment with 
Escherichia coli, Nature 461, 1243-1247. 
122. Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., 
Tomita, M., Wanner, B. L., and Mori, H. (2006) Construction of Escherichia coli K-12 in-
frame, single-gene knockout mutants: the Keio collection, Mol Syst Biol 2, 21. 
 161 
123. Leavitt, R. I., and Umbarger, H. (1962) ISOLEUCINE AND VALINE METABOLISM IN 
ESCHERICHIA COLI XI. K-12: Valine Inhibition of the Growth of Escherichia coli Strain, 
Journal of bacteriology 83, 624. 
124. Gollop, N., Chipman, D. M., and Barak, Z. (1983) Inhibition of acetohydroxy acid 
synthase by leucine, Biochimica et Biophysica Acta (BBA)-Protein Structure and 
Molecular Enzymology 748, 34-39. 
125. Guo, H. Y., Herrera, H., Groce, A., and Hoffman, R. M. (1993) Expression of the 
biochemical defect of methionine dependence in fresh patient tumors in primary 
histoculture, Cancer Res 53, 2479-2483. 
126. Morvan, D., Demidem, A., Guenin, S., and Madelmont, J. C. (2006) Methionine-
dependence phenotype of tumors: metabolite profiling in a melanoma model using L-
[methyl-13C]methionine and high-resolution magic angle spinning 1H-13C nuclear 
magnetic resonance spectroscopy, Magn Reson Med 55, 984-996. 
127. Pavillard, V., Drbal, A. A., Swaine, D. J., Phillips, R. M., Double, J. A., and Nicolaou, A. 
(2004) Analysis of cell-cycle kinetics and sulfur amino acid metabolism in methionine-
dependent tumor cell lines; the effect of homocysteine supplementation, Biochem 
Pharmacol 67, 1587-1599. 
128. Tan, Y., Xu, M., and Hoffman, R. M. (2010) Broad selective efficacy of recombinant 
methioninase and polyethylene glycol-modified recombinant methioninase on cancer 
cells In Vitro, Anticancer Res 30, 1041-1046. 
129. Tan, Y., Xu, M., Tan, X., Wang, X., Saikawa, Y., Nagahama, T., Sun, X., Lenz, M., and 
Hoffman, R. M. (1997) Overexpression and large-scale production of recombinant L-
methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer 
therapy, Protein Expr Purif 9, 233-245. 
130. Watkins, D. (1998) Cobalamin metabolism in methionine-dependent human tumour and 
leukemia cell lines, Clin Invest Med 21, 151-158. 
131. Jerant, A. F., Johnson, J. T., Sheridan, C. D., and Caffrey, T. J. (2000) Early detection and 
treatment of skin cancer, Am Fam Physician 62, 357-368. 
132. Bhatia, S., Tykodi, S. S., and Thompson, J. A. (2009) Treatment of metastatic melanoma: 
an overview, Oncology 23, 488-496. 
133. Miller, D. C., Hafez, K. S., Stewart, A., Montie, J. E., and Wei, J. T. (2003) Prostate 
carcinoma presentation, diagnosis, and staging: an update form the National Cancer 
Data Base, Cancer 98, 1169-1178. 
134. Li, S., Kennedy, M., Payne, S., Kennedy, K., Seewaldt, V. L., Pizzo, S. V., and Bachelder, R. 
E. (2014) Model of tumor dormancy/recurrence after short-term chemotherapy, PLoS 
ONE 9. 
135. Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., 
Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., Gottlieb, E., Green, D. R., 
Hengartner, M. O., Kepp, O., Knight, R. A., Kumar, S., Lipton, S. A., Lu, X., Madeo, F., 
Malorni, W., Mehlen, P., Nunez, G., Peter, M. E., Piacentini, M., Rubinsztein, D. C., Shi, 
Y., Simon, H. U., Vandenabeele, P., White, E., Yuan, J., Zhivotovsky, B., Melino, G., and 
Kroemer, G. (2012) Molecular definitions of cell death subroutines: recommendations of 
the Nomenclature Committee on Cell Death 2012, Cell Death Differ 19, 107-120. 
 162 
136. Stevens, J. B., Abdallah, B. Y., Liu, G., Horne, S. D., Bremer, S. W., Ye, K. J., Huang, J. Y., 
Kurkinen, M., Ye, C. J., and Heng, H. H. (2013) Heterogeneity of cell death, Cytogenet 
Genome Res 139, 164-173. 
137. Kokkinakis, D. M., Brickner, A. G., Kirkwood, J. M., Liu, X., Goldwasser, J. E., Kastrama, A., 
Sander, C., Bocangel, D., and Chada, S. (2006) Mitotic arrest, apoptosis, and sensitization 
to chemotherapy of melanomas by methionine deprivation stress, Mol Cancer Res 4, 
575-589. 
138. Elmore, S. (2007) Apoptosis: a review of programmed cell death, Toxicol Pathol 35, 495-
516. 
139. van Loo, G., Saelens, X., van Gurp, M., MacFarlane, M., Martin, S. J., and Vandenabeele, 
P. (2002) The role of mitochondrial factors in apoptosis: a Russian roulette with more 
than one bullet, Cell Death Differ 9, 1031-1042. 
140. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., 
Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. 
A., Kumar, S., Lipton, S. A., Malorni, W., Nunez, G., Peter, M. E., Tschopp, J., Yuan, J., 
Piacentini, M., Zhivotovsky, B., and Melino, G. (2009) Classification of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2009, Cell Death Differ 
16, 3-11. 
141. Sheen, J. H., Zoncu, R., Kim, D., and Sabatini, D. M. (2011) Defective regulation of 
autophagy upon leucine deprivation reveals a targetable liability of human melanoma 
cells in vitro and in vivo, Cancer Cell 19, 613-628. 
142. Eisenberg-Lerner, A., and Kimchi, A. (2009) The paradox of autophagy and its implication 
in cancer etiology and therapy, Apoptosis 14, 376-391. 
143. Jayaraman, S. (2003) Intracellular determination of activated caspases (IDAC) by flow 
cytometry using a pancaspase inhibitor labeled with FITC, Cytometry A 56, 104-112. 
144. al-Rubeai, M., Emery, A. N., and Chalder, S. (1991) Flow cytometric study of cultured 
mammalian cells, J Biotechnol 19, 67-81. 
145. Cain, K., Inayat-Hussain, S. H., Couet, C., and Cohen, G. M. (1996) A cleavage-site-
directed inhibitor of interleukin-1 beta-converting enzyme-like proteases inhibits 
apoptosis in primary cultures of rat hepatocytes, Biochem J 314, 27-32. 
146. Unglaub, F., Thomas, S. B., Kroeber, M. W., Dragu, A., Fellenberg, J., Wolf, M. B., and 
Horch, R. E. (2009) Apoptotic pathways in degenerative disk lesions in the wrist, 
Arthroscopy 25, 1380-1386. 
147. Barber, R. D., Harmer, D. W., Coleman, R. A., and Clark, B. J. (2005) GAPDH as a 
housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues, 
Physiol Genomics 21, 389-395. 
148. Kirkegaard, K., Taylor, M. P., and Jackson, W. T. (2004) Cellular autophagy: surrender, 
avoidance and subversion by microorganisms, Nat Rev Microbiol 2, 301-314. 
149. Tanida, I., Ueno, T., and Kominami, E. (2008) LC3 and Autophagy, Methods Mol Biol 445, 
77-88. 
150. Ha, J. Y., Kim, J. S., Kim, S. E., and Son, J. H. (2014) Simultaneous activation of mitophagy 
and autophagy by staurosporine protects against dopaminergic neuronal cell death, 
Neurosci Lett 561, 101-106. 
 163 
151. Alimirah, F., Chen, J., Basrawala, Z., Xin, H., and Choubey, D. (2006) DU-145 and PC-3 
human prostate cancer cell lines express androgen receptor: implications for the 
androgen receptor functions and regulation, FEBS Lett 580, 2294-2300. 
152. de Bruin, E. C., and Medema, J. P. (2008) Apoptosis and non-apoptotic deaths in cancer 
development and treatment response, Cancer Treat Rev 34, 737-749. 
153. Saha, A., Blando, J., Silver, E., Beltran, L., Sessler, J., and DiGiovanni, J. (2014) 6-Shogaol 
from dried ginger inhibits growth of prostate cancer cells both in vitro and in vivo 
through inhibition of STAT3 and NF-kappaB signaling, Cancer Prev Res 7, 627-638. 
154. Teicher, B. A. (2006) Tumor models for efficacy determination, Mol Cancer Ther 5, 2435-
2443. 
155. Psychogios, N., Hau, D. D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I., 
Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., Huang, P., 
Hollander, Z., Pedersen, T. L., Smith, S. R., Bamforth, F., Greiner, R., McManus, B., 
Newman, J. W., Goodfriend, T., and Wishart, D. S. (2011) The human serum 
metabolome, PLoS ONE 6, 0016957. 
156. Meister, A., and Anderson, M. E. (1983) Glutathione, Annu Rev Biochem 52, 711-760. 
157. Pompella, A., Visvikis, A., Paolicchi, A., De Tata, V., and Casini, A. F. (2003) The changing 
faces of glutathione, a cellular protagonist, Biochem Pharmacol 66, 1499-1503. 
158. Hanigan, M. H. (2014) Gamma-glutamyl transpeptidase: redox regulation and drug 
resistance, Adv Cancer Res 122, 103-141. 
159. Kumar, B., Koul, S., Khandrika, L., Meacham, R. B., and Koul, H. K. (2008) Oxidative stress 
is inherent in prostate cancer cells and is required for aggressive phenotype, Cancer Res 
68, 1777-1785. 
160. Rajasekaran, S. A., Gopal, J., Espineda, C., Ryazantsev, S., Schneeberger, E. E., and 
Rajasekaran, A. K. (2004) HPAF-II, a cell culture model to study pancreatic epithelial cell 
structure and function, Pancreas 29, e77-83. 
161. Mahe, C., Bernhard, M., Bobirnac, I., Keser, C., Loetscher, E., Feuerbach, D., Dev, K. K., 
and Schoeffter, P. (2004) Functional expression of the serotonin 5-HT7 receptor in 
human glioblastoma cell lines, Br J Pharmacol 143, 404-410. 
162. Xie, Q., Mittal, S., and Berens, M. E. Targeting adaptive glioblastoma: an overview of 
proliferation and invasion, Neuro Oncol. 2014 Jul 30. pii: nou147. 
163. Arslan, C., and Yalcin, S. (2014) Current and future systemic treatment options in 
metastatic pancreatic cancer, J Gastrointest Oncol 5, 280-295. 
164. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. (1979) 
Establishment and characterization of a human prostatic carcinoma cell line (PC-3), 
Invest Urol 17, 16-23. 
165. Cohen, A. A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva, I., Sigal, A., 
Milo, R., Cohen-Saidon, C., Liron, Y., Kam, Z., Cohen, L., Danon, T., Perzov, N., and Alon, 
U. (2008) Dynamic proteomics of individual cancer cells in response to a drug, Science 
322, 1511-1516. 
166. Heng, H. H., Liu, G., Stevens, J. B., Bremer, S. W., Ye, K. J., and Ye, C. J. (2010) Genetic 
and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy, Curr 
Drug Targets 11, 1304-1316. 
 164 
167. Heng, H. H., Stevens, J. B., Liu, G., Bremer, S. W., Ye, K. J., Reddy, P. V., Wu, G. S., Wang, 
Y. A., Tainsky, M. A., and Ye, C. J. (2006) Stochastic cancer progression driven by non-
clonal chromosome aberrations, J Cell Physiol 208, 461-472. 
168. Reed, J. C. (1999) Dysregulation of apoptosis in cancer, J Clin Oncol 17, 2941-2953. 
169. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer, Cell 100, 57-70. 
170. McBean, G. J. (2012) The transsulfuration pathway: a source of cysteine for glutathione 
in astrocytes, Amino Acids 42, 199-205. 
171. Deplancke, B., and Gaskins, H. R. (2002) Redox control of the transsulfuration and 
glutathione biosynthesis pathways, Curr Opin Clin Nutr Metab Care 5, 85-92. 
172. Conrad, M., and Sato, H. (2012) The oxidative stress-inducible cystine/glutamate 
antiporter, system x (c) (-) : cystine supplier and beyond, Amino Acids 42, 231-246. 
173. Doxsee, D. W., Gout, P. W., Kurita, T., Lo, M., Buckley, A. R., Wang, Y., Xue, H., Karp, C. 
M., Cutz, J. C., Cunha, G. R., and Wang, Y. Z. (2007) Sulfasalazine-induced cystine 
starvation: potential use for prostate cancer therapy, Prostate 67, 162-171. 
174. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., 
Thomas, G. V., and Sawyers, C. L. (2003) Myc-driven murine prostate cancer shares 
molecular features with human prostate tumors, Cancer cell 4, 223-238. 
175. Hu, J., and Cheung, N. K. V. (2009) Methionine depletion with recombinant 
methioninase: In vitro and in vivo efficacy against neuroblastoma and its synergism with 
chemotherapeutic drugs, International journal of cancer 124. 
176. Tiziani, S., Einwas, A. H., Lodi, A., Ludwig, C., Bunce, C. M., Viant, M. R., and Gunther, U. 
L. (2008) Optimized metabolite extraction from blood serum for 1H nuclear magnetic 
resonance spectroscopy, Analytical Biochemistry 377, 16-23. 
177. Tiziani, S., Kang, Y., Harjanto, R., Axelrod, J., Piermarocchi, C., Roberts, W., and 
Paternostro, G. (2013) Metabolomics of the tumor microenvironment in pediatric acute 
lymphoblastic leukemia, PloS one 8, e82859. 
178. Lodi, A., Tiziani, S., Khanim, F. L., Drayson, M. T., Gunther, U. L., Bunce, C. M., and Viant, 
M. R. (2011) Hypoxia triggers major metabolic changes in AML cells without altering 
indomethacin-induced TCA cycle deregulation, ACS Chem. Biol. 6, 169-175. 
179. Tiziani, S., Lodi, A., Khanim, F. L., Viant, M. R., Bunce, C. M., and Gunther, U. L. (2009) 
Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines, Plos 
One 4, e4251. 
180. Hwang, T. L., and Shaka, A. J. (1995) Water suppression that works - Excitation sculpting 
using arbitrary wave-forms and pulsed-field gradients, Journal of Magnetic Resonance 
Series A 112, 275-279. 
181. Ludwig, C., and Günther, U. L. (2011) MetaboLab - advanced NMR data processing and 
analysis for metabolomics, BMC bioinformatics 12, 366. 
182. Psychogios, N., Hau, D. D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I., 
Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J. G., Knox, C., Dong, E., Huang, 
P., Hollander, Z., Pedersen, T. L., Smith, S. R., Bamforth, F., Greiner, R., McManus, B., 
Newman, J. W., Goodfriend, T., and Wishart, D. S. (2011) The Human Serum 
Metabolome, Plos One 6. 
 165 
183. Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., 
Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., Sullards, C. M., Wang, E., 
Murphy, R. C., Barkley, R. M., Leiker, T. J., Raetz, C. R. H., Guan, Z. Q., Laird, G. M., Six, D. 
A., Russell, D. W., McDonald, J. G., Subramaniam, S., Fahy, E., and Dennis, E. A. (2010) 
Lipidomics reveals a remarkable diversity of lipids in human plasma, Journal of Lipid 
Research 51, 3299-3305. 
184. Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., 
Mandal, R., Aziat, F., and Dong, E. (2013) HMDB 3.0—The Human Metabolome Database 
in 2013, Nucleic Acids Research 41, D801-D807. 
185. Ludwig, C., Easton, J. M., Lodi, A., Tiziani, S., Manzoor, S. E., Southam, A. D., Byrne, J. J., 
Bishop, L. M., He, S., and Arvanitis, T. N. (2012) Birmingham metabolite library: A 
publicly accessible database of 1-D 1H and 2-D 1H J-resolved NMR spectra of authentic 
metabolite standards (BML-NMR), Metabolomics 8, 8-18. 
186. Chou, T. C. (2006) Theoretical basis, experimental design, and computerized simulation 
of synergism and antagonism in drug combination studies, Pharmacol Rev 58, 621-681. 
187.    Ungard R, Singh G. Oxidative stress and glutamate release in glioma. In: Ghosh A, 
editor. Glioma - Exploring Its Biology and Practical Relevance.Rijeka: Intech; 2011. p. 
451-65 
 
